<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>NOD2 Mastery ‚Äî ISEF 2026</title>
<link href="https://fonts.googleapis.com/css2?family=Sora:wght@300;400;500;600;700;800&family=Outfit:wght@300;400;500;600;700;800;900&family=JetBrains+Mono:wght@400;600&display=swap" rel="stylesheet">
<style>
:root{--bg:#0a0a0f;--s1:#12121c;--s2:#1a1a2a;--s3:#222236;--brd:#2a2a44;--txt:#cccce0;--dim:#6666a0;--w:#f0f0ff;
--f1:#ff6b2b;--f2:#ff9a44;--f3:#ffd066;--gl:linear-gradient(135deg,#ff6b2b,#ff9a44);--glh:linear-gradient(135deg,#ff9a44,#ffd066);
--grn:#22c55e;--red:#ef4444;--cyn:#38bdf8;--pnk:#f472b6;--vio:#a78bfa}
*{margin:0;padding:0;box-sizing:border-box}::selection{background:rgba(255,107,43,.35)}
body{background:var(--bg);color:var(--txt);font-family:'Sora',sans-serif;line-height:1.85;font-size:15px;overflow-x:hidden}
h1,h2,h3{font-family:'Outfit',sans-serif;font-weight:700}h1{font-size:clamp(1.6rem,3.5vw,2.4rem);color:var(--w);margin-bottom:6px}
h2{font-size:1.3em;color:var(--f2);margin:32px 0 14px;position:relative;padding-left:14px}h2::before{content:'';position:absolute;left:0;top:4px;bottom:4px;width:4px;border-radius:2px;background:var(--gl)}
h3{font-size:1em;color:var(--cyn);margin:20px 0 8px;font-family:'Sora',sans-serif;font-weight:600}
code,pre{font-family:'JetBrains Mono',monospace}
.sub{color:var(--dim);font-size:13px;margin-bottom:24px;font-weight:300;letter-spacing:.2px}
a{color:var(--f2);text-decoration:none}a:hover{color:var(--f3)}
.shell{display:flex;min-height:100vh}.nav{width:240px;background:var(--s1);border-right:1px solid var(--brd);position:fixed;top:0;left:0;bottom:0;overflow-y:auto;z-index:50;padding:20px 0}
.nav-logo{padding:0 18px 18px;font-family:'Outfit',sans-serif;font-weight:800;font-size:18px;color:var(--w);border-bottom:1px solid var(--brd);margin-bottom:10px}
.nav-logo span{background:var(--gl);-webkit-background-clip:text;-webkit-text-fill-color:transparent}
.nav-label{font-size:9px;letter-spacing:2px;text-transform:uppercase;color:var(--dim);padding:16px 18px 6px;font-weight:600}
.nb{display:flex;align-items:center;gap:10px;width:100%;text-align:left;background:none;border:none;color:var(--dim);padding:10px 18px;font-size:13px;font-family:'Sora',sans-serif;cursor:pointer;transition:all .15s;border-left:3px solid transparent;font-weight:400}
.nb:hover{color:var(--txt);background:rgba(255,107,43,.04)}.nb.on{color:var(--f2);background:rgba(255,107,43,.08);border-left-color:var(--f1);font-weight:500}
.nb .ni{font-size:16px;width:22px;text-align:center;flex-shrink:0}
.ct{margin-left:240px;flex:1;padding:32px 48px 80px;max-width:1400px}
@media(max-width:900px){.nav{display:none}.ct{margin-left:0;padding:16px 16px 60px}.mn{display:flex!important}}
.mn{display:none;position:sticky;top:0;z-index:50;background:rgba(10,10,15,.92);backdrop-filter:blur(12px);overflow-x:auto;border-bottom:1px solid var(--brd);padding:0 8px}
.mb{background:none;border:none;color:var(--dim);padding:11px 14px;font-size:11px;font-family:'Sora',sans-serif;cursor:pointer;white-space:nowrap;border-bottom:2px solid transparent;transition:all .12s}
.mb.on{color:var(--f2);border-bottom-color:var(--f1)}
.sec{display:none;animation:fu .3s ease-out}.sec.on{display:block}@keyframes fu{from{opacity:0;transform:translateY(8px)}to{opacity:1;transform:none}}
p{margin-bottom:12px}strong{color:var(--w)}em{color:var(--f2)}
pre{background:#08080e;border:1px solid var(--brd);border-radius:10px;padding:14px 16px;overflow-x:auto;font-size:12.5px;line-height:1.7;margin:10px 0;color:#b0b0d0}.cmt{color:#6a9955}.kw{color:#c586c0}.str{color:#ce9178}.fn{color:#dcdcaa}
code{background:rgba(255,107,43,.08);padding:1px 5px;border-radius:4px;font-size:.85em;color:var(--f2)}
table{width:100%;border-collapse:collapse;margin:10px 0;font-size:13px}th{background:var(--s2);padding:8px 12px;text-align:left;border-bottom:2px solid var(--f1);font-weight:600;font-size:10px;text-transform:uppercase;letter-spacing:.6px;color:var(--f2)}td{padding:8px 12px;border-bottom:1px solid rgba(42,42,68,.6)}tr:hover td{background:rgba(255,107,43,.02)}
.n{color:var(--f3);font-weight:700;font-family:'JetBrains Mono',monospace;font-size:.95em}
ol,ul{padding-left:22px;margin-bottom:10px}li{margin-bottom:5px}
/* Audio buttons */
.au{display:inline-flex;align-items:center;gap:3px;background:rgba(255,107,43,.08);border:1px solid rgba(255,107,43,.2);color:var(--f2);padding:2px 9px;border-radius:20px;font-size:11px;cursor:pointer;font-family:'Sora',sans-serif;transition:all .15s;margin:1px;vertical-align:middle;font-weight:500}
.au:hover{background:rgba(255,107,43,.18);transform:scale(1.03)}.au.pl{background:rgba(255,107,43,.3);box-shadow:0 0 12px rgba(255,107,43,.2)}
/* Cards */
.c{background:var(--s1);border:1px solid var(--brd);border-radius:12px;padding:18px 20px;margin:14px 0;position:relative;overflow:hidden}
.c::after{content:'';position:absolute;top:0;left:0;right:0;height:1px;background:linear-gradient(90deg,transparent,rgba(255,154,68,.15),transparent)}
.ca{border-left:3px solid var(--f1)}.cg{border-left:3px solid var(--grn)}.co{border-left:3px solid var(--f3)}.cr{border-left:3px solid var(--red)}.cc{border-left:3px solid var(--cyn)}.cp{border-left:3px solid var(--pnk)}.cv{border-left:3px solid var(--vio)}
/* Expandable sections */
.ex{margin:10px 0}.exh{display:flex;align-items:center;gap:8px;cursor:pointer;padding:12px 14px;background:var(--s2);border:1px solid var(--brd);border-radius:10px;font-weight:500;transition:all .15s;font-size:13px}
.exh:hover{background:var(--s3);border-color:rgba(255,107,43,.2)}.ea{transition:transform .15s;font-size:10px;color:var(--f1)}.exh.op .ea{transform:rotate(90deg)}
.exb{display:none;padding:16px;background:var(--s1);border:1px solid var(--brd);border-top:none;border-radius:0 0 10px 10px;font-size:13.5px;line-height:1.85}.exb.op{display:block}
/* Tags */
.tg{display:inline-block;padding:2px 8px;border-radius:20px;font-size:9px;font-weight:700;letter-spacing:.5px;text-transform:uppercase;margin-right:4px}
.tw{background:rgba(255,107,43,.15);color:var(--f2)}.tc{background:rgba(56,189,248,.12);color:var(--cyn)}.tj{background:rgba(34,197,94,.12);color:var(--grn)}.tx{background:rgba(239,68,68,.12);color:var(--red)}.tl{background:rgba(244,114,182,.12);color:var(--pnk)}.ti{background:rgba(255,208,102,.12);color:var(--f3)}.tv{background:rgba(167,139,250,.12);color:var(--vio)}
/* VS comparison */
.vs{display:grid;grid-template-columns:1fr 1fr;gap:14px;margin:14px 0}@media(max-width:700px){.vs{grid-template-columns:1fr}}
.vw{padding:16px;border-radius:10px;background:rgba(34,197,94,.04);border:1px solid rgba(34,197,94,.18)}.vl{padding:16px;border-radius:10px;background:rgba(239,68,68,.03);border:1px solid rgba(239,68,68,.12)}
/* Key insight box */
.ky{background:linear-gradient(135deg,rgba(255,107,43,.05),rgba(56,189,248,.05));border:1px solid rgba(255,107,43,.15);border-radius:12px;padding:18px 20px;margin:14px 0}
/* WHY box */
.why{background:var(--s2);border:1px solid var(--brd);border-radius:10px;padding:16px 18px;margin:12px 0;position:relative;border-left:3px solid var(--f1)}
.why::before{content:'WHY THIS STEP?';position:absolute;top:-9px;left:12px;font-size:9px;font-weight:700;letter-spacing:1px;color:var(--f1);background:var(--s2);padding:0 6px}
/* LIMITATION box */
.lim{background:rgba(239,68,68,.03);border:1px solid rgba(239,68,68,.12);border-radius:10px;padding:16px 18px;margin:12px 0;position:relative}
.lim::before{content:'‚ö†Ô∏è LIMITATIONS';position:absolute;top:-9px;left:12px;font-size:9px;font-weight:700;letter-spacing:1px;color:var(--red);background:var(--bg);padding:0 6px}
/* PROS/CONS */
.pc{display:grid;grid-template-columns:1fr 1fr;gap:12px;margin:12px 0}@media(max-width:600px){.pc{grid-template-columns:1fr}}
.pros{background:rgba(34,197,94,.04);border:1px solid rgba(34,197,94,.15);border-radius:10px;padding:14px}.pros::before{content:'‚úÖ STRENGTHS';display:block;font-size:9px;font-weight:700;letter-spacing:1px;color:var(--grn);margin-bottom:8px}
.cons{background:rgba(239,68,68,.03);border:1px solid rgba(239,68,68,.12);border-radius:10px;padding:14px}.cons::before{content:'‚ö†Ô∏è WEAKNESSES';display:block;font-size:9px;font-weight:700;letter-spacing:1px;color:var(--red);margin-bottom:8px}
/* Bridge */
.bridge{background:linear-gradient(90deg,rgba(255,107,43,.06),rgba(56,189,248,.06));border:1px solid rgba(255,107,43,.1);border-radius:10px;padding:14px 18px;margin:20px 0;color:var(--f2);font-size:14px;font-style:italic;font-weight:300}
/* ISEF rubric tag */
.rubric{display:inline-flex;align-items:center;gap:4px;background:rgba(167,139,250,.1);border:1px solid rgba(167,139,250,.2);color:var(--vio);padding:3px 10px;border-radius:20px;font-size:10px;font-weight:600;letter-spacing:.3px}
/* Glossary grid */
.gg{display:grid;grid-template-columns:repeat(auto-fill,minmax(170px,1fr));gap:8px;margin:12px 0}
.gi{background:var(--s2);border:1px solid var(--brd);border-radius:8px;padding:8px 10px;font-size:12px;cursor:pointer;transition:all .15s}
.gi:hover{border-color:var(--f1);background:var(--s3);transform:translateY(-1px)}
.gi strong{font-size:13px}
/* Glow card for results */
.glow{position:relative;overflow:hidden}.glow::before{content:'';position:absolute;top:-50%;left:-50%;width:200%;height:200%;background:conic-gradient(from 0deg,transparent,rgba(255,107,43,.06),transparent,rgba(56,189,248,.06),transparent);animation:spin 8s linear infinite}@keyframes spin{to{transform:rotate(360deg)}}
.glow-inner{position:relative;background:var(--s1);border-radius:11px;padding:20px}
</style>
</head>
<body>
<div class="mn" id="mn"></div>
<div class="shell">
<nav class="nav" id="sb">
<div class="nav-logo">üß¨ NOD2 <span>Mastery</span></div>
</nav>
<main class="ct" id="ct"></main>
</div>
<script>
let cA=null;
function pa(f,b){if(cA){cA.pause();document.querySelectorAll('.au.pl').forEach(x=>x.classList.remove('pl'))}
const a=new Audio('audio/'+f+'.mp3');cA=a;if(b)b.classList.add('pl');
a.onended=()=>{if(b)b.classList.remove('pl')};
a.onerror=()=>{if('speechSynthesis'in window){const u=new SpeechSynthesisUtterance(b?.dataset?.fb||f);u.rate=0.7;speechSynthesis.speak(u)}if(b)setTimeout(()=>b.classList.remove('pl'),2e3)};a.play()}
function au(f,l,fb){return`<button class="au" data-fb="${fb||l}" onclick="pa('${f}',this)">üîä ${l}</button>`}
function ex(t,ti,bo){const id='e'+Math.random().toString(36).substr(2,6);const tc={w:'tw',c:'tc',j:'tj',x:'tx',l:'tl',i:'ti',v:'tv'}[t]||'tw';const tn={w:'WHY',c:'CODE',j:'JUDGE Q&A',x:'CRASH STORY',l:'HOW I LEARNED',i:'WHAT-IF',v:'ISEF RUBRIC'}[t]||'';
return`<div class="ex"><div class="exh" onclick="this.classList.toggle('op');document.getElementById('${id}').classList.toggle('op')"><span class="ea">‚ñ∂</span><span class="tg ${tc}">${tn}</span>${ti}</div><div class="exb" id="${id}">${bo}</div></div>`}

const S=[

// ============ ISEF JUDGING GUIDE ============
{id:'isef',icon:'üèÜ',label:'ISEF Judging Guide',ct:`
<h1>What ISEF Judges Actually Score ‚Äî The Real Rubric</h1>
<p class="sub">From the actual scoring forms judges hold in their hands. Know exactly what LOW vs HIGH looks like.</p>

<div class="c ca">
<p>Judges score 6 criteria on a 1-5 scale, each multiplied by a weight. Total = <span class="n">100 points</span>. The <strong>Interview alone is worth 25%</strong> (√ó5 multiplier ‚Äî the highest weight). Your poster could be perfect, but if you can't explain it, you lose a quarter of your score.</p>
<p><strong>At Fort Worth regional:</strong> Expect 8-10 minutes per judge, one at a time. Multiple judges visit. They'll ask questions rather than let you give a long prepared speech. Some judges may be PhDs, others may be engineers, teachers, or business professionals.</p>
</div>

<h2>The Actual Scoring Form (1-5 Scale √ó Weight)</h2>
<table>
<tr><th>Category</th><th>√ó</th><th>Max</th><th style="color:var(--red)">LOW (1-2)</th><th style="color:var(--yel)">MID (3)</th><th style="color:var(--grn)">HIGH (4-5)</th></tr>

<tr><td colspan="6" style="background:rgba(255,107,43,0.1);font-weight:700;padding:8px">Research Question</td></tr>
<tr><td>Purpose, Contribution, Method</td><td>√ó2</td><td class="n">10</td>
<td style="font-size:0.85em">Purpose unclear. No contribution to field identified. Not testable with scientific methods.</td>
<td style="font-size:0.85em">Lacks focus. Vague contribution. Partly testable.</td>
<td style="font-size:0.85em">Clear purpose. Identified contribution. Testable with sound methods.</td></tr>
<tr><td colspan="3"></td><td colspan="3"><strong>YOUR PROJECT:</strong> ‚úÖ HIGH ‚Äî Clear question (can computation ID mutation-sensitive binders?). Novel contribution (zero NOD2 binding data exists). Testable hypothesis with defined pipeline.</td></tr>

<tr><td colspan="6" style="background:rgba(255,107,43,0.1);font-weight:700;padding:8px">Design & Methodology</td></tr>
<tr><td>Data collection plan, Variables, Controls</td><td>√ó3</td><td class="n">15</td>
<td style="font-size:0.85em">Poorly designed plan. Variables/controls not defined, inappropriate, or incomplete.</td>
<td style="font-size:0.85em">Clear plan but data collection methods lack clarity. Variables somewhat vague. Replication unclear.</td>
<td style="font-size:0.85em">Well-designed plan with clear methods. Variables explicitly described. Easily replicable from description.</td></tr>
<tr><td colspan="3"></td><td colspan="3"><strong>YOUR PROJECT:</strong> ‚úÖ HIGH ‚Äî Multi-stage pipeline (dock‚ÜíML‚ÜíADMET‚ÜíMD‚ÜíFEP). Independent: compound identity + WT/R702W. Dependent: ŒîG, RMSD, occupancy. Controls: shuffled labels, non-binder, apo.</td></tr>

<tr><td colspan="6" style="background:rgba(255,107,43,0.1);font-weight:700;padding:8px">Execution: Data Collection & Analysis</td></tr>
<tr><td>Reproducibility, Systematic analysis, Math/stats, Sufficient data</td><td>√ó4</td><td class="n">20</td>
<td style="font-size:0.85em">Not systematic. No reproducibility. Erroneous math. Insufficient data for conclusions.</td>
<td style="font-size:0.85em">Organized but moderate reproducibility. Stats weak or incomplete. Insufficient data for full support.</td>
<td style="font-size:0.85em">Systematic collection. Reproducible. Appropriate statistics. Sufficient data for conclusions.</td></tr>
<tr><td colspan="3"></td><td colspan="3"><strong>YOUR PROJECT:</strong> ‚úÖ HIGH ‚Äî 3 replicates in MD. MBAR statistics on 120 FEP windows. 8œÉ significance. Scaffold-split CV (AUC 0.85-0.93). 520 ns total simulation. Shuffled control AUC ~0.50.</td></tr>

<tr><td colspan="6" style="background:rgba(255,107,43,0.1);font-weight:700;padding:8px">Creativity</td></tr>
<tr><td>Imagination, new perspectives, alternatives</td><td>√ó4</td><td class="n">20</td>
<td style="font-size:0.85em">Cookbook / no new ideas. Fails to demonstrate imagination. No new perspectives.</td>
<td style="font-size:0.85em">Some imagination. Offers different perspectives but weak.</td>
<td style="font-size:0.85em">Clearly demonstrates imagination and inventiveness. Offers perspectives that open new possibilities.</td></tr>
<tr><td colspan="3"></td><td colspan="3"><strong>YOUR PROJECT:</strong> ‚úÖ HIGH ‚Äî Student-initiated (personal genetic motivation). Novel finding (ligand-dependent mutation effects). New perspective (pharmacogenomic drug selection for NOD2). No one has done this before.</td></tr>

<tr><td colspan="6" style="background:rgba(255,107,43,0.1);font-weight:700;padding:8px">Poster</td></tr>
<tr><td>Organization, graphics, supporting docs</td><td>√ó2</td><td class="n">10</td>
<td style="font-size:0.85em">Illogical or unreadable. Graphics/legends unclear or absent. No supporting docs.</td>
<td style="font-size:0.85em">Somewhat scattered. Graphics appropriate but legends weak. Could use more documentation.</td>
<td style="font-size:0.85em">Clearly articulated and logical organization. Excellent graphics and legends. Supporting docs displayed.</td></tr>
<tr><td colspan="3"></td><td colspan="3"><strong>YOUR PROJECT:</strong> ‚ö†Ô∏è Make sure: logbook visible, abstract copies ready (bring 30), Form 1C if applicable, figures have clear legends, flow is left‚Üíright logical.</td></tr>

<tr><td colspan="6" style="background:rgba(255,154,68,0.15);font-weight:700;padding:8px">üéØ INTERVIEW (highest weight!)</td></tr>
<tr><td>Responses, understanding, limitations, independence, impact, future</td><td><strong>√ó5</strong></td><td class="n"><strong>25</strong></td>
<td style="font-size:0.85em">Poor responses. Basic misunderstanding of science. Doesn't understand results/limitations. No independence. No recognition of impact. No future ideas.</td>
<td style="font-size:0.85em">Moderately clear responses. Limited understanding. Limited grasp of limitations. Moderate independence. Some recognition of impact. Struggles with future research.</td>
<td style="font-size:0.85em">Very clear, concise, thoughtful responses. Understands basic science. Understands interpretation AND limitations. Demonstrates independence. Recognizes impact. Quality future ideas.</td></tr>
<tr><td colspan="3"></td><td colspan="3"><strong>YOUR PROJECT:</strong> ‚ö†Ô∏è THIS IS WHAT THIS ENTIRE WEBSITE TRAINS YOU FOR. The interview has the highest multiplier (√ó5). Every point matters 5√ó here.</td></tr>
</table>

<h2>What Gets a 5 vs a 3 vs a 1 on Interview</h2>
<div class="vs">
<div class="vl"><h3 style="color:var(--red)">Score 1-2 (FAIL)</h3>
<p>Memorized speech. Can't answer when interrupted. Says "I don't know" without trying to reason. Doesn't understand basic terms they used. Can't explain limitations. Says "it was perfect." Doesn't know what they'd do next. Can't distinguish their work from AI/mentor work.</p></div>
<div class="vw"><h3 style="color:var(--grn)">Score 4-5 (WIN)</h3>
<p>Stops mid-sentence to answer a question. Explains WHY each method was chosen. Volunteers limitations before asked. Says "I don't know, but my hypothesis would be..." and reasons through it. Clearly separates "Claude coded this" from "I decided this." Connects to patients. Has specific next experiments (SPR, ITC, HDX-MS).</p></div>
</div>

<h2>The Standard Interview Questions</h2>
<p><em>From actual ISEF judge training documents. Full scripted answers in Section 8.</em></p>
<div class="c cc">
<ol>
<li>"<strong>Please spend a minute describing your project.</strong>" ‚Äî Look at the board.</li>
<li>"<strong>How did you get the idea?</strong>" ‚Äî Personal story.</li>
<li>"<strong>Describe the timeline for this project.</strong>" ‚Äî Look at the notebook.</li>
<li>"<strong>What are the independent and dependent variables? Controls?</strong>"</li>
<li>"<strong>How did you decide the number of trials to do?</strong>" ‚Äî 3 replicates.</li>
<li>"<strong>What obstacles or unexpected results did you encounter?</strong>" ‚Äî Crashes, data leakage.</li>
<li>"<strong>On what basis did you reach your conclusion?</strong>" ‚Äî FEP + statistics.</li>
<li>"<strong>What could be done to strengthen the work?</strong>" ‚Äî Experimental validation.</li>
</ol>
</div>

<h2>Critical Tips from the Actual Judge Guide</h2>
<div class="ky">
<p><strong>"Ask many questions to form an opinion, rather than letting the student deliver a long prepared speech."</strong> ‚Äî This means they WILL interrupt you. When they do ‚Äî STOP and answer immediately. Don't try to finish your sentence.</p>
<p><strong>"Watch out for memorized speeches that reflect little understanding of principles."</strong> ‚Äî If you sound rehearsed, you score LOW on Clarity. Speak naturally. It's okay to pause and think.</p>
<p><strong>"If the student can't explain it to your satisfaction, then the student doesn't understand the science."</strong> ‚Äî They will ask you to define terms you used. If you say "allosteric" ‚Äî they'll say "what does that mean?" Know EVERY word on your poster.</p>
<p><strong>"Never assume the student knows what the technical terms mean."</strong> ‚Äî They'll test terminology as an impostor check. Real understanding = you can explain it simply. Fake understanding = you repeat jargon without knowing what it means.</p>
<p><strong>8-10 minutes per judge.</strong> ~1-2 min pitch + 6-8 min Q&A. Have 30 copies of your abstract ready to hand out. Point at your poster physically ‚Äî guide their eyes.</p>
</div>

<h2>Self-Assessment: Score Yourself Honestly</h2>
<div class="c co">
<p>Before Saturday, score yourself 1-5 on each criterion. Be brutally honest ‚Äî judges will be.</p>
<table>
<tr><th>Criterion</th><th>Can you...</th><th>Your Score (1-5)</th></tr>
<tr><td>Research Q</td><td>State the purpose in one sentence? Explain why it's novel?</td><td>___</td></tr>
<tr><td>Design</td><td>Name all variables and controls without looking at the poster?</td><td>___</td></tr>
<tr><td>Execution</td><td>Explain why 3 replicates? Why scaffold split? What 8œÉ means?</td><td>___</td></tr>
<tr><td>Creativity</td><td>Explain what's new that nobody has done before?</td><td>___</td></tr>
<tr><td>Poster</td><td>Walk someone through Figure 16 in 60 seconds?</td><td>___</td></tr>
<tr><td>Interview</td><td>Define every term on your poster? Explain every number?</td><td>___</td></tr>
</table>
<p>Any criterion below 4 ‚Üí study that section of this website until it's a 5.</p>
</div>

<h2>Alternative Rubric: Grand Awards Format</h2>
<p><em>Some fairs use this older system instead of the √ó2/√ó3/√ó4/√ó5 form above. Know both.</em></p>
<table>
<tr><th>Category</th><th>Points</th><th>What They Check</th></tr>
<tr><td><strong>I. Creative Ability</strong></td><td class="n">30</td><td>Originality in questions asked, approach to solving, analysis, interpretation. "Distinguish between gadgeteering and ingenuity."</td></tr>
<tr><td><strong>IIa. Scientific Thought</strong></td><td class="n">30</td><td>Problem clearly stated? Variables defined? Controls correct? Adequate data? Knows limitations? Understands related research? Cites scientific literature (not just newspapers)?</td></tr>
<tr><td><strong>III. Thoroughness</strong></td><td class="n">15</td><td>Carried to completion? Replication or single experiment? How complete are notes? Aware of other approaches? How much time spent?</td></tr>
<tr><td><strong>IV. Skill</strong></td><td class="n">15</td><td>Has required computation/lab skills? Where was project done? How much help? Built equipment independently?</td></tr>
<tr><td><strong>V. Clarity</strong></td><td class="n">10</td><td>"Watch out for memorized speeches that reflect little understanding." Data clearly presented? Orderly? Done without tricks?</td></tr>
</table>

<h2>Two Types of Judges You'll See</h2>
<div class="c ca">
<p><strong>A. Category Place Judges</strong> ‚Äî determine 1st, 2nd, 3rd place awards. These are the main judges who score your project on the rubric above.</p>
<p><strong>B. Special Awards Judges</strong> ‚Äî represent specific organizations (companies, professional societies). They look for projects matching their organization's interests. These can award internships, scholarships, gift cards, etc. Be ready for ANYONE to walk up.</p>
</div>

<h2>17 Presentation Pointers (From Official Fair Guide)</h2>
<div class="c cc">
<ol>
<li><strong>Eye contact and smile.</strong> Always look judges in the eye.</li>
<li><strong>Shake their hand.</strong> Greet them. First impressions matter.</li>
<li><strong>Speak clearly and loud enough.</strong> Don't talk too fast. Stop and breathe if you need to organize your thinking.</li>
<li><strong>Neat appearance.</strong> Not sloppy.</li>
<li><strong>Use your resources.</strong> Pick up and refer to your logbook, photos, extra data.</li>
<li><strong>Hand judges a copy of your abstract.</strong> Have at least 30 copies printed.</li>
<li><strong>Use your abstract as the basis.</strong> It helps flow.</li>
<li><strong>Initial presentation: 2-3 minutes MAX.</strong> Be brief and concise. Leave time for questions. Do NOT read off notecards.</li>
<li><strong>Start with what you did.</strong> Identify your variables.</li>
<li><strong>Tell them WHY you chose this study.</strong> Make real-world connections. (Your personal story is your biggest weapon here.)</li>
<li><strong>Do NOT read your procedure.</strong> It's long and wastes time. Highlight what you did.</li>
<li><strong>Discuss data by describing TRENDS.</strong> Do NOT read off data tables to the judges.</li>
<li><strong>Answer what they actually asked.</strong> Don't stray off topic.</li>
<li><strong>If you don't understand the question ‚Äî ask them to explain.</strong> They know you're nervous and won't mind.</li>
<li><strong>Practice, practice, practice.</strong> With peers and parents. Get feedback. Have them time you.</li>
<li><strong>Show pride.</strong> Let judges see you care about this project.</li>
<li><strong>Thank them when they leave.</strong></li>
</ol>
</div>

<div class="ky"><strong>From a past ISEF competitor:</strong> "This guy just asked me everything that was on my board. He also asked biology topics I needed to know in order to actually do the project." ‚Äî The impostor check is REAL. If you wrote "allosteric" on your poster, you better be able to explain what allosteric means from scratch.</div>
`},


// ============ BIOLOGY ============
{id:'bio',icon:'üß¨',label:'1. Biology',ct:`
<h1>1. The Biology ‚Äî Your Immune System's Broken Fire Alarm</h1>
<p class="sub">Starting from what you know. Every new term gets a real explanation before it's used.</p>

<div class="why"><p><strong>Why start here?</strong> If a judge says "explain NOD2" and you freeze, nothing else matters. Biology is the foundation everything else stands on.</p></div>

<h2>What You Already Know</h2>
<div class="c">
<p><strong>DNA ‚Üí mRNA ‚Üí Protein.</strong> Genes get transcribed into mRNA. Ribosomes read mRNA and build chains of amino acids. Those chains fold into 3D shapes called proteins. Proteins do everything ‚Äî speed up reactions, build structures, send signals. A <strong>mutation</strong> = a change in DNA that can swap one amino acid for another, potentially changing the protein's shape and breaking its function.</p>
<p>That's your starting point. Everything below builds from here.</p>
</div>

<h2>What Is NOD2? ${au('NOD2','NOD2')}</h2>
<p>Your body has ~38 trillion bacteria in your gut. Usually they stay in the tube (the lumen). But sometimes bacteria cross the intestinal wall and get <strong>inside your cells</strong>. Your immune system needs a way to detect this invasion.</p>

<p>${au('NOD2','NOD2')} is a protein that floats around inside the cytoplasm of your gut cells. It's not on the surface ‚Äî it's <strong>inside</strong>. Its one job: detect a specific molecule called ${au('MDP','MDP')} (${au('muramyl_dipeptide','muramyl dipeptide')}). MDP is a small fragment of the cell wall that ALL bacteria have, but human cells never make. So if MDP shows up inside your cell, it means bacteria broke in.</p>

<p>Think of NOD2 as a <strong>smoke detector inside your house</strong>. MDP is the smoke. When smoke hits the detector ‚Üí alarm goes off ‚Üí firefighters come ‚Üí fire gets put out.</p>

<h2>What Happens When NOD2 Detects Bacteria (The Signaling Cascade)</h2>
<p>In AP Bio you learned about signal transduction ‚Äî one protein activating the next in a chain. Here's the full chain for NOD2:</p>

<div class="c cc">
<ol>
<li><strong>MDP enters the cell</strong> through special transporters in the membrane</li>
<li><strong>MDP physically touches NOD2's LRR domain</strong> ‚Äî the "sensor" part of the protein (we'll explain domains in a second)</li>
<li><strong>NOD2 changes shape</strong> ‚Äî the sensor part was acting like a lid keeping the protein turned off. MDP pops the lid open.</li>
<li><strong>The opened NOD2 grabs another protein called ${au('RIPK2','RIPK2')}</strong> ‚Äî this is like the smoke detector calling the fire department</li>
<li><strong>RIPK2 activates ${au('TAK1','TAK1')}</strong> ‚Üí TAK1 activates a complex called IKK</li>
<li><strong>IKK destroys a protein called IŒ∫BŒ±</strong> ‚Äî IŒ∫BŒ± was acting like a handcuff on a powerful molecule called ${au('NF_kappa_B','NF-Œ∫B')}</li>
<li><strong>NF-Œ∫B is freed</strong> ‚Üí it enters the nucleus ‚Üí it turns on genes that make inflammatory signals (cytokines)</li>
<li><strong>Cytokines recruit immune cells</strong> ‚Üí bacteria get killed</li>
</ol>
<p>Bottom line: MDP (bacterial fragment) ‚Üí NOD2 (sensor) ‚Üí chain of proteins ‚Üí NF-Œ∫B ‚Üí inflammation ‚Üí bacteria die.</p>
</div>

<h2>The Protein's Parts (Domain Map)</h2>
<p>Proteins are long chains, but different regions do different jobs. These regions are called <strong>domains</strong> ‚Äî like rooms in a house. NOD2 has 5 domains:</p>

<table>
<tr><th>Domain</th><th>Position</th><th>What It Does</th><th>Why You Care</th></tr>
<tr><td>CARD</td><td>amino acids 1‚Äì120</td><td>Grabs RIPK2 to start the alarm</td><td>Not your target</td></tr>
<tr><td>NBD</td><td>273‚Äì577</td><td>Uses ATP energy to cluster NOD2 molecules together</td><td>The engine</td></tr>
<tr><td>HD1</td><td>577‚Äì640</td><td>Connecting link between domains</td><td>Structural</td></tr>
<tr><td><strong>HD2</strong></td><td><strong>640‚Äì744</strong></td><td>Flexibility hinge ‚Äî lets the protein flex and move</td><td>‚ö†Ô∏è <strong>YOUR MUTATION IS HERE</strong></td></tr>
<tr><td><strong>LRR</strong></td><td><strong>744‚Äì1040</strong></td><td>The sensor ‚Äî detects MDP. Also has a pocket where drugs can sit.</td><td>‚ö†Ô∏è <strong>YOUR DRUGS BIND HERE</strong></td></tr>
</table>

<p><strong>The key detail:</strong> Your mutation is at position 702 (in HD2). Your drugs bind in the LRR domain (starting at position 744). The distance between them: <span class="n">79.4 √Ö</span> (√Öngstr√∂ms ‚Äî one √Ö is one ten-billionth of a meter, about the width of a single atom). At the molecular scale, 79.4 √Ö is HUGE. They're nowhere near each other.</p>

<p>This means the mutation doesn't directly touch where drugs bind. Instead, it changes the protein's behavior <em>at a distance</em>. Scientists call this an <strong>${au('allosteric','allosteric')} effect</strong> ‚Äî "allo" (other) + "steric" (shape). A shape change in one place causing effects somewhere else. Like pressing the brake pedal in a car changes what happens at the wheels, even though your foot is far from the wheels.</p>

${ex('l','HOW I chose NOD2 and the LRR pocket as my target',`
<p><strong>Personal starting point:</strong> At 14, a clinical genetic test revealed you carry R702W. During Remicade infusions (2-4√ó per month), you asked your doctor "are there drugs that target NOD2 itself?" Answer: "No." That was the starting question.</p>
<p><strong>Why LRR domain for drugs?</strong> Literature review during infusions. The LRR domain is where MDP (the bacterial fragment) binds. If MDP binds there, small drug molecules might too. The concave face of the LRR has a pocket-like cavity visible in the AlphaFold structure. Published Crohn's research focuses on downstream targets (TNF-Œ±, IL-12/23) ‚Äî nobody had tried targeting NOD2 directly because no crystal structure of the binding pocket existed.</p>
<p><strong>Why AlphaFold2?</strong> PDB search for "NOD2 human" returned 5IRM ‚Äî rabbit NOD2, only CARD+NBD domains (residues 1-577). The LRR domain (744-1040) where drugs would bind was completely missing. AlphaFold2 predicted full-length human NOD2 with pLDDT confidence >90 in the LRR region. No alternative existed ‚Äî without AlphaFold, this project couldn't happen.</p>
<p><strong>Why R702W and not G908R or 1007fs?</strong> R702W is the most common NOD2 Crohn's variant (~10% of patients) and the one you personally carry. Starting with the mutation you understand best made scientific and personal sense. G908R and 1007fs are planned future work ‚Äî you acknowledge this limitation.</p>
`)}

<h2>The R702W Mutation ‚Äî What Actually Changed ${au('R702W','R702W')}</h2>
<p>To understand R702W, you need to know that the 20 amino acids have different physical properties. Two matter here:</p>

<div class="c co">
<p><strong>${au('arginine','Arginine')} (abbreviated "R") ‚Äî the NORMAL amino acid at position 702:</strong></p>
<p>Arginine has a <strong>positive electrical charge</strong>. It's also long and flexible, like a tentacle. Because of its charge, it can form strong connections with nearby amino acids that have negative charges. These connections are called <strong>salt bridges</strong> ‚Äî like magnets sticking together (positive attracts negative). Arginine can also form what are called <strong>hydrogen bonds</strong> (we'll explain these properly in the docking section ‚Äî for now, think of them as weak but precise "sticky" connections between atoms). Arginine can form up to 5 of these at once. All these connections create a network that keeps HD2 (the hinge domain) <strong>flexible</strong> ‚Äî it can move freely, like a well-oiled door hinge.</p>

<p><strong>${au('tryptophan','Tryptophan')} (abbreviated "W") ‚Äî the MUTANT amino acid:</strong></p>
<p>Tryptophan is the <strong>biggest</strong> amino acid. It has a large flat ring structure. It has <strong>no electrical charge</strong> ‚Äî it's neutral and "oily" (hydrophobic, meaning it avoids water). It can only form 1 hydrogen bond instead of 5. It CANNOT form salt bridges because it has no charge. So all those connections Arginine was making? Gone.</p>

<p><strong>Result:</strong> The HD2 hinge loses its network of connections ‚Üí it becomes <strong>rigid</strong> instead of flexible ‚Üí this stiffness spreads through the protein like a frozen joint ‚Üí eventually reaches the LRR domain 79.4 √Ö away ‚Üí changes the shape of the pocket where drugs bind.</p>
</div>

<p>Your MD simulations proved this rigidification. Wild-type protein backbone moves around with an average deviation of <span class="n">4.05 √Ö</span>. R702W mutant: only <span class="n">3.27 √Ö</span>. The mutant protein literally moves less ‚Äî it's stiffer.</p>

<h2>The Crohn's Paradox ${au('crohns',"Crohn's Disease")}</h2>
<div class="c cr">
<p>Here's what confuses even scientists: Crohn's disease is an <strong>inflammatory</strong> disease (too much immune activity). But it's caused by <strong>too little</strong> immune sensing. How?</p>

<p>With the R702W mutation, NOD2 can't properly detect MDP ‚Üí bacteria aren't caught early ‚Üí they multiply ‚Üí the body eventually notices through BACKUP immune systems that are less precise ‚Üí these backups launch a massive, sustained inflammatory response ‚Üí chronic tissue damage = Crohn's disease.</p>

<p><strong>Analogy:</strong> A fire alarm with dead batteries. The alarm doesn't go off. The fire smolders for hours. Eventually someone sees smoke and calls EVERY fire department in the city. The flood of water and boots does more damage than the original small fire would have.</p>

<p>You receive <strong>Remicade</strong> (infliximab) infusions. Remicade blocks TNF-Œ± ‚Äî one of the inflammatory signals at the END of the cascade. It treats the water damage (inflammation). Your project asks: can we fix the fire alarm itself (NOD2)?</p>
</div>

<div class="pc">
<div class="pros"><p>Strong personal motivation ‚Äî judges respond to this</p><p>Understudied target ‚Äî genuinely novel</p><p>Clear biological logic for the approach</p></div>
<div class="cons"><p>NOD2 is inside the cell ‚Äî drugs must cross the membrane to reach it</p><p>Allosteric mechanism is complex to explain quickly</p><p>No experimental proof yet ‚Äî all computational</p></div>
</div>

<div class="lim"><p style="margin-top:8px">Protein structure predicted by AlphaFold2 (AI), not determined experimentally. Only one mutation (R702W) tested ‚Äî two other Crohn's mutations (G908R, 1007fs) remain unexplored. Even if a drug binds NOD2, it might not actually fix the sensing problem ‚Äî binding ‚â† function.</p></div>

<div class="bridge">üîó You now understand: NOD2 detects bacteria. R702W breaks that detection by stiffening the protein. Your drugs target the LRR pocket. The mutation is 79.4 √Ö away and affects drug binding indirectly. Next: how you screened 9,566 compounds against this pocket.</div>
`},


// ============ DOCKING ============
{id:'dock',icon:'üîë',label:'2. Docking',ct:`
<h1>2. GNINA Docking ‚Äî Fitting 9,566 Keys Into One Lock ${au('GNINA','GNINA')}</h1>
<p class="sub">How a computer scores whether a drug fits into a protein pocket. Every scoring term explained from scratch.</p>

<div class="why"><p><strong>Why do this step?</strong> You have 9,566 candidate drugs and one protein pocket. Testing all of them in a lab would take years and cost millions. Docking lets a computer try each one in minutes. It's the first filter ‚Äî fast and cheap enough to screen thousands, accurate enough to narrow the list.</p><p><strong>What happens without it?</strong> You'd be picking drugs randomly. Docking gives you an educated ranking.</p></div>

<h2>The Lock-and-Key Concept</h2>
<p>You know from AP Bio that enzymes have active sites ‚Äî specific shapes that only certain molecules fit into. Docking is the same idea applied to drug discovery. The protein has a cavity on its surface (called a <strong>binding pocket</strong>) and the drug is a small molecule that might fit inside it.</p>

<p>The computer takes one drug, places it near the pocket, and tries thousands of orientations ‚Äî rotating it, flipping it, bending its flexible parts ‚Äî looking for the arrangement where the drug fits best. Then it calculates a <strong>score</strong> ‚Äî a number representing how well that drug interacts with the protein.</p>

<p>But what does "interacts" actually mean? There are four main types of physical forces between molecules. You need to understand all four, because they come back in EVERY later section:</p>

<h2>The Four Forces ‚Äî Explained From Scratch</h2>

<div class="c cc">
<h3>1. Hydrogen Bonds ("H-bonds") ‚Äî Precise Sticky Connections</h3>
<p>Water is H‚ÇÇO. The oxygen pulls electrons toward itself, making the hydrogens slightly positive and the oxygen slightly negative. When a slightly-positive hydrogen on one molecule lines up with a slightly-negative oxygen (or nitrogen) on another molecule ‚Äî they stick. That's a hydrogen bond.</p>
<p>H-bonds are <strong>weak individually</strong> (about 10-20√ó weaker than covalent bonds) but <strong>very specific</strong> ‚Äî they require exact geometry. The hydrogen has to point directly at the other atom, within a specific distance (less than 3.5 √Ö) and at a specific angle (120-180¬∞). Move the atoms even slightly and the bond breaks.</p>
<p><strong>Why this matters for your project:</strong> Febuxostat relies heavily on H-bonds with the pocket. When R702W shifts the pocket geometry even slightly ‚Üí H-bonds break ‚Üí binding gets 50√ó weaker.</p>

<h3>2. Van der Waals Forces ‚Äî Shape Fitting</h3>
<p>Even atoms with no charge attract each other weakly when they're at just the right distance (~3.5-4 √Ö apart). This happens because electrons are constantly moving around atoms, creating tiny temporary charges that induce matching charges in neighbors. It's very weak per atom ‚Äî but add up thousands of atom-atom contacts across a whole drug-protein interface, and it becomes significant.</p>
<p>Crucially: push atoms TOO CLOSE (below ~3 √Ö) and they repel VIOLENTLY ‚Äî like trying to push two tennis balls into the same space. This repulsion increases as 1/r¬π¬≤ ‚Äî astronomically fast. This "shape fitting" force is why molecular shape matters: the drug must fill the pocket without clashing.</p>
<p><strong>Why this matters:</strong> Bufadienolide binds mainly through van der Waals contacts with oily amino acids. These contacts are tolerant of small shape changes ‚Äî even when R702W shifts the pocket, the drug still fits.</p>

<h3>3. Electrostatic Interactions ‚Äî Charges Attract</h3>
<p>Coulomb's law from physics: opposite charges attract, same charges repel. Force = kq‚ÇÅq‚ÇÇ/r¬≤. Some amino acids are positively charged (arginine, lysine). Some are negatively charged (aspartate, glutamate). If a drug has a positive group near a negative amino acid ‚Üí strong attraction. Wrong charge ‚Üí repulsion.</p>
<p><strong>Why this matters:</strong> Febuxostat has electrostatic contacts with ${au('ASP1011','ASP1011')} (aspartate = negatively charged). When the pocket shifts, these charge-charge interactions break.</p>

<h3>4. Hydrophobic Interactions ‚Äî Oil and Water</h3>
<p>Some parts of molecules are "oily" ‚Äî they have no charges, no H-bond capability. Think of the carbon-hydrogen chains in fat. These oily surfaces can't form good interactions with water. So when two oily surfaces come together, water molecules that were awkwardly surrounding them can leave and form proper H-bonds with each other instead. This release of trapped water is energetically favorable.</p>
<p>It's like two introverts at a party finding each other ‚Äî they're not making a strong connection, but they're more comfortable together than surrounded by extroverts (water).</p>
<p><strong>Why this matters:</strong> Bufadienolide has a large oily steroid structure that packs against oily amino acids (leucine, isoleucine, valine) in the pocket. This type of contact is geometry-TOLERANT ‚Äî you don't need perfect positioning, just rough surface contact. That's why Bufadienolide survives the mutation's shape change.</p>
</div>

<p><strong>A docking score</strong> = sum of all four forces across every atom pair between drug and protein. Lower total energy = better fit = higher rank.</p>

<h2>Classical Docking vs. GNINA ‚Äî Why You Used AI</h2>

<div class="vs">
<div class="vl"><h3 style="color:var(--red)">‚ùå AutoDock Vina (2010)</h3>
<p>Uses a fixed formula written by humans: Score = weight‚ÇÅ √ó shape_fit + weight‚ÇÇ √ó H-bonds + weight‚ÇÉ √ó hydrophobic + weight‚ÇÑ √ó flexibility_penalty. The weights were fitted to just 1,300 crystal structures in 2010. It can never learn new patterns ‚Äî it's locked to that formula forever.</p>
<p>You tried Vina first ‚Äî installation failed on Windows.</p></div>
<div class="vw"><h3 style="color:var(--grn)">‚úÖ GNINA (2020) ${au('GNINA','GNINA')}</h3>
<p>Uses a <strong>Convolutional Neural Network (CNN)</strong> ‚Äî the same type of AI that recognizes faces in photos, except it works in 3D instead of 2D. It places a 3D grid over the drug-protein complex, records what atoms are where, and feeds this "3D image" into a neural network trained on <strong>20,000+</strong> real crystal structures where scientists measured actual binding in the lab.</p>
<p>Vina follows a recipe. GNINA is a chef who's cooked 20,000 meals and developed intuition.</p></div>
</div>

<h2>Your Setup ‚Äî Every Parameter Explained</h2>
<table>
<tr><th>Parameter</th><th>Value</th><th>What It Means in Plain English</th></tr>
<tr><td>Protein structure</td><td>AlphaFold2 NOD2</td><td>AI-predicted 3D structure (no lab-determined structure exists for the LRR domain)</td></tr>
<tr><td>Grid box size</td><td class="n">30 √ó 30 √ó 30 √Ö</td><td>A cube-shaped search zone around the pocket. The pocket itself is ~20 √Ö across, so 30 gives 5 √Ö of breathing room on each side for big drugs to rotate.</td></tr>
<tr><td>Exhaustiveness</td><td class="n">32</td><td>How many independent random searches to run. Default is 8. Higher = more thorough but slower. You used 4√ó default because your GPU made it fast enough.</td></tr>
<tr><td>Poses kept</td><td class="n">9 per drug</td><td>Keep the top 9 orientations in case the best one is a fluke.</td></tr>
<tr><td>Total time</td><td class="n">~13 hours</td><td>~2 minutes per compound √ó 9,566 compounds, on your RTX 4060 Ti GPU.</td></tr>
</table>

${ex('l','HOW I actually arrived at these parameters',`
<p><strong>Exhaustiveness 32:</strong> GNINA default is 8. Gemini (Google's AI) reviewed my Phase 1 plan and flagged this: "When you get to the docking step, set exhaustiveness = 32. The default of 8 is too lazy for a complex protein like NOD2." I verified this by reading GNINA benchmarks ‚Äî higher exhaustiveness means more random starting orientations are explored, reducing the chance of missing the best pose. The tradeoff is speed: 32 takes 4√ó longer than 8. On GPU this was acceptable (2 min/compound vs 30 sec).</p>
<p><strong>Grid box 30 √ó 30 √ó 30 √Ö:</strong> Also from Gemini review: "Ensure the grid box (20-30 √Ö) isn't too big ‚Äî if the box is too large, signal-to-noise drops and the computer finds fake binding spots." I measured the pocket visually in PyMOL (~20 √Ö across) and added 5 √Ö padding on each side = 30 √Ö. Large enough for bulky compounds to rotate freely inside, small enough to focus the search.</p>
<p><strong>Grid center (12.5, ‚àí3.2, 8.7):</strong> Calculated as the geometric centroid of known pocket-lining residues in the LRR domain. Identified residues from the AlphaFold structure by looking at the concave face where MDP-sensing residues cluster. This wasn't automated ‚Äî I selected the residues manually based on literature about the LRR binding surface.</p>
<p><strong>9 poses per compound:</strong> GNINA default is 9. Kept it because more poses = higher chance of capturing the true binding mode if the top-ranked pose is wrong. Minimal cost since only the scoring adds time, not additional searching.</p>
<p><strong>CNN rescoring (not CNN scoring):</strong> GNINA offers two modes ‚Äî CNN scoring during the search (slow, accurate) or Vina search + CNN rescore at the end (fast, nearly as accurate). Used rescore mode because the benchmarks show only ~2% difference in enrichment, but 3√ó faster.</p>
<p><strong>What I tried first that failed:</strong> AutoDock Vina. Installation failed on Windows WSL2 due to missing dependencies. Switched to GNINA because it was available as a pre-built binary with GPU support.</p>
`)}

${ex('x','ARG_MAX Crash ‚Äî 9,566 filenames broke Linux',`
<p><strong>What you tried:</strong> <code>gnina -l ligands/*.pdbqt</code> ‚Äî feeding all 9,566 filenames at once using a wildcard.</p>
<p><strong>What happened:</strong> Linux has a maximum command-line length (called ARG_MAX, about 2 MB). 9,566 filenames √ó ~30 characters each = ~287 KB. Exceeded the limit. But GNINA didn't show an error ‚Äî it just printed its help menu and exited successfully (exit code 0). No results, no error message. You had to figure out WHY a valid-looking command produced nothing.</p>
<p><strong>Fix:</strong> A shell for-loop that processes one file at a time: <code>for f in ligands/*.pdbqt; do gnina ... "$f" ...; done</code></p>
`)}

${ex('x','GPU Running at 1% ‚Äî Missing Library Path',`
<p><strong>What you saw:</strong> <code>nvidia-smi</code> showed your RTX 4060 Ti at 1% utilization. GNINA was running entirely on CPU (10-50√ó slower).</p>
<p><strong>Why:</strong> GNINA needs CUDA libraries (files that let software talk to the GPU). In WSL2 (Windows Subsystem for Linux), these files existed but weren't in the search path.</p>
<p><strong>Fix:</strong> <code>export LD_LIBRARY_PATH=/usr/local/cuda/lib64:$LD_LIBRARY_PATH</code> ‚Äî told Linux where to find the GPU libraries. Utilization jumped to ~50%.</p>
`)}

<div class="pc">
<div class="pros"><p>CNN scoring > classical (benchmarked on 20K+ structures)</p><p>GPU-accelerated: 13 hours for 9,566 compounds</p><p>Exhaustiveness 32 = thorough search</p></div>
<div class="cons"><p>Docking is a frozen snapshot ‚Äî proteins actually wiggle (that's what MD fixes later)</p><p>CNN was trained on general proteins, not NOD2 specifically</p><p>Scores are relative rankings, not exact binding energies ‚Äî they say "A probably binds better than B" not "A binds with exactly X energy"</p></div>
</div>

<div class="lim"><p style="margin-top:8px">AlphaFold2 structure adds uncertainty. Grid box center was chosen manually. Exhaustiveness 32 may still miss poses in very flexible molecules. CNN predictions have ~1.5 pKd units of error. Docking ignores water molecules in the pocket (they get pushed aside, but in reality they sometimes stay and help).</p></div>

<div class="bridge">üîó All 9,566 compounds now have CNN scores ranking how well they fit the pocket. But these scores are noisy ‚Äî some high scores are lucky flukes, some low scores are missed opportunities. Next: machine learning to find the real pattern in this data.</div>
`},


// ============ ML ============
{id:'ml',icon:'ü§ñ',label:'3. ML Model',ct:`
<h1>3. NOD2-Scout ‚Äî Teaching a Computer to Spot Binders ${au('XGBoost','XGBoost')}</h1>
<p class="sub">From "what's a decision tree" to catching your own data leakage. Every concept explained from zero.</p>

<div class="why"><p><strong>Why ML after docking?</strong> Docking scored each compound individually ‚Äî "does this one specific molecule fit?" ML looks at ALL 9,566 compounds together and asks a deeper question: "what PROPERTIES make molecules good NOD2 binders?" It finds patterns across the entire dataset that docking can't see. Think of docking as grading individual exams, and ML as figuring out what study habits predict good grades.</p><p><strong>What happens without it?</strong> You'd only have docking scores, which are noisy. ML filters the noise and finds the real signal.</p></div>

<h2>What Is a Decision Tree?</h2>
<p>In AP Bio, you may have used a dichotomous key ‚Äî "Does it have feathers? Yes ‚Üí bird. No ‚Üí continue." A <strong>decision tree</strong> is the exact same idea, applied to data.</p>

<p>Imagine sorting molecules into "binder" vs "non-binder." The tree asks questions about each molecule's properties:</p>

<div class="c">
<p><em>"Is this molecule's molecular weight above 350?"</em> ‚Üí If no ‚Üí probably too small to fill the pocket ‚Üí lean toward non-binder.<br>
<em>"Does it have at least 2 ring structures?"</em> ‚Üí If yes ‚Üí rings provide rigid shape that fits pockets ‚Üí lean toward binder.</p>
<p>The tree <strong>learns</strong> which questions to ask and where to set thresholds by looking at hundreds of examples. It tries every possible question at every possible cutoff value, and picks the one that best separates binders from non-binders at each step.</p>
</div>

<p><strong>Problem with one tree:</strong> It memorizes the training data instead of learning general rules. Like a student who memorizes specific exam answers instead of understanding the subject ‚Äî they ace that exact test but fail any new test. This is called <strong>overfitting</strong>.</p>

<h2>From One Tree to 100: XGBoost ${au('XGBoost','XGBoost')}</h2>
<div class="c ca">
<p><strong>XGBoost (Extreme Gradient Boosting)</strong> fixes overfitting by building <strong>100 trees in sequence</strong>, where each new tree specifically targets the mistakes of all previous trees:</p>
<ol>
<li><strong>Tree 1</strong> makes predictions on all compounds. Gets about 70% right, 30% wrong.</li>
<li><strong>Tree 2</strong> is trained ONLY on the 30% that Tree 1 got wrong. It specializes in the hard cases.</li>
<li><strong>Tree 3</strong> focuses on whatever Trees 1+2 combined still get wrong.</li>
<li>Continue for 100 rounds.</li>
<li><strong>Final prediction</strong> = all 100 trees vote together (weighted sum of their individual predictions).</li>
</ol>
<p>Each individual tree is weak and simple. But 100 trees, each correcting the last one's mistakes, become a strong collective. It's like 100 tutors, each one specializing in whatever the previous tutor couldn't teach.</p>
<p>"Gradient" means it uses calculus (gradient descent ‚Äî the same optimization method used in neural networks) to figure out exactly HOW MUCH each tree should correct. "Boosting" means each tree boosts the overall performance.</p>
</div>

<h2>The Labeling Problem ‚Äî Nobody Has Measured This Before</h2>
<p>Machine learning needs labeled data ‚Äî examples where you already know the answer. You need compounds labeled "this binds NOD2" and "this doesn't bind NOD2." But <strong>nobody in the history of science has ever experimentally measured NOD2 binding</strong> for any of these 9,566 compounds. The ChEMBL database (the world's largest collection of drug-target data) has literally zero entries for NOD2 binding.</p>

<div class="c co">
<p><strong>Solution: Pseudo-labels ${au('pseudo_label','pseudo-labels')}</strong> ‚Äî use your docking scores as proxies for real binding data.</p>
<p>Rank all 9,566 compounds by their GNINA CNN score (from docking). Then:</p>
<ul>
<li><strong>Top 25%</strong> (highest CNN scores) ‚Üí label as "1" = "likely binder"</li>
<li><strong>Bottom 25%</strong> (lowest CNN scores) ‚Üí label as "0" = "likely non-binder"</li>
<li><strong>Middle 50%</strong> ‚Üí THROW AWAY. These are ambiguous ‚Äî including them would add noise, not signal.</li>
</ul>
<p>This gives you <span class="n">~858</span> labeled compounds. Are these labels perfect? No ‚Äî docking scores are noisy. But the EXTREMES (very high and very low scores) are more reliable than the middle. Good enough to train on.</p>
</div>

${ex('l','HOW I chose XGBoost and these specific hyperparameters',`
<p><strong>Why XGBoost over neural networks or random forests?</strong> My dataset has only ~858 labeled compounds with 2,050 features. Neural networks need thousands to millions of examples to train well ‚Äî they'd memorize 858 samples instantly. Random forests are good but don't do sequential error correction. XGBoost is the standard choice for small tabular datasets in drug discovery (it wins most Kaggle competitions on tabular data). Claude Code (CLI AI tool) helped implement it, but the choice was based on reading papers about ML in virtual screening.</p>
<p><strong>Hyperparameters ‚Äî how I got these exact numbers:</strong></p>
<p><em>n_estimators = 100:</em> Started with Claude Code's suggestion of 100-500. With only 858 samples and learning_rate=0.05, each tree contributes 5%. After 100 trees = effectively all signal captured. Tried 200 and 500 ‚Äî AUC didn't improve, training loss kept dropping (overfitting). 100 was the sweet spot.</p>
<p><em>max_depth = 6:</em> Each tree has at most 2‚Å∂ = 64 leaf nodes. With 858 samples, that's 858 √∑ 64 ‚âà 13 samples per leaf ‚Äî enough to be statistically meaningful. Depth 3 (8 leaves, 107/leaf) was too coarse ‚Äî couldn't capture patterns. Depth 12 (4096 leaves, <1 sample/leaf) memorized everything.</p>
<p><em>learning_rate = 0.05:</em> Each tree corrects only 5% of the remaining error. Low rate = more trees needed but less overfitting. Standard practice: pair low learning rate with moderate n_estimators.</p>
<p><em>subsample = 0.8, colsample_bytree = 0.8:</em> Each tree sees only 80% of rows and 80% of features. Double randomization prevents any single tree from memorizing the full dataset. Common default in drug discovery ML papers.</p>
<p><strong>Was this tuned with Optuna or grid search?</strong> No formal hyperparameter optimization ‚Äî these are well-established defaults from XGBoost documentation and drug discovery ML literature. With 858 pseudo-labeled samples, heavy tuning would just overfit to noise. I tested a few alternatives (depth 3-12, lr 0.01-0.1) and confirmed these were reasonable.</p>
`)}

<h2>Features ‚Äî Translating Molecules Into Numbers</h2>
<p>A computer can't look at a molecular structure. It needs numbers. You need to convert each molecule into a list of numbers called a <strong>feature vector</strong>. You used <span class="n">2,050</span> numbers per molecule:</p>

<div class="c cc">
<h3>${au('morgan_fingerprint','Morgan Fingerprints')} ‚Äî 2,048 Numbers (a Molecular Barcode)</h3>
<p>For each atom in the molecule, look at its chemical neighborhood ‚Äî what other atoms are within 2 bonds? Hash that neighborhood into a position in a 2,048-digit binary code (each digit is 0 or 1). Different neighborhoods flip different positions to "1."</p>
<p>The result: every molecule gets a unique 2,048-digit barcode. If two molecules share chemical environments (similar atoms arranged similarly), they'll have similar barcodes ‚Äî and probably interact with proteins similarly.</p>

<h3>10 Physical Property Numbers</h3>
<p>Each captures a different measurable property of the molecule:</p>
<ul>
<li><strong>Molecular weight (MW)</strong> ‚Äî how heavy is the molecule (in daltons). Bigger molecules may fit tighter but have trouble getting into cells.</li>
<li><strong>LogP</strong> ‚Äî a measure of how "oily" vs "watery" a molecule is. Take the molecule and shake it in a mixture of oil and water. LogP is the log‚ÇÅ‚ÇÄ of the ratio (how much dissolves in oil / how much dissolves in water). High LogP = oily. Low LogP = watery. LogP matters because cell membranes are oily ‚Äî a very watery molecule (low LogP) can't cross them.</li>
<li><strong>TPSA (Topological Polar Surface Area)</strong> ‚Äî the total surface area of the molecule covered by oxygen and nitrogen atoms (polar atoms). High TPSA = lots of polar surface = interacts strongly with water = HARD to cross oily membranes. This is critical for NOD2 because it's inside the cell ‚Äî drugs must cross the membrane.</li>
<li><strong>H-bond donors/acceptors</strong> ‚Äî count of groups that can form hydrogen bonds. More = stickier with water = harder to get into cells.</li>
<li><strong>Rotatable bonds</strong> ‚Äî how flexible the molecule is. Each bendable bond is a degree of freedom. When the drug binds, these freeze ‚Äî losing freedom costs energy.</li>
<li><strong>Aromatic rings, Fsp3, heavy atoms, ring count</strong> ‚Äî other shape and complexity measures.</li>
</ul>
</div>

<h2>Scaffold Split ‚Äî The Most Important Decision You Made ${au('scaffold_split','Scaffold Split')}</h2>
<p>ML needs to be tested on data it hasn't seen during training. The standard approach: split data 80/20 into training and test sets. <strong>But HOW you split matters enormously.</strong></p>

<div class="vs">
<div class="vl"><h3 style="color:var(--red)">‚ùå Random Split ‚Üí AUC 0.998 (FAKE)</h3>
<p>Randomly assign compounds to train or test. Problem: many compounds share the same <strong>core backbone</strong> (called a ${au('Murcko','Murcko scaffold')} ‚Äî strip away side chains and you get the skeleton). If compound A and compound B have the same skeleton, and A is in training while B is in testing, the model just learns "this skeleton = binder." It memorized the family, not the chemistry.</p>
<p>Your result with random split: AUC = 0.998. Almost perfect. <strong>This was fake.</strong> The model was cheating ‚Äî recognizing scaffolds it had already seen.</p></div>
<div class="vw"><h3 style="color:var(--grn)">‚úÖ Scaffold Split ‚Üí AUC 0.85‚Äì0.93 (REAL)</h3>
<p>Group ALL molecules with the same skeleton together. ALL of them go into the SAME set ‚Äî either ALL in training or ALL in testing. The model is tested on entirely new chemical families it has never encountered.</p>
<p>Your result: AUC 0.85‚Äì0.93. Lower, but <strong>honest</strong>. The model actually learned binding chemistry, not scaffold identity.</p></div>
</div>

<p><strong>What is AUC?</strong> Area Under the ROC Curve. It measures how well the model distinguishes binders from non-binders. AUC = 1.0 = perfect. AUC = 0.50 = coin flip (random guessing). Your honest AUC of 0.85‚Äì0.93 means the model is genuinely good at ranking compounds.</p>

<h2>Negative Control ‚Äî Proving the Signal Is Real</h2>
<div class="c cg">
<p>Take your training labels and <strong>scramble them randomly</strong>. Break the connection between molecules and their labels. Retrain with identical settings. If the model still scores high ‚Üí something is wrong (the model is learning from data structure, not real signal).</p>
<p>Your result: shuffled AUC = <span class="n">~0.50</span> = pure coin flip. Real AUC = 0.85‚Äì0.93. The difference proves your model learned real binding patterns.</p>
</div>

${ex('x','Data Leakage Discovery ‚Äî Your AUC was 0.998',`
<p>First run used random split. AUC = 0.998 ‚Äî essentially perfect. No biological data is that clean. Investigation: feature importance showed fingerprint bits encoding common scaffolds dominated. The model was saying "if I see scaffold X ‚Üí high score." Not actual binding chemistry.</p>
<p>You caught this. You diagnosed it (scaffold overlap between train/test). You fixed it (scaffold split). AUC dropped to 0.85‚Äì0.93.</p>
<p><strong>Why judges love this:</strong> Catching and correcting your own error demonstrates more scientific maturity than having perfect results. It shows you understand WHY things work, not just what buttons to press.</p>
`)}

<div class="pc">
<div class="pros"><p>Scaffold split is gold-standard evaluation (rare even in published papers)</p><p>Shuffled control proves signal is real</p><p>Caught and corrected own data leakage ‚Äî shows integrity</p><p>AUC 0.85‚Äì0.93 is strong given pseudo-labels</p></div>
<div class="cons"><p>Training labels come from docking, not experiments ‚Äî they're proxies, not ground truth</p><p>858 compounds is small for ML (most models train on thousands to millions)</p><p>Morgan fingerprints lose 3D shape info ‚Äî molecule shape matters for binding</p></div>
</div>

<div class="lim"><p style="margin-top:8px">Pseudo-labels inherit docking errors. 2D fingerprints miss 3D binding geometry. 5-fold CV may still have some scaffold similarity between folds (Murcko scaffolds don't capture ALL structural similarity). Model may not generalize to chemical classes outside the training distribution (e-Drug3D + COCONUT).</p></div>

<p>NOD2-Scout selected the top <span class="n">2,129</span> predicted binders. These were clustered down to 150 diverse representatives to avoid redundancy ‚Üí ADMET filtering next.</p>
`},


// ============ ADMET ============
{id:'admet',icon:'üíä',label:'4. ADMET',ct:`
<h1>4. ADMET ‚Äî Can This Drug Survive a Human Body? ${au('ADMET','ADMET')}</h1>
<p class="sub">A drug can bind perfectly in a computer simulation and still fail in a person. These filters catch the reasons why.</p>

<div class="why"><p><strong>Why this step?</strong> ~90% of drug candidates that work in computer simulations or lab tests FAIL in human clinical trials. The most common reasons: the drug can't be absorbed through the gut, the liver destroys it too fast, or it's toxic. ADMET filters check for these problems computationally ‚Äî in seconds ‚Äî before you waste months on expensive simulations.</p><p><strong>What happens without it?</strong> You'd waste GPU time simulating compounds that could never work in a real patient.</p></div>

<p>ADMET stands for: <strong>A</strong>bsorption (can it get from your gut into your blood?), <strong>D</strong>istribution (does it reach the right tissue?), <strong>M</strong>etabolism (does the liver destroy it?), <strong>E</strong>xcretion (is it cleared from the body appropriately?), <strong>T</strong>oxicity (is it poisonous?).</p>

<h2>Your Four Filter Layers ‚Äî Each Explained</h2>

<div class="c cc">
<h3>Filter 1: ${au('lipinski','Lipinski\'s Rule of 5')} ‚Äî "Can it be swallowed as a pill?"</h3>
<p>In the 1990s, a Pfizer scientist named Christopher Lipinski looked at every successful oral drug and found they almost all share four properties. He noticed they're all divisible by 5, so he called it the "Rule of 5":</p>
<ul>
<li><strong>Molecular Weight ‚â§ 500</strong> ‚Äî molecules bigger than this can't diffuse through the intestinal membrane easily. They're physically too large to squeeze between the lipid molecules in cell membranes.</li>
<li><strong>LogP ‚â§ 5</strong> ‚Äî remember, LogP measures oiliness. Too oily (LogP > 5) = the drug gets stuck IN the membrane instead of passing through it. It dissolves into the fat and stays there.</li>
<li><strong>Hydrogen Bond Donors ‚â§ 5</strong> ‚Äî each H-bond donor group on the drug is tightly gripped by surrounding water molecules. To enter the oily membrane, the drug must BREAK those water interactions. Each one costs energy. Too many = the drug prefers staying in water over entering the membrane.</li>
<li><strong>Hydrogen Bond Acceptors ‚â§ 10</strong> ‚Äî same logic. More polar groups = harder to cross the membrane.</li>
</ul>

<h3>Filter 2: Veber's Rules ‚Äî "Flexibility and polarity"</h3>
<ul>
<li><strong>${au('TPSA','TPSA')} ‚â§ 140 √Ö¬≤</strong> ‚Äî Topological Polar Surface Area = total area of oxygen and nitrogen atoms on the molecule's surface. This is <strong>CRITICAL for NOD2 specifically</strong> because NOD2 is INSIDE the cell (cytoplasmic). The drug must cross the plasma membrane (a lipid bilayer ~30 √Öngstr√∂ms thick). High polar surface = strong water interactions = can't enter the oily membrane interior = the drug never reaches NOD2. For targets on the cell surface, this matters less. For NOD2, it's a hard requirement.</li>
<li><strong>Rotatable bonds ‚â§ 10</strong> ‚Äî rotatable bonds are single bonds that can spin freely. More rotatable bonds = more flexible molecule. When a flexible molecule binds to a protein, all those spinning bonds must freeze into one specific arrangement. Each frozen bond costs ~0.5 kcal/mol of entropy (lost freedom). Too many = the binding penalty is too high.</li>
</ul>

<h3>Filter 3: ${au('PAINS','PAINS')} ‚Äî "Chemical liars"</h3>
<p>PAINS = Pan-Assay INterference compoundS. These are 480 known chemical patterns that appear to bind EVERYTHING in every experiment ‚Äî not because they truly bind, but because they interfere with the measurement itself. They include:</p>
<ul>
<li>Quinones (redox cyclers ‚Äî they mess up electron-based assays)</li>
<li>Michael acceptors (they form permanent covalent bonds with any nearby cysteine)</li>
<li>Rhodanines (aggregate and create false signals)</li>
</ul>
<p>About 7% of all screened compounds contain PAINS alerts. You found 2 in your 150.</p>

<h3>Filter 4: Brenk ‚Äî "Known toxic structures"</h3>
<p>105 chemical patterns that are known to cause toxicity: epoxides (damage DNA), nitroso compounds (carcinogens), acyl halides (react with everything in the body). Any compound with ‚â•2 of these alerts is removed.</p>
</div>

<p><strong>Result: <span class="n">148 of 150 passed (98.7%)</span>.</strong> The high pass rate makes sense ‚Äî your FDA-approved drugs and filtered natural products are already designed to be drug-like. The 2 failures had PAINS alerts (Michael acceptors).</p>

${ex('l','HOW I chose these specific filters',`
<p><strong>Why Lipinski + Veber + PAINS + Brenk?</strong> This is the standard ADMET filtering stack used in published drug discovery papers. I learned about it from a YouTube series on computational drug discovery and then read the original papers. Claude Code implemented it using RDKit's built-in filter functions.</p>
<p><strong>Why these specific cutoffs?</strong> Lipinski's Rule of 5 cutoffs (MW ‚â§ 500, LogP ‚â§ 5, HBD ‚â§ 5, HBA ‚â§ 10) are directly from Lipinski's 1997 paper ‚Äî based on analysis of FDA-approved oral drugs. Veber's rules (TPSA ‚â§ 140, RotBonds ‚â§ 10) from Veber et al. 2002. These aren't my choices ‚Äî they're field standards.</p>
<p><strong>Why TPSA ‚â§ 140 and not a stricter cutoff?</strong> For surface receptors, TPSA ‚â§ 140 is fine. For intracellular targets like NOD2, some researchers use TPSA ‚â§ 90 √Ö¬≤ (more stringent membrane crossing). I kept 140 because my library includes FDA drugs already proven to reach intracellular targets, and being too strict might filter out real candidates. A judge might ask why I didn't use a stricter cutoff ‚Äî honest answer: 140 is the published standard and I didn't want to introduce an arbitrary tighter cutoff without justification.</p>
<p><strong>Order of filters:</strong> Lipinski first (fast, eliminates obvious non-drug-like), Veber next (catches remaining membrane-impermeable), PAINS (catches false-positive liabilities), Brenk last (catches toxicity). Order doesn't matter for the final set, but this progression makes logical sense.</p>
`)}

<p>148 compounds ‚Üí expert manual curation ‚Üí 8 ‚Üí 5 to molecular dynamics ‚Üí 2 to FEP.</p>

<div class="pc">
<div class="pros"><p>TPSA filter is target-specific (intracellular NOD2 = membrane crossing required)</p><p>PAINS catches invisible false positives that docking and ML miss</p><p>Fast ‚Äî seconds per compound</p></div>
<div class="cons"><p>Rules are guidelines, not laws ‚Äî some successful drugs violate Lipinski (e.g. cyclosporin)</p><p>No actual metabolism prediction ‚Äî just substructure alerts</p><p>98.7% pass rate means this filter didn't narrow much</p></div>
</div>

<div class="lim"><p style="margin-top:8px">Lipinski violations don't always mean failure (about 15% of approved drugs break at least one rule). ADMET doesn't predict actual metabolic half-life or CYP enzyme interactions. Brenk filter is conservative ‚Äî may flag compounds that are actually safe in context.</p></div>

<div class="bridge">üîó 148 safe, drug-like compounds remain. Expert curation selected 8, then 5 went to MD. Now the real test: does the drug STAY in the pocket when the protein is actually moving around at body temperature?</div>
`},


// ============ MD ============
{id:'md',icon:'üß™',label:'5. MD Simulation',ct:`
<h1>5. Molecular Dynamics ‚Äî Watching Atoms Move in Real Time ${au('molecular_dynamics','MD')}</h1>
<p class="sub">Docking gave you a frozen snapshot. MD gives you a 20-nanosecond movie of every atom at body temperature.</p>

<div class="why"><p><strong>Why this step?</strong> Docking freezes the protein in one pose and asks "does this drug fit?" But proteins aren't frozen ‚Äî at body temperature (37¬∞C), every atom is constantly vibrating, the protein backbone breathes and flexes, water molecules rush in and out of pockets. A drug that looks great in a frozen docking snapshot might wobble out of the pocket after 2 nanoseconds of real movement. MD answers the real question: <strong>does the drug STAY when everything is moving?</strong></p>
<p><strong>What else MD gives you:</strong> By simulating the protein WITHOUT any drug (called "apo" simulation), you can compare wild-type vs R702W flexibility ‚Äî directly proving the allosteric stiffening effect.</p></div>

<h2>The Basic Idea ‚Äî Newton's Laws for Atoms</h2>
<p>You know Newton's second law: <strong>F = ma</strong> (force = mass √ó acceleration). MD applies this equation to every single atom in the system:</p>

<div class="c cc">
<ol>
<li><strong>Calculate forces on every atom.</strong> For each atom, add up all the forces from every other atom it interacts with. This includes:
<ul>
<li>Bond stretching: atoms connected by covalent bonds are like balls connected by springs. Pull them apart ‚Üí spring pulls them back. Push them together ‚Üí spring pushes them apart. Energy = k(r ‚àí r‚ÇÄ)¬≤ where r‚ÇÄ is the natural bond length.</li>
<li>Angle bending: three atoms connected in a chain prefer a specific angle (like 109.5¬∞ for a carbon tetrahedron). Force pushes angles back toward their preferred value.</li>
<li>Torsion: rotation around bonds. Some rotational positions are preferred over others (think of the "staggered" vs "eclipsed" conformations from organic chemistry).</li>
<li>Van der Waals: the shape-fitting force explained in Section 2. Attracts at medium range, repels violently when atoms overlap.</li>
<li>Electrostatics: Coulomb's law (charges attract/repel). Computed for every charged atom pair.</li>
</ul></li>
<li><strong>F = ma ‚Üí calculate acceleration.</strong> You know the force (from step 1) and the mass (known for every element: C = 12 amu, N = 14 amu, O = 16 amu, H = 1 amu). So acceleration = F/m.</li>
<li><strong>Update velocity and position.</strong> New velocity = old velocity + acceleration √ó timestep. New position = old position + velocity √ó timestep. Each atom moves a tiny bit.</li>
<li><strong>Repeat.</strong> Go back to step 1 with the new positions. Do this 5,000,000 times. Each cycle advances time by 4 femtoseconds (4 √ó 10‚Åª¬π‚Åµ seconds). After 5 million steps: 20 nanoseconds of simulated real time.</li>
</ol>
</div>

<h2>Force Fields ‚Äî The Rules for How Atoms Interact ${au('force_field','Force Field')}</h2>
<p>To calculate the forces in step 1, you need precise numbers: How strong is a C-N bond spring? What's the preferred angle for an O-C-O bend? What's the charge on the nitrogen in an amide group? These numbers come from <strong>force fields</strong> ‚Äî massive databases of parameters fitted to quantum mechanics calculations and real experiments.</p>

<p>You used three different force fields because different molecules need different parameters:</p>
<ul>
<li><strong>${au('AMBER14','AMBER14')}</strong> ‚Äî for the protein. Optimized for amino acids, protein backbone angles, side chain interactions. Thousands of parameters from decades of protein simulation research.</li>
<li><strong>${au('OpenFF','OpenFF')} 2.1 (Sage)</strong> ‚Äî for the drug molecules. Optimized for small organic molecules. Uses a newer approach that automatically assigns parameters based on chemical patterns.</li>
<li><strong>${au('TIP3P_FB','TIP3P-FB')}</strong> ‚Äî for water. Represents each water molecule as 3 point charges with specific geometry. "FB" = "force balance" ‚Äî refit to match real water density and other physical properties.</li>
</ul>

<h2>The 4-Stage Protocol ‚Äî And Why Each Stage</h2>
<table>
<tr><th>Stage</th><th>What Happens</th><th>Duration</th><th>Why You Need This</th></tr>
<tr><td><strong>1. Minimize</strong></td><td>Nudge all atoms to remove any bad overlaps from setup</td><td>5,000 steps</td><td>When you place a drug from docking into the solvated protein, some atoms may overlap slightly. Minimization relaxes these clashes so the simulation doesn't explode on the first step.</td></tr>
<tr><td><strong>2. NVT Heating</strong></td><td>Gradually heat from 0 K to 310.15 K (37¬∞C)</td><td>100 ps</td><td>${au('NVT','NVT')} = constant Number of atoms, Volume, Temperature. A thermostat (${au('Langevin','Langevin')} ‚Äî adds random kicks and friction to mimic heat bath) brings the system to body temperature. You heat gradually because jumping straight to 310 K would shock the system.</td></tr>
<tr><td><strong>3. NPT Pressure</strong></td><td>Adjust box size for correct pressure and density</td><td>500 ps</td><td>${au('NPT','NPT')} = constant Number, Pressure, Temperature. A ${au('barostat','barostat')} (Monte Carlo ‚Äî randomly tries shrinking/expanding the box) adjusts until pressure = 1 atmosphere and density ‚âà 1.0 g/mL. Without this, the water might be unnaturally compressed or expanded.</td></tr>
<tr><td><strong>4. Production</strong></td><td>Run real dynamics and record data</td><td>20 ns √ó 3 replicates</td><td>This is where science happens. Record atom positions every 20 ps. 3 replicates (each starting with different random velocities) ensure your results aren't a fluke of one lucky trajectory.</td></tr>
</table>

<h2>Key Parameters</h2>
<table>
<tr><th>Setting</th><th>Value</th><th>Plain English Explanation</th></tr>
<tr><td>Timestep</td><td class="n">4 fs</td><td>Each simulation step advances time by 4 femtoseconds (4 √ó 10‚Åª¬π‚Åµ seconds). Made possible by ${au('HMR','HMR')} (Hydrogen Mass Repartitioning) ‚Äî you artificially increase hydrogen mass from 1.008 to 1.5 amu. Heavier hydrogen vibrates slower (like a heavier pendulum swings slower), so you can take bigger time steps without missing its motion. This makes the simulation 2√ó faster than the default 2 fs timestep.</td></tr>
<tr><td>Temperature</td><td class="n">310.15 K</td><td>= 37¬∞C = human body temperature. The drug needs to work HERE, not at some arbitrary temperature.</td></tr>
<tr><td>Total atoms</td><td class="n">~217,986</td><td>Protein (~16,000 atoms) + drug (~50 atoms) + ~65,000 water molecules (~195,000 atoms) + ~200 sodium/chloride ions. Water makes up 90% of the system.</td></tr>
<tr><td>Electrostatics</td><td>${au('PME','PME')}</td><td>Particle Mesh Ewald ‚Äî a mathematical trick using Fourier transforms to compute long-range charge interactions efficiently. Without it, you'd need to calculate force between every atom pair (N¬≤ calculations ‚Äî trillions). PME reduces this to N√ólog(N).</td></tr>
<tr><td>Total simulated time</td><td class="n">520 ns</td><td>26 trajectories (apo WT, apo R702W, 5 drugs √ó WT/R702W √ó 3 replicates) √ó 20 ns each. About 8 hours per trajectory on your RTX 4060 Ti.</td></tr>
</table>

${ex('l','HOW I arrived at every MD parameter ‚Äî the full decision trail',`
<p><strong>Why OpenMM?</strong> Tried GROMACS first ‚Äî installation on Windows WSL2 was a nightmare (GPU driver conflicts). OpenMM installed with conda in one command and had native Python API. Claude Code could write and debug OpenMM scripts directly. Amber and NAMD were alternatives but required separate licenses or complex compilation.</p>
<p><strong>Why AMBER14 force field for protein?</strong> Industry standard for protein simulations since ~2015. Extensively validated against experimental NMR and X-ray data. ff14SB variant specifically optimized for protein backbone and side chain torsions. The alternative (CHARMM36) is equally valid ‚Äî AMBER14 was chosen because OpenMM's built-in force field files include it directly (<code>amber14-all.xml</code>), making setup simpler.</p>
<p><strong>Why OpenFF 2.1 Sage for drugs?</strong> GAFF (General Amber Force Field) is the traditional choice for small molecules, but it's older and less accurate for unusual scaffolds. OpenFF 2.1 uses automated parameter assignment based on chemical patterns ‚Äî better for novel compounds like Bufadienolide (unusual steroid scaffold). Tried GAFF initially; some compounds had missing parameters. OpenFF handled them all.</p>
<p><strong>Why 4 fs timestep + HMR?</strong> Standard MD uses 2 fs timestep. I learned about HMR from a YouTube tutorial on OpenMM optimization. HMR increases hydrogen mass from 1.008 to ~1.5 amu, slowing their vibration ‚Üí you can safely use 4 fs ‚Üí simulation runs 2√ó faster. I suggested this to Claude Code, which implemented it. <strong>But:</strong> HMR + heavy restraints + 4 fs caused the NaN crash (see crash story). After that, I use 2 fs during restrained equilibration and 4 fs only during production.</p>
<p><strong>Why 310.15 K?</strong> = 37¬∞C = human body temperature. The drug needs to work inside a patient, not at room temperature (298 K). This is standard for biomedical MD simulations.</p>
<p><strong>Why 20 ns √ó 3 replicates?</strong> 20 ns is a practical minimum for observing ligand stability ‚Äî enough time for a non-binder to drift away (your negative control left by 5 ns) but short enough to run on a single consumer GPU in ~8 hours. 3 replicates (each starting with different random velocities from the Maxwell-Boltzmann distribution) ensure results aren't a fluke of one lucky trajectory. Papers in this field typically use 10-100 ns; 20 ns √ó 3 is defensible for ISEF given compute constraints.</p>
<p><strong>Why 1.0 nm cutoff + PME?</strong> Standard protocol. Atoms beyond 1.0 nm have their van der Waals interactions truncated (negligible at that distance). Electrostatics beyond 1.0 nm are handled by PME (Fourier transform trick) instead of direct calculation. 1.0 nm is the most common cutoff in published MD papers.</p>
<p><strong>Restraint force constant k = 100 kJ/mol/nm¬≤:</strong> Originally tried k = 1000 (from an OpenMM tutorial). Combined with HMR + 4 fs ‚Üí NaN crash. Reduced to k = 100 after debugging. This is gentler but sufficient to hold the protein backbone during equilibration while allowing side chains to relax.</p>
`)}

${ex('x','NaN Explosion ‚Äî January 1 (Worst Crash)',`
<p><strong>What happened:</strong> The simulation ran for about 200 steps and then OpenMM printed "Particle coordinate is NaN" (Not a Number) and crashed.</p>
<p><strong>The physics of the crash:</strong> You had three settings that were individually fine but lethal together: (1) heavy restraints on the protein (k = 1000 kJ/mol/nm¬≤ ‚Äî strong springs holding atoms in place), (2) HMR making hydrogens heavier, and (3) a 4 fs timestep. With strong springs, a slightly displaced atom experiences a massive restoring force. F = ma, and with HMR the effective mass is redistributed ‚Äî some atoms accelerate violently. In one timestep, an atom flew across the simulation box and landed on top of another atom. Van der Waals repulsion at very short distances goes as 1/r¬π¬≤ ‚Äî when r approaches zero, the force becomes essentially infinite ‚Üí the position calculation returns "infinity" ‚Üí which the computer stores as NaN ‚Üí crash.</p>
<p><strong>Fix:</strong> Reduced restraint strength to k = 100, ramped up gradually, and used 2 fs timestep during the restrained phase. Each change individually would have prevented the crash. The lethal combination of all three was the problem.</p>
`)}

<h2>Key MD Results</h2>
<div class="c cg">
<h3>Apo (No Drug) ‚Äî Proving the Allosteric Effect</h3>
<table>
<tr><th>What Was Measured</th><th>Wild-Type</th><th>R702W Mutant</th><th>What This Means</th></tr>
<tr><td>${au('RMSD','RMSD')} (average backbone deviation from starting structure)</td><td class="n">4.05 √Ö</td><td class="n">3.27 √Ö</td><td>The mutant protein moves LESS. It's stiffer.</td></tr>
<tr><td>Frames where RMSD > 5 √Ö</td><td class="n">12.6%</td><td class="n">0%</td><td>Wild-type regularly visits large open conformations. R702W NEVER does.</td></tr>
</table>
<p>This directly proves R702W rigidifies the protein ‚Äî and this stiffness propagates 79.4 √Ö to change the drug binding pocket.</p>

<h3>Drug Binding Stability</h3>
<table>
<tr><th>Compound</th><th>% Time Drug Stays in Pocket</th><th>Verdict</th></tr>
<tr><td>${au('febuxostat','Febuxostat')}</td><td class="n">~73%</td><td>Stays ‚úÖ</td></tr>
<tr><td>${au('bufadienolide','Bufadienolide')}</td><td class="n">~80%</td><td>Most stable ‚úÖ</td></tr>
<tr><td>Negative control (known non-binder)</td><td class="n">~0% (left by 5 ns)</td><td>Validates method ‚úÖ</td></tr>
</table>
<p>The negative control is essential ‚Äî it proves your simulation correctly identifies compounds that DON'T bind. Without it, high occupancy for Febuxostat and Bufadienolide could be a simulation artifact.</p>
</div>

<div class="pc">
<div class="pros"><p>520 ns total ‚Äî substantial for a high school project</p><p>3 replicates per system for statistical confidence</p><p>Negative control validates the entire methodology</p><p>Apo dynamics independently prove the allosteric mechanism</p></div>
<div class="cons"><p>20 ns is short compared to real biological events (protein folding takes microseconds to milliseconds ‚Äî 1,000-1,000,000√ó longer)</p><p>Force field parameters for novel natural compounds (like Bufadienolide) are less validated</p><p>Starting from an AlphaFold-predicted structure, not experimental</p></div>
</div>

<div class="lim"><p style="margin-top:8px">20 ns may miss slow conformational changes that happen on longer timescales. Pocket occupancy is a proxy for binding strength ‚Äî it doesn't directly tell you HOW tightly the drug binds (just that it stays nearby). Force field accuracy is ~1 kcal/mol. OpenFF parameters for unusual natural product scaffolds are less thoroughly validated than for typical drug molecules.</p></div>

<div class="bridge">üîó MD confirmed that Febuxostat and Bufadienolide stay in the pocket. But "stays" isn't a number ‚Äî you need to know EXACTLY how tightly each one binds, and whether R702W changes that. Only FEP gives you that number.</div>
`},


// ============ FEP ============
{id:'fep',icon:'‚ö°',label:'6. FEP',ct:`
<h1>6. Free Energy Perturbation ‚Äî The Gold Standard ${au('FEP','FEP')}</h1>
<p class="sub">The most expensive and accurate calculation in your project. Pharma companies pay $100K+/year for this. You built it for free.</p>

<div class="why"><p><strong>Why this step?</strong> MD told you "the drug stays in the pocket." That's a yes/no answer. FEP gives you a <strong>precise number</strong>: "this drug binds with exactly ‚àí10.36 ¬± 0.18 kcal/mol of energy." Then you run it on the mutant protein: ‚àí8.02 ¬± 0.19 kcal/mol. The difference (+2.34 kcal/mol) tells you PRECISELY how much R702W weakens binding. No other computational method gives numbers this accurate.</p>
<p><strong>What happens without it?</strong> You'd know drugs stay, but not how tightly ‚Äî and not whether the mutation changes anything quantitatively.</p></div>

<h2>Free Energy ‚Äî Starting from AP Chemistry</h2>
<p>In AP Chemistry you learned the equation <strong>ŒîG = ŒîH ‚àí TŒîS</strong>. Negative ŒîG means a process happens spontaneously. This exact equation governs drug binding. Let's unpack each term for drug binding specifically:</p>

<div class="c ca">
<p><strong>ŒîH (${au('enthalpy','enthalpy')} change) ‚Äî the energy from molecular interactions:</strong></p>
<p>When a drug enters a protein pocket, it forms new interactions ‚Äî hydrogen bonds, van der Waals contacts, electrostatic attractions (all four forces from Section 2). Each interaction releases energy. More interactions = more negative ŒîH = more favorable binding. Think of ŒîH as "how many good contacts did the drug make?"</p>

<p><strong>TŒîS (temperature √ó ${au('entropy','entropy')} change) ‚Äî the freedom penalty:</strong></p>
<p>Before binding, the drug floats freely in water ‚Äî it can rotate, tumble, and flex in any direction. When it binds to the protein, it gets locked into one specific position and orientation. Every degree of freedom it loses costs energy. Each frozen rotatable bond costs about 0.5 kcal/mol. This is the "price of admission" ‚Äî you have to pay it to bind.</p>
<p>Think of entropy as "how much freedom did the drug sacrifice?" Freezing a flexible molecule = big entropy penalty = less favorable.</p>

<p><strong>ŒîG = ŒîH ‚àí TŒîS:</strong> If the new contacts (ŒîH) release more energy than the freedom penalty (TŒîS) costs ‚Üí ŒîG is negative ‚Üí binding happens spontaneously ‚Üí the drug sticks.</p>
</div>

<h2>How FEP Works ‚Äî The Disappearing Drug Trick</h2>
<p>You can't directly calculate ŒîG for binding because the process involves the drug leaving bulk water and entering the pocket ‚Äî trillions of water molecules rearranging, the protein flexing to accommodate the drug, entropy changes everywhere. Too complex to compute directly.</p>

<p>Instead, FEP uses a clever thermodynamic trick:</p>

<div class="c cc">
<p><strong>Gradually make the drug "disappear"</strong> from the simulation, one tiny step at a time.</p>
<p>Imagine a dimmer switch called <strong>Œª (lambda)</strong>:</p>
<ul>
<li>Œª = 1.0 ‚Üí drug is fully present. All its forces (charges, shape, interactions) are at full strength.</li>
<li>Œª = 0.5 ‚Üí drug is "half there." Its forces are at 50% strength. It's like a ghost that half-interacts with the protein.</li>
<li>Œª = 0.0 ‚Üí drug has completely vanished. It's a ghost that interacts with nothing.</li>
</ul>
<p>You don't just flip from 1 to 0 ‚Äî that would be too violent (like yanking a magnet off a fridge vs. slowly sliding it). Instead, you use <span class="n">20</span> intermediate values of Œª. At EACH value, you run a separate MD simulation and measure the energy. This gives you <strong>20 ${au('lambda_window','lambda windows')}</strong>.</p>

<p><strong>Do this twice:</strong></p>
<ol>
<li>Disappear the drug from the <strong>protein pocket</strong> ‚Üí measure ŒîG<sub>complex</sub> (how much energy it costs to remove the drug from the protein). Lots of contacts ‚Üí expensive to remove.</li>
<li>Disappear the drug from <strong>pure water</strong> ‚Üí measure ŒîG<sub>solvent</sub> (how much energy it costs to remove the drug from water). Fewer contacts ‚Üí cheaper to remove.</li>
</ol>
<p><strong>ŒîG<sub>bind</sub> = ŒîG<sub>solvent</sub> ‚àí ŒîG<sub>complex</sub></strong></p>
<p>This is the ${au('thermodynamic_cycle','thermodynamic cycle')}. It works because free energy is a "state function" ‚Äî the path doesn't matter, only the start and end states. This is mathematically exact ‚Äî no approximations.</p>
</div>

<h2>The 20 Lambda Windows ‚Äî What Changes at Each Step</h2>
<table>
<tr><th>Windows</th><th>What's Being Changed</th><th>Why This Order</th></tr>
<tr><td>0‚Äì4</td><td><strong>${au('Boresch','Boresch restraints')} turn on:</strong> springs that hold the drug's position and orientation fixed relative to the protein.</td><td>Before you start removing the drug's forces, you need to pin it in place. Otherwise, as it becomes a ghost, it would drift randomly through the protein ‚Äî making energy measurements meaningless.</td></tr>
<tr><td>5‚Äì12</td><td><strong>Electrostatic charges fade out:</strong> the drug's atomic charges (the sources of H-bonds and charge-charge interactions) are gradually turned to zero.</td><td>Charge removal is smooth ‚Äî no mathematical singularities. Done first because charge interactions are long-range and their removal is numerically stable.</td></tr>
<tr><td>13‚Äì19</td><td><strong>Steric shape fades out:</strong> the drug's van der Waals size (its physical "shape") shrinks to nothing. Uses ${au('softcore','softcore potentials')}.</td><td>This is the dangerous part. As the drug loses its shape, other atoms can overlap with where the drug was. Without softcore, this overlap ‚Üí 1/r¬π¬≤ ‚Üí infinite force ‚Üí crash. Softcore potentials modify the equation to cap the repulsion at a finite value.</td></tr>
</table>

<p>Each compound needs <strong>3 legs</strong>: WT protein complex, R702W protein complex, and pure water (solvent). √ó 2 compounds = <strong>6 legs √ó 20 windows = 120 total simulations</strong>. Each window: 100 ps equilibration + 1 ns production. Total FEP compute: ~120 ns.</p>

${ex('l','HOW I got to FEP ‚Äî and why these specific settings',`
<p><strong>Why FEP at all?</strong> My first attempt at quantifying binding used MM-GBSA ‚Äî a faster, cheaper method. But MM-GBSA gave a DIFFERENT ranking of mutation sensitivity than FEP did later. Reading Schr√∂dinger's FEP+ papers showed MM-GBSA errors of 2-5 kcal/mol ‚Äî too imprecise when the ŒîŒîG I'm measuring is 2.34 kcal/mol. A pharma researcher on Twitter recommended "if you want to compare WT vs mutant, FEP is the only rigorous path."</p>
<p><strong>Why 20 lambda windows?</strong> Standard in published FEP studies. Fewer (5-10) = poor overlap between adjacent states = MBAR fails. More (30-40) = diminishing returns. 20 is what Schr√∂dinger FEP+ and most academic papers use.</p>
<p><strong>Why this phase order (restraints ‚Üí charges ‚Üí shape)?</strong> From decades of FEP methodology papers. Pin the drug first (Boresch restraints), then remove charges (smooth, no singularities), then remove shape last (causes overlaps ‚Äî needs softcore potentials). Reversing the order crashes immediately.</p>
<p><strong>Why Boresch restraints?</strong> They define 6 degrees of freedom (distance + angles + dihedrals) with an analytical correction term ‚Äî no approximation needed. Claude Code selected the restraint atoms by finding stable geometric triplets.</p>
<p><strong>Why 1 ns per window?</strong> Published FEP papers use 1-5 ns. I checked convergence: first-half vs second-half energy estimates agreed within 0.3 kcal/mol. 120 windows √ó 1 ns = 120 ns total was at my compute budget limit.</p>
<p><strong>Why 2 fs (not 4 fs like MD)?</strong> Ghost-like drug states at low Œª are fragile. HMR + 4 fs contributed to endpoint catastrophe crashes. Conservative 2 fs was stable across all 120 windows.</p>
<p><strong>Why only 2 compounds?</strong> Each compound needs 60 windows (3 legs √ó 20). Total = 120 windows at ~48 GPU-hours per compound. All 148 would cost 3,500+ GPU-hours. Febuxostat and Bufadienolide represent distinct binding mechanisms (electrostatic vs hydrophobic) ‚Äî sufficient to demonstrate the principle.</p>
`)}

<h2>MBAR ‚Äî The Statistical Analysis ${au('MBAR','MBAR')}</h2>
<p>At each lambda window, you collected energy samples. But you didn't just measure energy at that one Œª value ‚Äî at each sample, you ALSO computed what the energy WOULD HAVE BEEN at all 19 other Œª values. This cross-evaluation creates a giant matrix (1,000 samples √ó 20 states = 20,000 numbers per leg).</p>
<p>MBAR (Multistate Bennett Acceptance Ratio) takes this entire matrix and computes the statistically optimal free energy estimate. It's mathematically proven to have the smallest possible error bars given the data ‚Äî the gold standard in pharmaceutical FEP.</p>

${ex('x','13 Windows Crashed ‚Äî Endpoint Catastrophe',`
<p><strong>What happened:</strong> 13 of 60 lambda windows crashed with NaN errors. All at high lambda (windows 15-19) where sterics are being removed.</p>
<p><strong>Why:</strong> ${au('endpoint_catastrophe','Endpoint catastrophe')}. At low Œª_sterics, the drug is nearly a ghost ‚Äî its van der Waals repulsion is very weak. But the initial atom coordinates were taken from the "drug fully present" simulation. Water molecules rush into the space where the solid drug was, and at ghost-level Œª, there's nothing stopping them from overlapping with the drug's remaining atoms. Overlap ‚Üí 1/r¬π¬≤ (even with softcore, the initial coordinates are too far from equilibrium) ‚Üí NaN.</p>
<p><strong>Fix: Sequential seeding.</strong> Instead of starting every window from the same coordinates, start each window from the FINAL coordinates of the previous window. Window 14 starts from window 13's last frame. Window 15 starts from window 14's. The system is already relaxed at nearby Œª ‚Äî no cold-start crashes. All 120 windows completed after this fix.</p>
`)}

${ex('w','Why FEP instead of MM-GBSA (your cheaper first attempt)',`
<p><strong>MM-GBSA:</strong> Takes snapshots from MD, replaces explicit water molecules with a smooth mathematical field (implicit solvent), and estimates binding energy. Fast (minutes), but error bars are 2-5 kcal/mol ‚Äî too imprecise for your needs.</p>
<p><strong>FEP:</strong> Simulates the full thermodynamic path with explicit water, 20 intermediate states, and MBAR statistics. Error: 0.5-1.5 kcal/mol ‚Äî pharmaceutical grade.</p>
<p><strong>Critical finding:</strong> MM-GBSA gave a DIFFERENT compound ranking than FEP. If you'd stopped at MM-GBSA, your conclusions about which drugs are mutation-sensitive would have been WRONG. The subtle water rearrangements that FEP captures are invisible to MM-GBSA's implicit solvent.</p>
`)}

<div class="pc">
<div class="pros"><p>Gold standard accuracy ‚Äî used by pharma companies</p><p>Thermodynamically exact (state function, no approximations)</p><p>8œÉ significance on Febuxostat result ‚Äî extraordinarily robust</p><p>You built it for free using OpenMM + pymbar (pharma pays $100K+/yr for Schr√∂dinger FEP+)</p></div>
<div class="cons"><p>Extremely expensive: 48 GPU-hours per compound pair</p><p>Only 2 compounds could be characterized (3,500+ GPU-hrs for all 148)</p><p>Requires careful setup (Boresch restraints, softcore parameters, sequential seeding)</p><p>Accuracy depends on force field quality</p></div>
</div>

<div class="lim"><p style="margin-top:8px">1 ns per window may be insufficient for slow protein motions. Only 2 of 148 compounds fully characterized ‚Äî broader coverage would strengthen conclusions. Force field parameters for Bufadienolide (unusual steroid scaffold) are less validated than for standard drugs. Boresch restraint atom selection can affect results. No experimental binding data exists for NOD2 to calibrate against.</p></div>

<div class="bridge">üîó FEP gives you the numbers. Now let's decode every single one on your poster ‚Äî what each value means and why it matters.</div>
`},


// ============ RESULTS ============
{id:'res',icon:'üìä',label:'7. Results',ct:`
<h1>7. Results ‚Äî Every Number on Your Poster Decoded</h1>
<p class="sub">Figure 16 is the money slide. Let's walk through every number until you can explain each one to a PhD committee.</p>

<h2>The Main Results Table (Poster Figure 16)</h2>
<div class="glow" style="border-radius:12px;border:1px solid var(--brd);margin:14px 0"><div class="glow-inner">
<table>
<tr><th>Compound</th><th>${au('delta_G','ŒîG')}<sub>bind</sub> (WT)</th><th>ŒîG<sub>bind</sub> (R702W)</th><th>${au('delta_delta_G','ŒîŒîG')}</th><th>Significance</th></tr>
<tr><td><strong>${au('febuxostat','Febuxostat')}</strong></td><td class="n">‚àí10.36 ¬± 0.18</td><td class="n">‚àí8.02 ¬± 0.19</td><td class="n" style="color:var(--red)">+2.34 ¬± 0.26</td><td class="n">~8œÉ, p < 0.001</td></tr>
<tr><td><strong>${au('bufadienolide','Bufadienolide')}</strong></td><td class="n">‚àí15.22 ¬± 0.26</td><td class="n">‚àí15.66 ¬± 0.26</td><td class="n" style="color:var(--grn)">‚àí0.44 ¬± 0.37</td><td>1.8œÉ, not significant</td></tr>
</table>
</div></div>

<h2>Let's Decode Every Single Number</h2>

<h3>What does "ŒîG = ‚àí10.36" mean?</h3>
<div class="c ca">
<p>${au('delta_G','ŒîG')} is the Gibbs free energy of binding ‚Äî the total energy balance of the drug entering the pocket (all the good contacts minus the freedom penalty, as explained in FEP section). The unit is ${au('kcal_mol','kcal/mol')} (kilocalories per mole ‚Äî a standard energy unit in biochemistry).</p>
<p><strong>Negative = binding happens.</strong> ‚àí10.36 means the drug-protein complex is 10.36 kcal/mol more stable than the drug floating free in water. For context: typical drug binding ranges from ‚àí6 to ‚àí10 kcal/mol. Anything more negative than ‚àí8 is considered "strong binding." ‚àí10.36 is excellent.</p>
</div>

<h3>What does "¬± 0.18" mean?</h3>
<div class="c">
<p>This is the <strong>statistical uncertainty</strong> ‚Äî the error bar. You ran each lambda window for 1 nanosecond, not infinity. With finite sampling, there's always some uncertainty in the calculated value. MBAR estimates this error from the variance in the energy samples.</p>
<p>¬±0.18 kcal/mol is remarkably small. Typical FEP calculations have errors of ¬±0.5 to ¬±1.5 kcal/mol. Your low uncertainty means the simulations converged well ‚Äî they ran long enough for the energy estimates to stabilize.</p>
</div>

<h3>What does "ŒîŒîG = +2.34" mean?</h3>
<div class="c co">
<p><strong>ŒîŒîG = ŒîG(mutant) ‚àí ŒîG(wild-type) = (‚àí8.02) ‚àí (‚àí10.36) = +2.34 kcal/mol</strong></p>
<p>Positive ŒîŒîG = the drug binds WEAKER to the mutant. R702W makes Febuxostat lose 2.34 kcal/mol of binding energy. In drug discovery, anything > 1 kcal/mol difference is considered significant.</p>
<p><strong>Converting to fold-change</strong> ‚Äî how many TIMES weaker? The ${au('Boltzmann','Boltzmann')} equation connects energy to binding strength:</p>
<p>At body temperature (310 K): RT = 0.616 kcal/mol (R = gas constant, T = temperature)</p>
<p><strong>Fold-change = e<sup>(ŒîŒîG/RT)</sup> = e<sup>(2.34 / 0.616)</sup> = e<sup>3.80</sup> ‚âà <span class="n" style="font-size:1.15em">45‚Äì50 times weaker</span></strong></p>
<p>What this means practically: if Febuxostat binds wild-type NOD2 with a dissociation constant (Kd) of 10 nanomolar, it would bind R702W with Kd ‚âà 500 nanomolar. In drug development, that magnitude of affinity loss typically separates a viable drug from a failed clinical candidate.</p>
</div>

<h3>What does "8œÉ" mean?</h3>
<div class="c co">
<p><strong>œÉ (sigma)</strong> = the standard deviation of the uncertainty. Sigma level = how many standard deviations your result is away from zero (no effect):</p>
<p>œÉ level = |ŒîŒîG| / error = 2.34 / 0.26 ‚âà <strong>9œÉ</strong> (poster rounds to 8œÉ)</p>
<p>Context from other fields: in particle physics, <strong>5œÉ is considered a "discovery"</strong> (that's the threshold used to announce the Higgs boson). In drug discovery, 3œÉ is "significant." Your 8œÉ is extraordinarily robust ‚Äî the probability of this result being a random fluctuation is less than 1 in a quadrillion (p < 10‚Åª¬π‚Åµ). <strong>This is definitively not noise.</strong></p>
</div>

<h3>Bufadienolide: ŒîŒîG = ‚àí0.44 ¬± 0.37</h3>
<div class="c cg">
<p>The ‚àí0.44 slightly suggests Bufadienolide binds the mutant a tiny bit BETTER. But 0.44 / 0.37 = 1.2œÉ ‚Äî well below the 2œÉ threshold for statistical significance. This means the value is <strong>indistinguishable from zero</strong> within the uncertainty of the measurement. The safe conclusion: R702W has <strong>no significant effect</strong> on Bufadienolide binding.</p>
</div>

<h2>WHY They Behave Differently ‚Äî The Mechanism</h2>

<div class="vs">
<div class="vl">
<h3 style="color:var(--red)">Febuxostat ‚Äî BREAKS with the mutation</h3>
<p>Febuxostat's binding depends on <strong>hydrogen bonds and electrostatic contacts</strong> with ${au('ASP1011','ASP1011')} (aspartate at position 1011 ‚Äî a negatively charged amino acid in the pocket).</p>
<p>H-bonds require PRECISE geometry: the two atoms must be within 3.5 √Ö AND at the right angle (120-180¬∞). When R702W rigidifies the protein, the pocket shifts subtly ‚Äî just 0.5-1.0 √Ö. That's enough to break the H-bond geometry. Broken H-bonds = lost enthalpy = +2.34 kcal/mol penalty = 50√ó weaker binding.</p>
</div>
<div class="vw">
<h3 style="color:var(--grn)">Bufadienolide ‚Äî SURVIVES the mutation</h3>
<p>Bufadienolide's binding depends on <strong>hydrophobic (van der Waals) contacts</strong> with nonpolar amino acids (leucine, isoleucine, valine) lining the pocket.</p>
<p>Hydrophobic contacts are GEOMETRY-TOLERANT ‚Äî they work as long as oily surfaces are within 4-6 √Ö, without needing precise angles. Even though R702W rigidifies the pocket and shifts things slightly, the nonpolar surface remains similar enough. Contacts survive ‚Üí binding energy barely changes ‚Üí ŒîŒîG ‚âà 0.</p>
</div>
</div>

<div class="ky">
<p style="font-size:1.05em"><strong>üéØ THE DISCOVERY:</strong> The same mutation has OPPOSITE effects on different drugs. Febuxostat loses 50√ó affinity. Bufadienolide is unaffected. This means mutation effects on drug binding are <strong>ligand-dependent</strong>.</p>
<p><strong>The implication:</strong> You can't develop a "one-size-fits-all NOD2 drug." Drug selection must account for the patient's genotype. If you carry R702W ‚Üí Febuxostat-type drugs (H-bond dependent) won't work ‚Üí choose Bufadienolide-type drugs (hydrophobic) instead. This is ${au('pharmacogenomics','pharmacogenomics')} ‚Äî choosing drugs based on genetics. That's ${au('precision_medicine','precision medicine')}.</p>
<p><strong>Novel:</strong> No prior reports of Bufadienolide interacting with NOD2 exist anywhere in the literature. This is a genuinely new finding.</p>
</div>
`},


// ============ PRESENTATION ============
{id:'talk',icon:'üé§',label:'8. Presentation',ct:`
<h1>8. Your Pitch + 12 Judge Q&As</h1>
<p class="sub">35 points ‚Äî the single biggest scoring category. Practice these answers until they're automatic.</p>

<div class="rubric">üìã ISEF: Presentation = 35/100 points (Poster 10 + Interview 25)</div>

<h2>60-Second Pitch</h2>
<div class="c ca">
<p><em>"I carry the R702W variant of NOD2 ‚Äî a mutation linked to Crohn's disease. Current treatments like Remicade target downstream inflammation, but not the defective sensor itself. I built a computational drug discovery pipeline starting with 9,566 compounds, using CNN-based docking, machine learning with scaffold-split validation, and 520 nanoseconds of molecular dynamics.</em></p>
<p><em>The key finding: Free Energy Perturbation across 120 lambda windows shows Febuxostat binds 50-fold weaker to the mutant protein at 8-sigma significance, while Bufadienolide ‚Äî a natural cardiac glycoside ‚Äî is completely unaffected. Mutation effects are ligand-dependent, meaning drug selection should match patient genotype. That's pharmacogenomic precision medicine."</em></p>
</div>

<h2>Full Judge Q&A Bank</h2>

${ex('j','"How did you come up with this idea?"',`
<p>"At 14, a genetic test showed I carry the R702W variant. My geneticist explained what it meant, but when I asked about drugs that target NOD2 directly, the answer was 'none exist.' I wanted to understand what R702W does at the molecular level and whether any existing drugs could bind NOD2 despite the mutation."</p>
`)}

${ex('j','"Why AlphaFold instead of a crystal structure?"',`
<p>"No complete crystal structure of human NOD2 exists. PDB entry 5IRM covers only the CARD and NBD domains ‚Äî residues 1 through 577. The LRR domain where our drugs bind, residues 744 to 1040, is completely absent. AlphaFold2 predicted full-length NOD2 with confidence scores above 90 in the LRR region ‚Äî indicating reliability comparable to approximately 2-Angstrom experimental resolution. We acknowledge this is a limitation and plan to validate with experimental structures when available."</p>
`)}

${ex('j','"How do you know the ML isn\'t memorizing?"',`
<p>"Three controls. First, scaffold-split cross-validation: no molecule in the test set shares a core backbone with any training molecule, so the model must generalize to entirely new chemical families. Second, shuffled-label control: randomize labels, retrain identically, AUC drops to 0.50 ‚Äî pure chance. Third, we caught our own data leakage: random splits initially gave AUC 0.998. We diagnosed scaffold overlap as the cause and corrected it. The honest AUC is 0.85 to 0.93."</p>
`)}

${ex('j','"Explain the ŒîŒîG of +2.34 in practical terms"',`
<p>"Through the Boltzmann relationship at body temperature, 2.34 kcal/mol converts to approximately 50-fold weaker binding. If Febuxostat had a dissociation constant of 10 nanomolar for wild-type NOD2, it would be about 500 nanomolar for R702W. In drug development, that magnitude of affinity loss typically separates a viable drug from a failed clinical candidate. The 8-sigma significance means this result is far beyond statistical noise."</p>
`)}

${ex('j','"How does a mutation 79 Angstroms away affect binding?"',`
<p>"Classic allosteric mechanism, directly supported by our MD data. Apo simulations show R702W reduces backbone RMSD from 4.05 to 3.27 Angstroms ‚Äî the mutant is quantifiably more rigid. Wild-type visits large conformations above 5 Angstroms in 12.6% of frames; R702W never does. This rigidification propagates through the HD2-to-LRR helical interface. Febuxostat loses its hydrogen bond network with ASP1011 because the pocket geometry shifts. Bufadienolide's hydrophobic contacts are shape-tolerant and survive."</p>
`)}

${ex('j','"Did AI write your code?"',`
<p>"Claude Code CLI helped implement and debug ‚Äî OpenMM setup scripts, CUDA errors, batch processing. The scientific decisions were mine: which methods to use, what parameters to set, how to interpret results, and how to design the pipeline. Every AI interaction is timestamped in my logbook with a dedicated AI Prompt Log appendix. I can show you specific examples of what I asked AI versus what I decided independently."</p>
`)}

${ex('j','"What are the limitations?"',`
<p>"Five main ones. First, this is entirely computational ‚Äî no experimental validation yet. Second, the protein structure comes from AlphaFold2 rather than crystallography. Third, only R702W was tested ‚Äî two other Crohn's-associated mutations, G908R and 1007fs, remain unexplored. Fourth, only 2 compounds went through FEP due to computational cost. Fifth, binding doesn't prove functional rescue ‚Äî a drug could bind NOD2 without actually restoring its bacterial sensing."</p>
`)}

${ex('j','"What would you do next?"',`
<p>"Three experimental approaches. SPR ‚Äî surface plasmon resonance ‚Äî for binding kinetics, confirming the predicted 50-fold affinity difference. ITC ‚Äî isothermal titration calorimetry ‚Äî to decompose binding into enthalpy and entropy, testing whether Febuxostat's penalty is enthalpic as we predict. HDX mass spectrometry to map which residues change dynamics upon drug binding, directly testing the allosteric mechanism. Computationally, extend FEP to G908R and 1007fs for a complete mutation sensitivity profile. And cell-based NF-Œ∫B reporter assays to test functional rescue."</p>
`)}

${ex('j','"What is Febuxostat normally used for?"',`
<p>"It's an FDA-approved xanthine oxidase inhibitor prescribed for gout ‚Äî it reduces uric acid production. No known connection to NOD2 or Crohn's. This is a drug repurposing approach: finding new therapeutic applications for existing approved drugs. The advantage is that safety data and pharmacokinetic profiles already exist, so if it showed promise for NOD2, clinical development would be years faster than designing a new molecule from scratch."</p>
`)}

${ex('j','"Why only 2 compounds through FEP?"',`
<p>"FEP requires 120 lambda windows total ‚Äî each with 1 nanosecond of MD simulation. On my RTX 4060 Ti, each compound pair required about 48 GPU-hours. Running all 148 ADMET-passing compounds would take over 3,500 GPU-hours. The two selected represent fundamentally different binding mechanisms ‚Äî electrostatic-dependent versus hydrophobic-dependent ‚Äî which is sufficient to demonstrate the principle that mutation effects are ligand-specific."</p>
`)}

${ex('j','"Why is Crohn\'s inflammatory if the mutation reduces sensing?"',`
<p>"The paradox: initial immune deficiency leads to chronic inflammation. When NOD2 can't detect bacteria through MDP sensing, the innate immune system fails to clear bacteria early. Bacteria proliferate, and the body compensates through alternative pathways ‚Äî Toll-like receptors, the inflammasome ‚Äî which trigger a massive, sustained inflammatory response. It's a fire alarm with dead batteries: the fire smolders until someone calls every fire department in the city."</p>
`)}

${ex('j','"What are your variables and controls?"',`
<p>"Independent variables: compound identity and genotype ‚Äî wild-type versus R702W. Dependent variables: ŒîG binding free energy, backbone RMSD, pocket occupancy, hydrogen bond count. Controls: shuffled-label negative control in ML (AUC drops to 0.50). Non-binding compound in MD (leaves pocket by 5 nanoseconds). Apo simulations ‚Äî no drug ‚Äî to prove the allosteric effect exists independently of drug binding."</p>
`)}

<h2>Curveball Questions by Judge Type</h2>
<p>At Fort Worth regional, your judges could be biologists, MDs, chemists, engineers, or computer scientists. They'll ask from THEIR expertise. A biologist won't ask about lambda windows. An MD won't care about XGBoost hyperparameters. Be ready for ALL of them.</p>

<h3>üß¨ If the Judge is a BIOLOGIST / BIOCHEMIST</h3>
<p><em>They know proteins, signaling, and disease. They'll push your biology hard.</em></p>

${ex('j','"What\'s the protonation state of ASP1011 at physiological pH? Does it matter?"',`
<p>"Aspartate has a pKa around 3.9, so at physiological pH of 7.4 it's fully deprotonated ‚Äî carrying a negative charge. Yes, this matters a lot. Febuxostat forms hydrogen bonds with that negative carboxylate group. If the protonation state were wrong in our simulation, the entire electrostatic interaction profile would be different. OpenMM's force field assigns standard protonation states at pH 7, which correctly deprotonates ASP1011."</p>
<p><em>If you don't know pKa: "Aspartate is negatively charged at body pH. Our force field assigns the standard charged state. I haven't done constant-pH simulations to test pH sensitivity ‚Äî that would be good future work."</em></p>
`)}

${ex('j','"NOD2 forms oligomers when activated. Did you account for that?"',`
<p>"No ‚Äî I simulated a single NOD2 monomer. In the cell, MDP binding triggers NOD2 self-oligomerization through the NBD domain, which brings CARD domains together to recruit RIPK2. My drugs bind the LRR domain, which is the sensing domain, not the oligomerization interface. So monomer simulation is appropriate for studying drug-LRR interactions specifically. But you're right that oligomerization could indirectly affect LRR pocket shape ‚Äî that's a limitation I haven't explored."</p>
`)}

${ex('j','"You said R702W reduces NF-Œ∫B signaling. How much? Is it a complete loss of function?"',`
<p>"It's partial, not complete. Published studies show R702W reduces MDP-induced NF-Œ∫B activation by roughly 50-70% compared to wild-type ‚Äî it's a hypomorphic mutation, not a null. Homozygous R702W carriers have more severe reduction than heterozygous. This partial loss is actually what makes drug modulation plausible ‚Äî if NOD2 were completely non-functional, binding a drug to LRR wouldn't help. The remaining 30-50% function suggests the protein is still structurally intact enough to be a viable drug target."</p>
<p><em>If pressed further: "I'm heterozygous for R702W, so I have one functional copy and one impaired copy. The impaired copy still produces protein ‚Äî it just doesn't sense MDP as efficiently."</em></p>
`)}

${ex('j','"Have you considered post-translational modifications of NOD2?"',`
<p>"NOD2 is known to be ubiquitinated and phosphorylated, which regulate its stability and signaling. My AlphaFold structure doesn't include these modifications ‚Äî it predicts the unmodified sequence. If phosphorylation near the LRR domain changes the local charge distribution, it could affect drug binding. This is a limitation I should acknowledge ‚Äî the simulated protein represents the unmodified baseline state."</p>
<p><em>If you don't know details: "I'm aware NOD2 undergoes modifications that regulate its activity, but I haven't modeled them. My simulations represent the unmodified protein. That's a fair limitation."</em></p>
`)}

${ex('j','"What about the gut microbiome? Wouldn\'t modulating NOD2 disrupt microbial balance?"',`
<p>"Great question. NOD2 helps maintain homeostasis between the host immune system and gut bacteria. A drug that hyperactivates NOD2 could trigger excessive inflammation. A drug that further suppresses it could worsen bacterial overgrowth. The ideal drug would RESTORE normal MDP sensing without overshooting. My project identifies compounds that bind the LRR pocket ‚Äî whether they activate, inhibit, or stabilize NOD2 would need to be tested in cell-based NF-Œ∫B reporter assays. That's a key next step."</p>
`)}

<h3>ü©∫ If the Judge is a PHYSICIAN / MD</h3>
<p><em>They care about patients, clinical relevance, and whether this could ever help someone. Less interested in computational details.</em></p>

${ex('j','"How would this actually help a Crohn\'s patient sitting in my clinic?"',`
<p>"Right now, a gastroenterologist prescribes biologics like Remicade without knowing the patient's NOD2 genotype ‚Äî it's one-size-fits-all. My work suggests that binding efficacy depends on the specific mutation. If validated experimentally, a clinician could genotype the patient, see R702W, and know that electrostatic-dependent drugs like Febuxostat won't bind as well ‚Äî choose a hydrophobic-contact drug like Bufadienolide instead. That's pharmacogenomic-guided prescribing, similar to how HER2 status guides breast cancer treatment."</p>
`)}

${ex('j','"Febuxostat is a gout drug. Isn\'t repurposing it for Crohn\'s a huge clinical leap?"',`
<p>"It's a big leap computationally to clinically, yes. But drug repurposing has major advantages: Febuxostat already has FDA safety data, known pharmacokinetics, established manufacturing, and years of post-market surveillance. If it showed NOD2 activity in cell assays, a clinical trial could start much faster than developing a novel molecule from scratch ‚Äî potentially years faster and millions of dollars cheaper. The clinical leap is real, but the safety shortcut is enormous."</p>
`)}

${ex('j','"You take Remicade. If your project succeeds, would you switch?"',`
<p>"Not based on computational data alone ‚Äî I'd need experimental validation first. SPR binding assays to confirm the predicted affinity difference, then cell-based NF-Œ∫B reporter assays to show functional rescue, then animal models, then clinical trials. That's a 10-15 year pipeline minimum. Remicade works for me right now. But my work could contribute to the early stages of that pipeline by identifying which compounds are worth testing experimentally."</p>
`)}

${ex('j','"What about the other Crohn\'s mutations ‚Äî G908R and the frameshift?"',`
<p>"G908R is in the same LRR domain but at a different position ‚Äî it could affect the pocket differently. 1007fs (Leu1007 frameshift) is more drastic ‚Äî it produces a truncated protein missing the last 33 amino acids of LRR, which likely destroys the pocket entirely. Extending FEP to G908R is computationally straightforward ‚Äî same pipeline, different mutation. 1007fs would require a completely different approach since the binding site may not exist. These are priority future experiments."</p>
`)}

${ex('j','"Is there any clinical evidence that NOD2 is actually druggable?"',`
<p>"Honestly, no ‚Äî there are no approved or clinical-stage NOD2-targeting drugs. That's both the limitation and the novelty of this project. NOD2 has been considered 'undruggable' partly because it's intracellular and partly because no one had characterized a binding pocket computationally. My AlphaFold-based approach identified a pocket in the LRR domain and showed compounds can occupy it stably. Whether this translates to druggability in the clinical sense requires experimental confirmation. But the computational evidence suggests the pocket is real and accessible."</p>
`)}

<h3>üíª If the Judge is a COMPUTER SCIENTIST / ENGINEER</h3>
<p><em>They understand ML, code, and computation. They'll test your technical depth and AI usage.</em></p>

${ex('j','"Your AUC is 0.85-0.93. What\'s the precision-recall curve look like? AUC-ROC can be misleading with imbalanced data."',`
<p>"You're right that AUC-ROC can be optimistic with class imbalance. My dataset is balanced by design ‚Äî I took top 25% and bottom 25%, so roughly 50/50 split after removing the middle. With balanced classes, AUC-ROC and AUC-PR should tell similar stories. I did check precision and recall per fold ‚Äî precision ranged from 0.80-0.88 and recall from 0.82-0.90. But you raise a good point ‚Äî if I'd used a different labeling threshold (say top 10%), the imbalance would make AUC-PR more informative."</p>
<p><em>If you don't remember exact PR numbers: "My dataset is balanced by design ‚Äî equal top and bottom quartiles. So AUC-ROC isn't misleading here. But for future work with imbalanced data, AUC-PR would be the right metric."</em></p>
`)}

${ex('j','"Did you do any hyperparameter optimization, or are these just defaults?"',`
<p>"These are literature-informed defaults, not formally tuned. With only 858 pseudo-labeled samples, running Optuna or grid search would likely overfit the hyperparameters to noise in this specific dataset. I tested a few alternatives manually ‚Äî depth 3 to 12, learning rate 0.01 to 0.1 ‚Äî and confirmed the published defaults performed well. For a dataset this small, the bigger gains come from better data (experimental labels instead of pseudo-labels) rather than hyperparameter tweaking."</p>
`)}

${ex('j','"Morgan fingerprints are 2D. Why not 3D descriptors or graph neural networks?"',`
<p>"Great question. 3D conformer-based descriptors or graph neural networks like SchNet or DimeNet would capture spatial relationships that Morgan fingerprints miss ‚Äî binding is fundamentally a 3D phenomenon. I didn't use them for two reasons: first, with 858 samples, GNNs would severely overfit (they typically need tens of thousands of examples). Second, the 3D information is already captured by docking ‚Äî GNINA places molecules in 3D and scores them with a 3D CNN. My ML model's job is to find PATTERNS across the scored compounds, where 2D fingerprints work well. But for larger datasets, 3D-aware models would be better."</p>
`)}

${ex('j','"How much of this code did Claude actually write vs. you?"',`
<p>"Claude Code CLI wrote most of the implementation code ‚Äî the Python scripts for docking automation, XGBoost training, OpenMM simulation setup, and FEP lambda window configuration. What I did: chose which methods to use and why (GNINA over Vina, XGBoost over neural nets, scaffold split over random), set scientific parameters (exhaustiveness 32, grid box dimensions, which compounds to advance), interpreted results, caught the data leakage error, and designed the experimental logic. I think of it like a lab: Claude was my very fast lab technician. I was the PI deciding what experiments to run and what the results mean. Every interaction is timestamped in my logbook."</p>
`)}

${ex('j','"What if your pseudo-labels are wrong? Garbage in, garbage out."',`
<p>"That's the fundamental limitation of this approach, and I want to be upfront about it. The pseudo-labels come from GNINA docking scores, which have approximately 1.5 pKd units of error. If GNINA ranked a compound wrong ‚Äî called a real binder a non-binder ‚Äî my ML model learns that error. Two things mitigate this: first, I used the EXTREMES (top and bottom 25%), where docking is most reliable. The middle 50% is where most errors live, and I threw that away. Second, the scaffold-split AUC of 0.85-0.93 shows the model learned generalizable patterns, not just noise. But ultimately, yes ‚Äî experimental labels would be better. They just don't exist for NOD2."</p>
`)}

<h3>‚öóÔ∏è If the Judge is a CHEMIST / PHARMACOLOGIST</h3>
<p><em>They know drugs, synthesis, and binding. They'll question your compound choices and drug-likeness.</em></p>

${ex('j','"Bufadienolide is a cardiac glycoside ‚Äî it\'s toxic. How is this a drug candidate?"',`
<p>"You're right ‚Äî bufadienolides at cardiac glycoside doses are toxic (they inhibit Na+/K+ ATPase). But dose makes the poison. Several cardiac glycosides are used therapeutically at low doses ‚Äî digoxin for heart failure, for example. The bufadienolide scaffold has also been investigated for anti-inflammatory properties at sub-toxic concentrations. My finding isn't that bufadienolide IS the drug ‚Äî it's that compounds with hydrophobic, shape-tolerant binding mechanisms survive the R702W mutation. The scaffold could be optimized to retain NOD2 binding while reducing cardiac toxicity."</p>
`)}

${ex('j','"Your ADMET passed 98.7%. Doesn\'t that mean the filter is too loose?"',`
<p>"It means my starting library was already drug-like. The FDA-approved drugs passed Lipinski by definition ‚Äî they're already approved oral medications. The natural products from COCONUT were pre-filtered for drug-likeness. If I'd started with a random chemical library (like ZINC with 750 million compounds), the pass rate would be much lower. The 2 failures were genuine PAINS alerts ‚Äî Michael acceptors that would give false positives in any assay. The high pass rate is a feature of the library, not a bug in the filter."</p>
`)}

${ex('j','"What\'s the synthetic accessibility of your top compounds?"',`
<p>"Febuxostat is already manufactured at scale ‚Äî it's a commercial FDA drug, so synthetic accessibility is not a concern. Bufadienolide is a natural product with a complex steroid skeleton ‚Äî harder to synthesize de novo, but it can be extracted from natural sources (toad venom, plants). If we wanted to optimize the bufadienolide scaffold, synthetic accessibility would become important. RDKit has an SA score (1-10 scale) ‚Äî I could calculate it but haven't included it in the current analysis. Good suggestion for future work."</p>
`)}

<h3>üéØ GOTCHA Questions ‚Äî Testing If You Really Understand</h3>
<p><em>These test reasoning, not memorization. The judge wants to see you THINK.</em></p>

${ex('j','"If your mutation is 79 √Öngstr√∂ms away, maybe the effect is just noise?"',`
<p>"Three independent lines of evidence argue against noise. First, the APO simulations ‚Äî no drug present ‚Äî show wild-type RMSD of 4.05 √Ö versus R702W at 3.27 √Ö. The rigidification exists independently of any drug. Second, Febuxostat shows 8-sigma significance ‚Äî the probability of this being random noise is less than 1 in 10 to the 15th. Third, the effect is mechanistically consistent: hydrogen bond contacts with ASP1011 break because the pocket geometry shifts, while hydrophobic contacts with LEU/ILE/VAL survive because they're shape-tolerant. Noise wouldn't produce a coherent mechanism."</p>
`)}

${ex('j','"You tested 2 compounds through FEP. How do you know this pattern generalizes?"',`
<p>"Honestly, I can't prove it generalizes from just 2 examples. What I can say is that these 2 represent the two major binding mechanisms present in the top hits: electrostatic-dependent (Febuxostat-like) and hydrophobic-dependent (Bufadienolide-like). The mechanism-based explanation ‚Äî H-bonds are geometry-sensitive, hydrophobic contacts are geometry-tolerant ‚Äî should apply to other compounds in each class. But confirming this requires running FEP on more compounds, which I plan to do. This is a proof-of-concept, not a comprehensive survey."</p>
`)}

${ex('j','"What if AlphaFold got the pocket wrong?"',`
<p>"Then my entire docking and MD analysis would be based on the wrong structure ‚Äî that's the single biggest risk in this project. I mitigate it three ways. First, pLDDT confidence in the LRR region exceeds 90, which correlates with experimental resolution around 2 Angstroms. Second, the pocket I identified is on the concave face of the LRR domain, which is the conserved ligand-binding surface across LRR proteins in general ‚Äî structurally expected. Third, my MD simulations show the pocket is stable over 20 nanoseconds ‚Äî it doesn't collapse or reshape, suggesting it's a real energy minimum. But ultimately, an experimental structure (cryo-EM or X-ray) would be definitive validation."</p>
`)}

${ex('j','"50-fold weaker sounds dramatic. But what if the absolute affinity is already so strong that 50-fold weaker is still enough?"',`
<p>"Excellent point. If Febuxostat binds wild-type at 1 nanomolar, then 50-fold weaker = 50 nanomolar ‚Äî still a viable drug. If it binds at 1 micromolar, then 50-fold weaker = 50 micromolar ‚Äî completely useless. Without experimental Kd measurements, I can't distinguish these scenarios. My ŒîG of negative 10.36 kcal/mol suggests low-nanomolar affinity, which would make 50-fold weaker still potentially useful. But the absolute values from FEP typically have systematic errors of 1-2 kcal/mol, so the true affinity could be different. This is exactly why SPR experimental validation is the critical next step."</p>
`)}

${ex('j','"You ran 520 nanoseconds total. Some papers run microseconds. Is 20 ns enough?"',`
<p>"For the specific question I'm asking ‚Äî does the drug stay in the pocket ‚Äî 20 nanoseconds is sufficient. My negative control compound left the pocket by 5 nanoseconds, proving the simulation can detect unbinding on this timescale. For questions about slow conformational changes like protein folding or domain rearrangements, 20 nanoseconds would be inadequate ‚Äî those happen on microsecond to millisecond timescales, which is 1,000 to 1,000,000 times longer. I chose 20 ns because it answers MY question, it's feasible on a single consumer GPU, and 3 replicates provide statistical confidence. Longer would be better but wasn't necessary for the conclusions I'm drawing."</p>
`)}

${ex('j','"Isn\'t this just a glorified virtual screen? What\'s actually novel?"',`
<p>"The virtual screen is the first half. Every drug discovery paper does some form of screening. What's novel is the second half: using FEP to quantify how a specific patient mutation changes drug binding, and discovering that the effect is ligand-dependent. Nobody has shown that the same NOD2 mutation makes one drug 50-fold weaker while leaving another unaffected. That finding ‚Äî mutation effects depend on binding mechanism ‚Äî is the scientific contribution. It transforms a standard screening paper into a pharmacogenomics study. The practical implication is that NOD2 drug selection should be genotype-guided."</p>
`)}

<h2>Curveball Questions by Judge Type</h2>
<p class="sub">Not every judge has the same background. An MD won't know lambda windows. A CS professor won't care about cytokines. Here's how to read the room and calibrate.</p>

<div class="c ca">
<p><strong>How to tell who you're talking to:</strong> Look at their badge or ask "What's your background?" at the start. It's not rude ‚Äî it helps you calibrate. If they say "I'm a gastroenterologist," lead with the Crohn's story, not the MBAR math. If they say "I'm a computer scientist," lead with the pipeline architecture and ML validation.</p>
</div>

<h3>ü©∫ The MD / Clinician ‚Äî Cares About Patients</h3>
<p><em>They understand Crohn's and Remicade. They DON'T know what FEP or lambda windows are. Explain computational methods in clinical terms.</em></p>

${ex('j','"How would this actually help a Crohn\'s patient?"',`
<p>"Right now, every Crohn's patient gets the same drugs regardless of genotype. If our computational predictions hold up experimentally, a patient carrying R702W could be steered away from drugs that rely on precise hydrogen bonding with the NOD2 pocket ‚Äî since the mutation disrupts that geometry ‚Äî and toward drugs that use hydrophobic contacts, which survive the shape change. It's the same principle as HER2 testing in breast cancer: genotype determines which drug works."</p>
`)}

${ex('j','"Febuxostat is a gout drug. Has anyone ever tried it for Crohn\'s?"',`
<p>"Not that I've found in the literature. There's no published connection between febuxostat and NOD2 or Crohn's. That's what makes this a drug repurposing discovery ‚Äî finding a new use for an existing approved drug. The advantage is that safety and pharmacokinetic data already exist from its gout approval, so if it showed promise for NOD2, clinical development would skip Phase 1 safety trials entirely."</p>
`)}

${ex('j','"Bufadienolide is a cardiac glycoside ‚Äî isn\'t that toxic?"',`
<p>"Great question. Cardiac glycosides like digoxin ARE used clinically at controlled doses ‚Äî they have a narrow therapeutic window. Bufadienolide specifically is found in traditional Chinese medicine preparations. The toxicity concern is real and would need to be addressed in dose-finding studies. But the key finding isn't that Bufadienolide itself should become a Crohn's drug ‚Äî it's that its BINDING MECHANISM (hydrophobic, geometry-tolerant) represents a class of interactions that survive the R702W mutation. Medicinal chemists could design safer analogs with the same binding mode."</p>
`)}

${ex('j','"Your simulations are 20 nanoseconds. Proteins fold on microsecond timescales. Isn\'t that too short?"',`
<p>"Yes, 20 nanoseconds is short compared to full protein folding or large conformational changes. But I'm not trying to observe folding ‚Äî I'm measuring whether a drug stays in a specific pocket. My negative control compound drifted out by 5 nanoseconds, confirming that 20 ns is long enough to distinguish binders from non-binders. For the allosteric rigidification effect, the RMSD difference between wild-type and R702W was already clear within the first 5 ns and stable throughout. Longer simulations ‚Äî 100 ns or microseconds ‚Äî would strengthen the results, and that's planned future work."</p>
`)}

${ex('j','"What about the other NOD2 mutations ‚Äî G908R and 1007fs?"',`
<p>"They're the next priority. G908R is in the same LRR domain but a different location, so it may affect the pocket differently. 1007fs is a frameshift that truncates the entire LRR domain ‚Äî it's a fundamentally different mutation that probably eliminates the binding pocket entirely, which would mean a completely different therapeutic strategy. I acknowledge this is a limitation ‚Äî testing all three would give a complete picture of NOD2 pharmacogenomics."</p>
`)}

<h3>üíª The CS / Data Science Judge ‚Äî Cares About Your Pipeline</h3>
<p><em>They understand ML, AUC, data leakage. They DON'T know what a force field is. Explain biology simply, computational methods in detail.</em></p>

${ex('j','"Why XGBoost and not a deep learning model? You only have 858 samples."',`
<p>"Exactly ‚Äî 858 samples is too small for deep learning. Neural networks with millions of parameters would memorize 858 datapoints instantly. XGBoost works well on small tabular datasets because each tree is shallow (max depth 6 = 64 leaves) and regularized (subsample 0.8, colsample 0.8). It's the standard choice for small-n biological datasets ‚Äî it wins most Kaggle competitions on tabular data. If I had 100,000+ experimental binding measurements, I'd use a graph neural network instead."</p>
`)}

${ex('j','"Your pseudo-labels come from docking scores. Isn\'t that circular ‚Äî ML trained on another model\'s predictions?"',`
<p>"It IS circular if you treat the ML predictions as ground truth. I don't. The pseudo-labels are a first-pass filter ‚Äî they capture the docking model's pattern in a faster, feature-interpretable form. The real validation comes AFTER ML: molecular dynamics (does it physically stay?) and FEP (what's the actual binding energy?). The ML is a ranking tool, not the final answer. And the scaffold-split cross-validation ensures the ML at least generalizes to new chemical families, not just memorized scaffolds."</p>
`)}

${ex('j','"How do you know your CNN docking scores aren\'t just predicting molecular size?"',`
<p>"Legitimate concern ‚Äî larger molecules tend to score better in docking because they make more contacts. That's why the ML features include molecular weight as an explicit descriptor and why I stratified by molecular weight during pseudo-labeling. The SHAP feature importance analysis shows that specific Morgan fingerprint bits (encoding chemical substructures) are more important than size alone. And critically, the scaffold-split ensures the model can't just learn 'big scaffold X = good score.'"</p>
`)}

${ex('j','"You used Claude Code to write your scripts. How much of the computational work is actually yours?"',`
<p>"Claude Code is a tool, like using a calculator for math. I made every scientific decision: which methods to use, what parameters to set, which compounds to advance, how to interpret results, and how to design controls. Claude helped translate those decisions into working Python code and debug CUDA errors. I could hand you my logbook right now and show you timestamped entries of every prompt I sent and every decision I made independently. The analogy is: I'm the architect who designed the building. Claude is the construction crew that poured the concrete."</p>
`)}

${ex('j','"What would you do with a larger compute budget?"',`
<p>"Three things. First, run FEP on all 148 ADMET-passing compounds instead of just 2 ‚Äî that's about 3,500 GPU-hours, or roughly $500 on cloud GPUs. Second, extend MD simulations to 100-200 ns per system for better sampling of slow conformational changes. Third, apply the entire pipeline to G908R and 1007fs mutants for a complete pharmacogenomic map. The pipeline scales linearly ‚Äî the bottleneck is purely computational cost, not methodology."</p>
`)}

<h3>üß™ The Chemistry / Biochemistry Judge ‚Äî Cares About Your Methods</h3>
<p><em>They understand force fields and thermodynamics. They'll probe whether you REALLY know the physics or just ran scripts.</em></p>

${ex('j','"What\'s the protonation state of ASP1011 at physiological pH?"',`
<p>"Aspartate has a pKa of about 3.7 for the side chain carboxyl group. At physiological pH of 7.4, that's well above the pKa, so the side chain is deprotonated and carries a negative charge. This is the standard protonation state assigned by OpenMM's force field preparation. I didn't do explicit pKa calculations with tools like PROPKA or H++ ‚Äî that's a valid limitation. If the local environment shifts the pKa significantly, it could affect the electrostatic interactions I'm measuring."</p>
<p><em>If you don't know: "The standard deprotonated state at pH 7.4. I used the default protonation assignment from the force field but didn't run explicit pKa predictions ‚Äî that's something I'd add in future work."</em></p>
`)}

${ex('j','"Can you explain what a softcore potential is and why you need it?"',`
<p>"In normal van der Waals calculations, the repulsion between two atoms goes as 1/r¬π¬≤. When r approaches zero ‚Äî which happens during FEP when a drug is being 'disappeared' and other atoms move into its space ‚Äî this becomes essentially infinite, which crashes the simulation. A softcore potential modifies the equation to cap the repulsion at a finite maximum value, even at r = 0. Mathematically, it replaces r with something like (Œ±¬∑œÉ‚Å∂¬∑Œª + r‚Å∂) so the denominator never hits zero. I used the standard OpenMM softcore implementation."</p>
`)}

${ex('j','"Your error bars are ¬± 0.18 and ¬± 0.19 kcal/mol. How did MBAR calculate those?"',`
<p>"MBAR computes the statistical uncertainty from the variance of the energy samples across all lambda windows. At each window, I collected 1,000 energy snapshots. MBAR uses the overlap between adjacent windows ‚Äî how well the energy distributions from window 5 overlap with window 6 ‚Äî to estimate how reliably it can interpolate the free energy. Good overlap = small error bars. My error bars being under 0.2 kcal/mol indicates good convergence. If they were above 1 kcal/mol, I'd know the windows weren't sampled long enough."</p>
`)}

${ex('j','"Have you done any convergence analysis on your FEP results?"',`
<p>"Yes, I checked convergence two ways. First, I compared the free energy estimate from the first half of each 1 ns window versus the second half ‚Äî they agreed within 0.3 kcal/mol, suggesting the simulations had equilibrated. Second, the MBAR error bars themselves are a convergence indicator ‚Äî small error bars mean the energy sampling was sufficient. A more rigorous approach would be block averaging or time-series analysis, which I haven't done but would add for a journal publication."</p>
`)}

${ex('j','"Why didn\'t you use enhanced sampling methods like metadynamics or replica exchange?"',`
<p>"For the FEP calculations, the lambda-based approach with 20 windows is already an enhanced sampling method ‚Äî it samples along the alchemical coordinate. For the standard MD simulations, 20 ns plain MD was sufficient because I'm asking a simple question: does the drug stay or leave? My negative control left by 5 ns. Enhanced sampling methods like metadynamics or REST2 would help if I were trying to observe rare events like drug unbinding from a tight pocket, but that wasn't my question. If I were studying binding kinetics ‚Äî how fast the drug enters and leaves ‚Äî then enhanced sampling would be essential."</p>
`)}

${ex('j','"How reliable is AlphaFold2 for a target you\'ve never seen crystallized?"',`
<p>"AlphaFold2's confidence score (pLDDT) in the LRR region is above 90, which correlates with experimental resolution of approximately 2 √Öngstr√∂ms or better based on the AlphaFold validation studies. However, pLDDT measures structural confidence, not necessarily binding pocket accuracy ‚Äî subtle side chain rotamers in the pocket could differ from reality. My MD simulations allow the structure to relax and find its preferred conformation, which partially addresses this. But ultimately, an experimental crystal or cryo-EM structure would be the definitive test. I acknowledge this as my biggest limitation."</p>
`)}

<h3>üî¨ The "I Don\'t Know This Field" Judge ‚Äî Needs the Big Picture</h3>
<p><em>This is the engineer, the physicist, or the behavioral scientist assigned to your category because the pool was small. They need a compelling narrative, not technical details.</em></p>

${ex('j','"I\'m not familiar with this area. Can you explain what you did and why it matters ‚Äî simply?"',`
<p>"I have Crohn's disease, caused by a mutation in a gene called NOD2. No drugs target NOD2 directly. I used a computer to test 9,566 existing drugs against NOD2 and found that the same mutation affects different drugs differently ‚Äî one drug loses 50 times its effectiveness, while another drug is completely unaffected. This means doctors shouldn't prescribe the same drug to every Crohn's patient. Instead, they should check the patient's genetic variant first and choose a drug that works despite that specific mutation. That's called precision medicine."</p>
<p><em>Then let THEM ask follow-up questions. Don't volunteer technical details unless asked.</em></p>
`)}

${ex('j','"What makes this different from what\'s already been done?"',`
<p>"Three things are genuinely new. First, nobody has ever screened drugs against the NOD2 protein ‚Äî the world's biggest drug database has zero binding data for it. Second, nobody has quantified how the R702W mutation changes drug binding at this level of precision. Third, the finding that mutation effects are ligand-dependent ‚Äî that the same mutation helps one drug and hurts another ‚Äî hasn't been reported for NOD2. The concept of pharmacogenomics isn't new, but applying it to this specific target is."</p>
`)}

${ex('j','"How confident are you in these results without lab validation?"',`
<p>"I'm confident in the COMPUTATIONAL results ‚Äî the statistics are robust (8 sigma, well beyond chance). But I'm appropriately uncertain about whether these predictions will hold up in a test tube. History shows that computational predictions are right about 50-70% of the time when validated experimentally. That's why my next steps are specific lab experiments: SPR for binding kinetics, ITC for thermodynamics, and cell-based assays for function. The computational work narrows 9,566 candidates down to 2 ‚Äî the expensive lab work then confirms or disproves those 2."</p>
`)}

<h3>üß† Deep Curveballs ‚Äî Any Judge Type</h3>
<p><em>These test whether you understand the science beyond what's on the poster. The honest answer is sometimes "I don't know."</em></p>

${ex('j','"Could your binding results be an artifact of the AlphaFold structure?"',`
<p>"Yes, potentially. AlphaFold predicts a single static structure ‚Äî the 'most likely' conformation. If the real pocket looks slightly different, my docking scores and even the FEP energies could shift. However: my MD simulations allowed the structure to relax for 20 nanoseconds before measuring anything. The final pocket conformation is the simulation's equilibrium, not just AlphaFold's prediction. And the RELATIVE comparison (wild-type vs mutant) partially cancels systematic AlphaFold errors since both start from the same base structure. But I absolutely acknowledge this as a limitation."</p>
`)}

${ex('j','"What if the drug binds somewhere else on NOD2, not in the LRR pocket?"',`
<p>"That's a real possibility I haven't addressed. I docked into one specific pocket ‚Äî the concave LRR face where MDP sensing occurs. NOD2 has other potential binding sites, including the NBD ATPase pocket and the CARD-CARD interface. A more comprehensive study would do blind docking across the entire protein surface, or use tools like FPocket to identify all druggable cavities. My results are specific to this one pocket, and I should be transparent about that."</p>
`)}

${ex('j','"Your 50-fold number comes from the Boltzmann equation. What assumptions does that make?"',`
<p>"The Boltzmann conversion from ŒîŒîG to fold-change assumes equilibrium binding ‚Äî that the drug has had enough time to reach its steady-state distribution between bound and free states. It also assumes the binding is a simple two-state process (bound or not bound), which ignores intermediate states or multiple binding modes. And it assumes my ŒîŒîG value is accurate ‚Äî the ¬±0.26 kcal/mol error bar translates to about 1.5-fold uncertainty on the fold-change (so 50-fold could really be 33-fold to 75-fold). The core conclusion ‚Äî dramatically weaker binding ‚Äî holds regardless of these uncertainties."</p>
`)}

${ex('j','"Have you considered water molecules in the binding site?"',`
<p>"In the docking step, water was ignored ‚Äî GNINA docks into a dry pocket, which is a known limitation. In the MD simulations, the pocket IS fully solvated ‚Äî roughly 65,000 water molecules surround the protein, and water freely enters and exits the pocket during the simulation. In FEP, explicit water is critical ‚Äî the thermodynamic cycle measures how much it costs to remove the drug from water versus from the protein. So my later, more accurate methods DO account for water, even if the initial docking filter doesn't."</p>
`)}

${ex('j','"If you had unlimited resources, what single experiment would most strengthen your conclusions?"',`
<p>"Surface Plasmon Resonance ‚Äî SPR. It would give me the experimental Kd (binding affinity) for both compounds against both wild-type and R702W NOD2 protein. If SPR shows Febuxostat has a 50-fold weaker Kd for R702W, exactly matching my FEP prediction, that would validate the entire computational pipeline. It's one experiment, about $5,000-10,000, and could be done in a few weeks with purified protein. That's what I'd do first."</p>
`)}

${ex('j','"What\'s the biggest thing that could be wrong with this entire project?"',`
<p>"The AlphaFold structure could be wrong in the pocket region. Everything downstream ‚Äî docking scores, ML training data, MD trajectories, FEP energies ‚Äî starts from that structure. If the real pocket has a different shape, the specific drug rankings could change. The RELATIVE finding that electrostatic binders are mutation-sensitive while hydrophobic binders are mutation-resistant is more robust ‚Äî it follows from basic physics (H-bonds need precise geometry, hydrophobic contacts don't) ‚Äî but the specific ŒîŒîG values depend on structural accuracy."</p>
`)}


<h3>üë®‚Äçüè´ If the Judge is a TEACHER / BUSINESS PERSON / NON-SPECIALIST</h3>
<p><em>They might not know what docking, FEP, or machine learning even are. They'll ask you to EXPLAIN. If you can't make a non-scientist understand, you'll lose their points. These judges are extremely common at regionals.</em></p>

${ex('j','"Can you explain what you did in simple terms ‚Äî like I\'m not a scientist?"',`
<p>"Sure. I carry a gene mutation linked to Crohn's disease ‚Äî a painful gut condition. Current drugs treat the symptoms but not the root cause. I used computers to search through nearly 10,000 existing drugs and natural compounds to find ones that might fix the broken protein in my immune system. I found that my mutation makes some drugs work 50 times worse ‚Äî but other drugs are completely unaffected by the mutation. That means someday, doctors could choose which drug to give based on a patient's DNA. Like choosing the right key for a specific lock."</p>
`)}

${ex('j','"What exactly is docking? I\'ve never heard of that."',`
<p>"Imagine you have a lock ‚Äî that's the protein in my body. And you have 10,000 keys ‚Äî those are potential drugs. Docking is when the computer tries each key in the lock, rotates it every which way, and scores how well it fits. The computer scores each one based on how snugly the key fits and how many good contact points it makes. At the end, I have a ranking from best-fitting to worst-fitting."</p>
`)}

${ex('j','"What\'s machine learning? Did the computer just do all the work?"',`
<p>"Machine learning is when you show a computer hundreds of examples ‚Äî 'this drug fits well, this one doesn't' ‚Äî and it figures out the PATTERN. Like if I showed you 500 photos of cats and 500 of dogs, eventually you'd notice patterns ‚Äî cats have pointy ears, dogs have longer snouts. My computer learned which chemical properties make a drug likely to fit the protein. I made the decisions about what data to feed it and how to test if it was actually learning vs just memorizing. The computer did the math. I did the science."</p>
`)}

${ex('j','"What was the hardest part?"',`
<p>"The crashes. On January 1st, my simulation exploded ‚Äî an atom literally flew across the virtual box because three settings that were individually fine became lethal together. NaN error, no helpful message, just 'your math produced infinity.' I spent hours debugging the physics of why it happened. That's when I learned the most ‚Äî not when things worked, but when I had to understand WHY they broke."</p>
`)}

${ex('j','"Who helped you? Be specific."',`
<p>"Three types of help. First, Claude ‚Äî an AI coding tool ‚Äî wrote most of the Python implementation code. I directed what to build and why. Every AI interaction is timestamped in my logbook. Second, I learned methods from YouTube tutorials, research papers I read during Remicade infusions, and Gemini AI for reviewing my plans. Third, my high school doesn't have a science mentor, so I was my own PI ‚Äî I designed the pipeline, chose which methods to use, interpreted the results, caught a major data error, and made every scientific decision. Nobody told me to use FEP or what compounds to test."</p>
`)}

${ex('j','"Why should anyone care about this? What\'s the real-world impact?"',`
<p>"One million Americans have Crohn's disease. About 10% carry the mutation I studied. Right now, all of them get the same drugs regardless of their genetics. My work shows that genetics change how well drugs bind to their target. If this is validated in the lab, doctors could someday run a genetic test and say 'your mutation means Drug A won't work well for you ‚Äî let's try Drug B instead.' That's precision medicine ‚Äî the right drug for the right patient. It could save years of trial-and-error treatment and reduce suffering."</p>
`)}

${ex('j','"This is all on a computer. How do you know it\'s real?"',`
<p>"Fair question. Three reasons I trust the computational results. First, my negative controls worked ‚Äî when I simulated a compound that SHOULDN'T bind, it fell out of the pocket within 5 nanoseconds, exactly as expected. When I scrambled my machine learning labels, accuracy dropped to a coin flip. The method correctly identifies what DOESN'T work. Second, FEP ‚Äî the technique I used for the final energy calculations ‚Äî is the same method pharmaceutical companies like Pfizer and Schr√∂dinger use to develop real drugs. It's not experimental ‚Äî it's industry standard. Third, my result was 8 standard deviations from zero. In particle physics, 5 standard deviations is enough to declare a discovery. But yes ‚Äî experimental confirmation is the necessary next step."</p>
`)}

${ex('j','"What would you do differently if you started over?"',`
<p>"Three things. First, I'd use scaffold-split cross-validation from day one instead of discovering data leakage after the fact ‚Äî I wasted a week thinking my model was near-perfect when it was just memorizing. Second, I'd budget more GPU time for FEP so I could test more than 2 compounds ‚Äî the pattern I found (electrostatic vs hydrophobic) needs more data points to be convincing. Third, I'd reach out to a university lab earlier to plan experimental validation in parallel with the computation. The computational and experimental work could have overlapped instead of being sequential."</p>
`)}

${ex('j','"What problems did you run into? How did you solve them?"',`
<p>"Constant problems. Linux crashed because 9,566 filenames exceeded the operating system's command-line limit ‚Äî no error message, just silence. My GPU ran at 1% because a library path was missing. My simulation exploded on New Year's Day because heavy restraints plus a fast timestep caused an atom to accelerate to infinity. An RTX 5090 GPU wouldn't run my code because the CUDA drivers were too new. My machine learning model scored 99.8% accuracy ‚Äî which turned out to be a bug, not brilliance. Each crash forced me to understand the physics or the code at a deeper level than I would have if everything worked perfectly."</p>
`)}

${ex('j','"You\'re a junior in high school. How do I know you actually understand all this and didn\'t just follow instructions?"',`
<p>"Ask me anything about the project and I'll explain the science behind it, not just the steps. I can tell you WHY exhaustiveness 32 matters for docking accuracy, WHY scaffold-split prevents data leakage, WHY hydrogen bonds break at 79 Angstroms through allosteric rigidification, and WHY 2.34 kcal/mol converts to 50-fold weaker binding through the Boltzmann equation at body temperature. I can also tell you about every crash, every mistake, and every limitation ‚Äî because I lived through all of them. Someone following instructions would give you the results. I can give you the reasoning."</p>
`)}

${ex('j','"What was the most important thing you learned?"',`
<p>"That being wrong is more valuable than being right. When my ML model scored 99.8%, I could have reported it and moved on ‚Äî it would have looked great on a poster. Instead, something felt off. I investigated, found data leakage, and corrected it. The honest score of 0.85-0.93 is less impressive on paper but infinitely more scientifically valid. The same lesson applied everywhere ‚Äî the NaN crash taught me more physics than a successful simulation ever would. Science isn't about getting clean results. It's about being honest when results are messy."</p>
`)}

${ex('j','"Could your data be explained any other way?"',`
<p>"Yes, and I should be honest about that. The ŒîŒîG of +2.34 could be partly an artifact of force field inaccuracy ‚Äî AMBER14 has systematic errors around 1 kcal/mol. The AlphaFold structure might have subtle errors in the pocket geometry. The pseudo-labels from docking could be teaching the ML model wrong patterns. Each of these could contribute noise. But: 8 sigma significance means even with substantial systematic error, the DIRECTION of the effect (mutation weakens Febuxostat binding) is almost certainly real. And the mechanistic explanation ‚Äî H-bonds break because the pocket shifts ‚Äî is physically consistent. Still, experimental confirmation is the only way to know for sure."</p>
`)}

<h2>Delivery Tips</h2>
<div class="c">
<p><strong>Point at your poster.</strong> Physically touch near each figure as you discuss it. Guide the judge's eyes.</p>
<p><strong>Slow down for key numbers:</strong> "Eight‚Ä¶ sigma‚Ä¶ significance." Pause after each major number. Let them land.</p>
<p><strong>If they interrupt ‚Äî STOP and answer.</strong> Don't finish your sentence. They're testing if you can think, not recite.</p>
<p><strong>"I don't know, but...":</strong> "That's a great question. I haven't investigated that specific aspect, but based on my results, my hypothesis would be‚Ä¶" ‚Äî then reason through it out loud. Judges LOVE honest scientific reasoning.</p>
<p><strong>Acknowledge limitations first.</strong> "One limitation is‚Ä¶" shows scientific maturity. Pretending your work is perfect shows the opposite.</p>
<p><strong>Timing:</strong> Interviews are 12-15 minutes. ~2 min pitch, ~10 min Q&A. Practice being CONCISE ‚Äî 30-second answers unless they explicitly want more.</p>
</div>
`},

// ============ GLOSSARY ============
{id:'poster',icon:'üîç',label:'9. Poster Walkthrough',ct:`
<h1>Poster Walkthrough ‚Äî Every Word Decoded</h1>
<p class="sub">A judge will point at ANY word on your poster and ask "what does that mean?" This section walks through every sentence, every number, every term ‚Äî left to right, top to bottom.</p>

<h2>TITLE</h2>
<div class="c ca">
<p><strong>"Deep Learning Guided Discovery and FEP Validation of NOD2 Binders for the R702W Crohn's Variant"</strong></p>
</div>

${ex('j','Word-by-word breakdown of the title',`
<p><strong>Deep Learning:</strong> A type of machine learning using neural networks with many layers. Here it refers to GNINA's CNN (Convolutional Neural Network) trained on real protein-drug complexes. NOT a generic buzzword ‚Äî GNINA literally uses deep learning to score how well a drug fits a protein.</p>
<p><strong>Guided Discovery:</strong> The deep learning (GNINA) GUIDED which compounds to study further. It didn't discover drugs by itself ‚Äî it scored 9,566 compounds and the top scorers were advanced through the pipeline.</p>
<p><strong>FEP:</strong> Free Energy Perturbation. The gold-standard computational method for calculating how tightly a drug binds. "Perturbation" = you slowly make the drug vanish (perturb the system) and measure the energy cost of removing it.</p>
<p><strong>Validation:</strong> FEP validated the docking/ML predictions. Docking says "this might bind." FEP says "here's exactly HOW STRONGLY it binds, with error bars."</p>
<p><strong>NOD2:</strong> Nucleotide-binding Oligomerization Domain 2. An immune sensor protein inside cells. It detects bacterial fragments and triggers inflammation.</p>
<p><strong>Binders:</strong> Compounds that physically attach to NOD2's LRR domain. Not all compounds that "dock" actually bind in reality ‚Äî binders are the ones confirmed by MD and FEP to stay attached.</p>
<p><strong>R702W:</strong> A specific mutation. Position 702 of the protein: Arginine (R) ‚Üí Tryptophan (W). Single amino acid substitution in the HD2 domain.</p>
<p><strong>Crohn's Variant:</strong> R702W is a Crohn's disease risk variant. ~10% of Crohn's patients carry it. Doubles disease risk.</p>
`)}

<h2>INTRODUCTION ‚Äî Left Column</h2>

<h3>Background</h3>
${ex('j','"Over 1 million Americans suffer from Crohn\'s disease, a painful, incurable inflammatory bowel disease"',`
<p><strong>1 million:</strong> CDC estimate. Crohn's is a type of IBD (inflammatory bowel disease) affecting any part of the GI tract, most commonly the terminal ileum (end of small intestine). "Incurable" = no cure exists, only symptom management. Treatments include biologics (Remicade, Humira), immunosuppressants, and surgery.</p>
`)}

${ex('j','"The NOD2 gene is the strongest genetic risk factor. The R702W mutation affects ~10% of patients, increasing disease risk ~2-fold."',`
<p><strong>Strongest genetic risk factor:</strong> Of ALL genes studied in Crohn's (200+ loci identified by GWAS), NOD2 has the largest effect size. Three major NOD2 variants: R702W (most common), G908R, and 1007fs (frameshift). Each independently increases risk.</p>
<p><strong>~10%:</strong> Approximately 10% of Crohn's patients are heterozygous for R702W. The ~2-fold risk means: if baseline risk is X, carrying one copy of R702W makes risk ~2X. Homozygous (two copies) = much higher risk (~20-40√ó).</p>
`)}

${ex('j','"No approved drugs directly target the NOD2 protein itself"',`
<p><strong>Key novelty claim.</strong> Current Crohn's drugs target DOWNSTREAM effects: anti-TNF biologics (Remicade blocks TNF-Œ± cytokine), anti-IL-12/23 (Stelara), JAK inhibitors. NOBODY targets NOD2 itself ‚Äî because no binding pocket was characterized and no crystal structure of the full protein exists. This is the gap your project fills.</p>
`)}

${ex('j','"NOD2 is an innate immune sensor that recognizes bacterial muramyl dipeptide (MDP) and activates NF-Œ∫B signaling"',`
<p><strong>Innate immune sensor:</strong> Part of the first-line defense system (innate immunity), not the adaptive immune system (T cells, B cells). NOD2 is a PRR (Pattern Recognition Receptor) ‚Äî it detects molecular patterns from bacteria.</p>
<p><strong>Muramyl dipeptide (MDP):</strong> A fragment of peptidoglycan, which is the mesh-like polymer in ALL bacterial cell walls. MDP = MurNAc-L-Ala-D-isoGln. It's the smallest fragment that NOD2 can detect.</p>
<p><strong>NF-Œ∫B:</strong> Nuclear Factor kappa-light-chain-enhancer of activated B cells. A transcription factor ‚Äî a protein that enters the nucleus and turns on genes. The genes it activates produce inflammatory cytokines (IL-8, TNF-Œ±, IL-6, IL-1Œ≤).</p>
`)}

${ex('j','"The R702W mutation lies 79.4 √Ö from the binding site, suggesting allosteric mechanisms"',`
<p><strong>79.4 √Ö:</strong> Measured in PyMOL as the straight-line distance between residue 702 (HD2 domain) and the center of the LRR binding pocket. 1 √Ö = 0.1 nanometers. 79.4 √Ö ‚âà 8 nanometers ‚Äî roughly the diameter of 80 water molecules lined up.</p>
<p><strong>Allosteric:</strong> "Allo" = other, "steric" = shape. A mutation at one site causing effects at a distant site through propagated conformational changes. Like pressing a brake pedal ‚Äî your foot is far from the wheels, but the hydraulic system transmits the force. R702W changes the protein's flexibility at position 702, and that rigidification propagates through the protein backbone to the LRR pocket 79.4 √Ö away.</p>
`)}

<h3>Research Question</h3>
${ex('j','"Can computational methods identify compounds that directly bind and modulate NOD2?"',`
<p><strong>Computational methods:</strong> The entire pipeline ‚Äî GNINA docking, XGBoost ML, MD simulation, FEP calculations. All done on a computer, not in a lab.</p>
<p><strong>Directly bind:</strong> Physically attach to the protein. Current drugs affect NOD2's pathway indirectly (by blocking downstream cytokines). This project asks about DIRECT binding to NOD2 itself.</p>
<p><strong>Modulate:</strong> Change NOD2's behavior. Could mean activate it, inhibit it, or stabilize it. The project doesn't determine which ‚Äî that requires cell-based assays (future work).</p>
`)}

<h3>Hypothesis</h3>
${ex('j','"(1) CNN-based docking + ML can prioritize binders (2) MD simulations will confirm stable binding (3) FEP can quantify mutation effects on affinity"',`
<p><strong>Three testable sub-hypotheses:</strong></p>
<p>(1) <strong>CNN-based docking + ML:</strong> GNINA (CNN) scores compounds ‚Üí XGBoost (ML) learns patterns ‚Üí together they can separate real binders from non-binders. TESTABLE: scaffold-split AUC > 0.50 means yes.</p>
<p>(2) <strong>MD confirms stable binding:</strong> If docking says a compound fits, does it STAY in the pocket over time? TESTABLE: pocket occupancy >50% over 20 ns means yes. Negative control leaving = validation.</p>
<p>(3) <strong>FEP quantifies mutation effects:</strong> Does R702W change binding strength? By how much? TESTABLE: ŒîŒîG ‚â† 0 with statistical significance means the mutation affects binding.</p>
`)}

<h2>METHODS ‚Äî Middle Column</h2>

<h3>1. PREPARATION</h3>
${ex('j','"AlphaFold2 ‚Üí e-Drug3D ‚Üí COCONUT ‚Äî Total: 9,566 unique compounds for screening"',`
<p><strong>AlphaFold2:</strong> Google DeepMind's AI that predicts protein 3D structures from amino acid sequences. Used because no experimental (X-ray/cryo-EM) structure of full-length human NOD2 exists. pLDDT >90 in LRR region = very high confidence.</p>
<p><strong>e-Drug3D:</strong> Database of 2,152 FDA-approved drugs with known 3D structures. FDA-approved = already proven safe in humans. Drug repurposing advantage.</p>
<p><strong>COCONUT:</strong> COlleCtion of Open Natural prodUcTs. 7,414 natural products with diverse chemical scaffolds. Natural products provide structural diversity that FDA drugs lack.</p>
<p><strong>9,566:</strong> 2,152 + 7,414 = 9,566 unique compounds. "Unique" means duplicates between databases were removed.</p>
`)}

<h3>2. GNINA</h3>
${ex('j','"CNN-scored molecular docking. Unlike AutoDock Vina/Glide, CNN learns binding patterns from real structures. Grid: 30√ó30√ó30 √Ö. Exhaustiveness = 32. CNN affinity range: 2.47‚Äì7.34 kcal/mol (mean: 4.57)"',`
<p><strong>CNN-scored:</strong> Convolutional Neural Network trained on PDBbind (~20,000 real protein-drug complexes). Classical docking (Vina) uses a fixed mathematical formula from 2010. GNINA's CNN learned from actual data ‚Äî like the difference between a calculator and a student who studied thousands of examples.</p>
<p><strong>Grid 30√ó30√ó30 √Ö:</strong> A cube-shaped search zone around the pocket. Pocket is ~20 √Ö across + 5 √Ö padding on each side = 30 √Ö. Search is confined to this box.</p>
<p><strong>Exhaustiveness 32:</strong> 4√ó the default (8). Number of independent random searches per compound. Higher = more thorough, less likely to miss the best pose.</p>
<p><strong>CNN affinity 2.47‚Äì7.34:</strong> GNINA outputs predicted binding affinity in pKd units (higher = tighter binding). Range across 9,566 compounds. Mean 4.57 = average compound has moderate predicted affinity.</p>
`)}

<h3>3. NOD2-SCOUT</h3>
${ex('j','"XGBoost classifier (100 trees, depth 6, lr=0.05). Top 25% = binders, bottom 25% = non-binders. 858 labeled compounds. Features: 2,048-bit Morgan fingerprints + 10 descriptors = 2,058 total. 5-fold scaffold-split CV. AUC = 0.85‚Äì0.93. Shuffled control: AUC = 0.50"',`
<p><strong>XGBoost:</strong> eXtreme Gradient Boosting. An ensemble of 100 sequential decision trees, each correcting the previous one's errors. "NOD2-Scout" is your name for this custom classifier.</p>
<p><strong>Top/bottom 25%:</strong> Pseudo-labeling. No experimental NOD2 binding data exists ANYWHERE. So you used GNINA docking scores as proxies: top 25% = "binder" (label 1), bottom 25% = "non-binder" (label 0), middle 50% = thrown away (too ambiguous).</p>
<p><strong>858:</strong> ~9,566 √ó 25% √ó 2 groups √∑ some filtering ‚âà 858 labeled compounds to train on.</p>
<p><strong>2,048-bit Morgan fingerprints:</strong> Each molecule hashed into a 2,048-digit binary barcode based on atom neighborhoods within radius 2 bonds.</p>
<p><strong>Scaffold-split:</strong> ALL molecules sharing the same chemical backbone go into the SAME fold. Prevents the model from memorizing scaffolds instead of learning binding patterns. This is why AUC drops from 0.998 (random split) to 0.85-0.93 (scaffold split) ‚Äî the lower number is the REAL performance.</p>
<p><strong>Shuffled control AUC = 0.50:</strong> When labels are randomized, model performs at coin-flip level. Proves the AUC 0.85-0.93 captures real signal, not artifacts.</p>
`)}

<h3>4. ADMET</h3>
${ex('j','"Lipinski Rule of 5, Veber rules, PAINS, Brenk. 148 of 150 passed (98.7%)"',`
<p><strong>Lipinski:</strong> MW ‚â§ 500, LogP ‚â§ 5, HBD ‚â§ 5, HBA ‚â§ 10. Predicts oral bioavailability.</p>
<p><strong>Veber:</strong> TPSA ‚â§ 140 √Ö¬≤, rotatable bonds ‚â§ 10. Predicts intestinal absorption.</p>
<p><strong>PAINS:</strong> 480 chemical patterns that cause false positives in assays (pan-assay interference).</p>
<p><strong>Brenk:</strong> 105 toxic substructure patterns (epoxides, nitroso groups, etc.).</p>
<p><strong>98.7%:</strong> High pass rate because FDA drugs are already drug-like by design. 2 failures = PAINS alerts (Michael acceptors).</p>
`)}

<h3>6. MOLECULAR DYNAMICS</h3>
${ex('j','"OpenMM GPU-accelerated. 240 ns total MD (20 ns √ó 3 replicates). Force fields: AMBER14, OpenFF 2.1, TIP3P-FB. 310.15 K (physiological). 520 ns total across 26 trajectories"',`
<p><strong>OpenMM:</strong> Open-source molecular dynamics engine with GPU acceleration. Runs on your RTX 4060 Ti.</p>
<p><strong>240 vs 520 ns:</strong> 240 ns = drug-bound simulations only. 520 ns = all 26 trajectories including apo (no drug) simulations for WT and R702W.</p>
<p><strong>AMBER14:</strong> Force field for protein (amino acid parameters).</p>
<p><strong>OpenFF 2.1:</strong> Force field for drug molecules (small organic molecule parameters).</p>
<p><strong>TIP3P-FB:</strong> Water model. Three-point (3 charges per water molecule). FB = "force balance" ‚Äî improved parameters.</p>
<p><strong>310.15 K:</strong> = 37¬∞C = human body temperature. Standard for biomedical simulations.</p>
`)}

<h2>RESULTS ‚Äî Right Column</h2>

<h3>APO DYNAMICS: WT vs R702W</h3>
${ex('j','"RMSD Distribution: WT mean 4.05 √Ö, R702W mean 3.27 √Ö. Frames exceeding 5 √Ö: WT 12.6%, R702W 0%. R702W = MORE RIGID than wild-type"',`
<p><strong>RMSD:</strong> Root Mean Square Deviation. Measures how much the protein moves from its starting position over time. Higher RMSD = more flexible.</p>
<p><strong>WT 4.05 vs R702W 3.27:</strong> Wild-type samples wider conformations (more flexible). Mutant is constrained (more rigid). The mutation STIFFENS the protein.</p>
<p><strong>12.6% vs 0%:</strong> WT explores conformations >5 √Ö away from the mean in 12.6% of simulation frames. R702W NEVER exceeds 5 √Ö. This rigidification is the allosteric mechanism ‚Äî the brake pedal analogy.</p>
<p><strong>Causality Flexibility (ŒîMobility):</strong> Poster shows ŒîŒî2: 1.0b ‚Üí 1.0 √Ö. The reduced flexibility propagates from the mutation site to the binding pocket.</p>
`)}

<h3>FEP Binding Free Energy: WT vs R702W NOD2</h3>
${ex('j','"Febuxostat: ŒîG(WT) = ‚àí10.36 ¬± 0.18, ŒîG(R702W) = ‚àí8.02 ¬± 0.19, ŒîŒîG = +2.34 ¬± 0.26, 8œÉ. Bufadienolide: ŒîG(WT) = ‚àí15.22 ¬± 0.26, ŒîG(R702W) = ‚àí15.66 ¬± 0.26, ŒîŒîG = ‚àí0.44 ¬± 0.37, 1.2œÉ"',`
<p><strong>ŒîG (delta G):</strong> Gibbs free energy of binding. Negative = binding happens spontaneously. More negative = tighter binding.</p>
<p><strong>‚àí10.36 kcal/mol:</strong> Febuxostat binds WT NOD2 with excellent affinity. Typical drug range: ‚àí6 to ‚àí10. This is strong.</p>
<p><strong>¬±0.18:</strong> Statistical uncertainty from MBAR analysis. Remarkably small (typical: ¬±0.5-1.5). 120 lambda windows gave precise estimates.</p>
<p><strong>ŒîŒîG = +2.34:</strong> ŒîG(mutant) ‚àí ŒîG(WT) = (‚àí8.02) ‚àí (‚àí10.36) = +2.34. POSITIVE = weaker binding in mutant. The R702W mutation costs Febuxostat 2.34 kcal/mol of binding energy.</p>
<p><strong>Boltzmann conversion:</strong> 2.34 kcal/mol at 310 K ‚Üí e^(2.34/0.616) ‚âà 45-50√ó weaker. If Kd was 10 nM in WT, it's ~500 nM in R702W.</p>
<p><strong>8œÉ:</strong> |ŒîŒîG|/error = 2.34/0.26 ‚âà 9œÉ. Poster rounds to 8œÉ. For reference, particle physicists require 5œÉ to claim a discovery (Higgs boson). 8œÉ = p < 10‚Åª¬π‚Åµ.</p>
<p><strong>Bufadienolide ŒîŒîG = ‚àí0.44 ¬± 0.37:</strong> |0.44|/0.37 = 1.2œÉ. Below the 2œÉ significance threshold. NOT significant = the mutation has NO meaningful effect on Bufadienolide binding. This is the key discovery: mutation effects are ligand-dependent.</p>
`)}

<h3>BIOLOGICAL INTERPRETATION</h3>
${ex('j','"FEBUXOSTAT ‚Äî Mutation-Sensitive: electrostatic hydrogen bonds with ASP1011. BUFADIENOLIDE ‚Äî Mutation-Resistant: hydrophobic van der Waals contacts"',`
<p><strong>Why Febuxostat is sensitive:</strong> Its binding depends on hydrogen bonds with ASP1011 (aspartate at position 1011). H-bonds require precise geometry (<3.5 √Ö distance, 120-180¬∞ angle). When R702W rigidifies the protein, the pocket shifts 0.5-1.0 √Ö ‚Äî enough to break H-bond geometry. +2.34 kcal/mol penalty.</p>
<p><strong>Why Bufadienolide is resistant:</strong> Its binding depends on hydrophobic (van der Waals) contacts with LEU, ILE, VAL residues. These interactions work at 4-6 √Ö without requiring precise angles. Small geometry shifts from rigidification don't disrupt them. ŒîŒîG ‚âà 0.</p>
<p><strong>The discovery:</strong> The SAME mutation makes one drug 50√ó weaker and leaves another completely unaffected. Drug response depends on binding mechanism, not just whether the mutation exists. ‚Üí Pharmacogenomic precision medicine.</p>
`)}

<h3>LEAD COMPOUNDS</h3>
${ex('j','"Febuxostat: FDA-approved gout drug. MW 316.37, LogP 1.87, TPSA 94.03. Bufadienolide: CID 10128, natural cardiac glycoside"',`
<p><strong>Febuxostat:</strong> Brand name Uloric. FDA-approved xanthine oxidase inhibitor for gout (reduces uric acid). Repurposing = using an existing drug for a new indication. Already has safety data, manufacturing, pharmacokinetics.</p>
<p><strong>MW 316.37:</strong> Molecular weight in g/mol. Well under Lipinski's 500 limit. Small enough to cross membranes.</p>
<p><strong>LogP 1.87:</strong> Partition coefficient between octanol and water. Between 0 and 3 is ideal for oral drugs. Not too oily (would get stuck in membrane), not too polar (can't enter membrane).</p>
<p><strong>TPSA 94.03 √Ö¬≤:</strong> Total Polar Surface Area. Under 140 = can cross intestinal membrane. Under 90 is better for brain penetration, but NOD2 is intracellular, not in the brain ‚Äî 94 is fine.</p>
<p><strong>Bufadienolide CID 10128:</strong> A steroidal compound from the bufadienolide class. Related to cardiac glycosides (like digoxin). Natural product from toad venom and plants. Not an approved drug ‚Äî would need extensive safety testing.</p>
`)}

<h3>DISCUSSION & CONCLUSIONS</h3>
${ex('j','"Mutation effects are ligand-dependent ‚Üí precision medicine. Hypothesis supported. Key findings, limitations, future directions"',`
<p><strong>Core finding restated:</strong> The R702W mutation doesn't uniformly affect all drugs ‚Äî it depends on the binding mechanism. Electrostatic-dependent drugs lose efficacy; hydrophobic-dependent drugs don't. This is pharmacogenomics ‚Äî choosing drugs based on genotype.</p>
<p><strong>Hypothesis supported:</strong> All three sub-hypotheses confirmed: (1) CNN+ML identified binders (AUC 0.85-0.93), (2) MD confirmed stable binding (70-80% occupancy), (3) FEP quantified mutation effects (ŒîŒîG +2.34, 8œÉ).</p>
<p><strong>Limitations (on poster):</strong> Computational only (no experimental validation yet). AlphaFold structure (not crystal). Only R702W tested (not G908R, 1007fs). Only 2 compounds through FEP. Binding ‚â† function (binding doesn't prove the drug actually works).</p>
<p><strong>Future directions:</strong> SPR (surface plasmon resonance) for binding kinetics. ITC (isothermal titration calorimetry) for thermodynamics. HDX-MS (hydrogen-deuterium exchange mass spectrometry) for dynamics. NF-Œ∫B reporter assays for function. Extend to G908R and 1007fs.</p>
`)}

<h2>FIGURES ‚Äî Quick Reference</h2>
<table>
<tr><th>Fig</th><th>What It Shows</th><th>What to Say If Asked</th></tr>
<tr><td>1</td><td>MDP structure + WT/R702W pathway</td><td>"MDP is the bacterial fragment NOD2 detects. Left pathway = normal signaling. Right = impaired by R702W."</td></tr>
<tr><td>2-3</td><td>WT vs R702W full-length NOD2</td><td>"AlphaFold-predicted structures. Red marker shows mutation site in HD2 domain."</td></tr>
<tr><td>4-9</td><td>RIPK2, TAK1, NF-Œ∫B active vs impaired</td><td>"The downstream cascade. Each protein is less activated when NOD2 is impaired by R702W."</td></tr>
<tr><td>10</td><td>Screening funnel (9,566 ‚Üí 2)</td><td>"The pipeline. 9,566 in, 2 computationally validated leads out. 99.98% reduction."</td></tr>
<tr><td>11</td><td>ROC curve + 5-fold AUC</td><td>"Each colored line is one cross-validation fold. AUC 0.85-0.93. Diagonal = random chance (0.50)."</td></tr>
<tr><td>12</td><td>RMSD distribution WT vs R702W</td><td>"WT is wider (more flexible). R702W is narrower (more rigid). The mutation stiffens the protein."</td></tr>
<tr><td>13</td><td>Pocket occupancy over 20 ns</td><td>"Green = Febuxostat 73% occupancy, Blue = Bufadienolide 80%. Red = negative control left by 5 ns."</td></tr>
<tr><td>14-15</td><td>2D structures of lead compounds</td><td>"Febuxostat (left) ‚Äî gout drug being repurposed. Bufadienolide (right) ‚Äî natural cardiac glycoside."</td></tr>
<tr><td>16</td><td>FEP ŒîG bar chart: WT vs R702W</td><td>"The key result. Febuxostat bars differ by 2.34 kcal/mol (8œÉ). Bufadienolide bars overlap (1.2œÉ, not significant). Mutation effects are ligand-dependent."</td></tr>
</table>

<div class="ky"><strong>Poster reading tip for judges:</strong> When a judge approaches, guide their eyes by PHYSICALLY POINTING at the poster. Say "Let me walk you through the flow" and trace left‚Üímiddle‚Üíright with your hand. Point at Figure 10 (funnel) as your roadmap. Point at Figure 16 (FEP bars) as your punchline.</div>
`},


{id:'audit',icon:'‚ö†Ô∏è',label:'10. Poster Audit',ct:`
<h1>‚ö†Ô∏è Poster Critical Audit ‚Äî Every Weak Spot</h1>
<p class="sub">If a judge wants to destroy you, HERE is where they'll aim. Know these before Saturday.</p>

<h2>üö® NUMBERS THAT DON'T MATCH</h2>
<p>Your poster and your study materials have several conflicting numbers. A judge who reads carefully will notice. You MUST know which is correct and why.</p>

<table>
<tr><th>Item</th><th style="color:var(--yel)">Poster Says</th><th style="color:var(--accent)">Website/Earlier Docs Say</th><th>Which Is Correct?</th></tr>
<tr><td><strong>XGBoost depth</strong></td><td>depth=4</td><td>max_depth=6</td><td>‚ö†Ô∏è YOU NEED TO CHECK YOUR CODE. If poster says 4, and your code says 6, one is wrong. Run <code>print(model.get_params()['max_depth'])</code>.</td></tr>
<tr><td><strong>Label threshold</strong></td><td>Top 20% / Bottom 20%</td><td>Top 25% / Bottom 25%</td><td>‚ö†Ô∏è CHECK YOUR CODE. Did you use 0.20 or 0.25 quantile? This changes labeled sample count.</td></tr>
<tr><td><strong>Labeled compounds</strong></td><td>856</td><td>858</td><td>Minor ‚Äî could be filtering difference. Know the exact number.</td></tr>
<tr><td><strong>Febuxostat MW</strong></td><td>315.37</td><td>316.37</td><td>‚ö†Ô∏è PubChem says 316.37 (C‚ÇÅ‚ÇÜH‚ÇÅ‚ÇÜN‚ÇÇO‚ÇÉS). Your poster may have a typo. Be ready to say "316.37 is the correct MW."</td></tr>
<tr><td><strong>Febuxostat LogP</strong></td><td>2.39</td><td>1.87</td><td>Both could be "correct" ‚Äî different calculation methods (RDKit vs ChemAxon vs XLogP3) give different values. Know WHICH method you used.</td></tr>
<tr><td><strong>Febuxostat TPSA</strong></td><td>86 √Ö¬≤</td><td>94.03 √Ö¬≤</td><td>‚ö†Ô∏è PubChem shows 94.03. If poster says 86, check if you used a different TPSA method (e.g., with/without phosphorus and sulfur atoms).</td></tr>
</table>

<div class="ky"><strong>WHAT TO DO IF A JUDGE CATCHES A DISCREPANCY:</strong> Don't panic. Say: "You're right ‚Äî the [poster/earlier version] has [X] and my calculation shows [Y]. The correct value from [PubChem/my code] is [correct]. I should have caught that before printing." Honesty scores HIGHER than defensiveness.</div>

<h2>üî¨ CLAIMS JUDGES WILL CHALLENGE</h2>

${ex('j','CLAIM: "The NOD2 gene is the strongest genetic risk factor"',`
<p><strong>Challenge:</strong> "Strongest" is a strong word. The HLA region actually has more overall genetic association with Crohn's in GWAS. NOD2 has the largest SINGLE-GENE effect size, but "strongest genetic risk factor" could be argued either way.</p>
<p><strong>Defense:</strong> "NOD2 variants have the highest per-allele odds ratio of any single gene in Crohn's GWAS meta-analyses ‚Äî OR ~2-4 for heterozygous carriers, OR 20-40 for compound heterozygotes. The HLA region contributes more overall risk but through many variants across multiple genes. NOD2 is the strongest individual gene."</p>
<p><strong>Safer phrasing if pressed:</strong> "One of the strongest" or "the strongest single-gene risk factor."</p>
`)}

${ex('j','CLAIM: "No approved drugs directly target the NOD2 protein itself"',`
<p><strong>Challenge:</strong> A judge may ask "have you checked recently? Are you sure nobody has published NOD2-targeting compounds since you wrote this?" or "what about MDP analogs like mifamurtide?"</p>
<p><strong>Defense:</strong> "I searched PubMed and ClinicalTrials.gov ‚Äî no approved drugs target NOD2 directly. Mifamurtide (Mepact) is a synthetic MDP analog that ACTIVATES NOD2, but it's approved only for osteosarcoma in Europe, not Crohn's. It's an agonist, not a modulator designed for mutation carriers. My project asks a different question ‚Äî can we find compounds whose binding CHANGES with the R702W mutation?"</p>
`)}

${ex('j','CLAIM: "allosteric mechanisms" ‚Äî 79.4 √Ö from binding site',`
<p><strong>Challenge:</strong> "How do you know it's allosteric? Maybe R702W just destabilizes the protein globally and the pocket effect is a secondary consequence of unfolding."</p>
<p><strong>Defense:</strong> "My APO dynamics show R702W makes the protein MORE rigid, not less stable ‚Äî mean RMSD drops from 4.05 to 3.27 √Ö and frames exceeding 5√Ö drop from 12.6% to 0%. A destabilized protein would be MORE flexible, not less. The RMSF data shows reduced flexibility specifically propagating from HD2 (1.46‚Üí1.23 √Ö) through to LRR (1.36‚Üí1.12 √Ö). This is consistent with allosteric rigidification, not global destabilization."</p>
<p><strong>This is actually one of your STRONGEST points</strong> ‚Äî you're challenging prior literature that calls R702W 'destabilizing.' Your data says it's actually rigidifying.</p>
`)}

${ex('j','CLAIM: Pseudo-labels from GNINA ‚Üí circular reasoning?',`
<p><strong>Challenge:</strong> "You used GNINA docking scores to label compounds, then trained an ML model to predict those same scores. Isn't that circular? What is the ML actually adding that GNINA didn't already tell you?"</p>
<p><strong>This is the HARDEST question about your ML pipeline.</strong></p>
<p><strong>Defense:</strong> "Good question ‚Äî and it's a real limitation. The ML model learns PATTERNS across the scored library that GNINA doesn't capture: which chemical features (fingerprint bits) are enriched in high-scoring compounds. Think of it as a second opinion that looks at the data from a completely different angle ‚Äî GNINA looks at 3D poses, XGBoost looks at 2D molecular patterns. The scaffold-split AUC of 0.85-0.93 shows the model generalizes to novel scaffolds GNINA hasn't seen in that exact pose context. But you're right ‚Äî the ceiling is limited by GNINA's accuracy. Experimental labels would be strictly better."</p>
`)}

${ex('j','CLAIM: "First computational drug screen targeting the NOD2 LRR domain" and "First FEP study"',`
<p><strong>Challenge:</strong> "How can you be sure you're the first? Have you done an exhaustive literature search?"</p>
<p><strong>Defense:</strong> "I searched PubMed for 'NOD2 virtual screening,' 'NOD2 docking,' 'NOD2 drug discovery,' and 'NOD2 free energy perturbation.' I found zero papers docking compounds against the NOD2 LRR domain and zero FEP studies on NOD2 variants. The closest work is on RIPK2 inhibitors, which target the KINASE downstream of NOD2, not NOD2 itself. If someone has done this and I missed it, I'd genuinely want to know ‚Äî but as of my literature search, this appears to be the first."</p>
`)}

${ex('j','CLAIM: "50√ó weaker predicted binding" from ŒîŒîG = +2.34 kcal/mol',`
<p><strong>Challenge:</strong> "Your error bar is ¬±0.26 kcal/mol. Through the exponential Boltzmann conversion, that means the fold-change could range from ~25√ó to ~100√ó. Why do you report just 50√ó?"</p>
<p><strong>Defense:</strong> "You're absolutely right that the uncertainty propagates non-linearly through the exponential. At the mean ŒîŒîG of 2.34 kcal/mol at 310K, the central estimate is e^(2.34/0.616) ‚âà 45√ó, which I round to ~50√ó. The 95% confidence range spans from e^(1.82/0.616) ‚âà 19√ó to e^(2.86/0.616) ‚âà 105√ó. The direction of the effect ‚Äî substantially weaker binding ‚Äî is robust across the entire confidence interval. I should present this as '~50√ó (19-105√ó 95% CI)' for full rigor."</p>
<p><strong>Prep:</strong> Memorize: 2.34 ¬± 0.26 kcal/mol ‚Üí ~50√ó (range ~20-100√ó). The 8œÉ means the DIRECTION is near-certain, even if the exact fold-change has a wide range.</p>
`)}

${ex('j','CLAIM: Generalization from N=2 compounds',`
<p><strong>Challenge:</strong> "You tested FEP on exactly 2 compounds and concluded that mutation effects are ligand-dependent. That's an N of 2. How can you generalize from two data points?"</p>
<p><strong>Defense:</strong> "You're right ‚Äî I can't generalize broadly from two compounds. What I CAN say is that ligand-dependent effects EXIST for R702W, because I found one compound where ŒîŒîG = +2.34 (8œÉ, clearly affected) and another where ŒîŒîG = -0.44 (1.2œÉ, clearly unaffected). If mutation effects were universal, both would shift in the same direction by similar amounts. They didn't. This proves the PHENOMENON exists. Quantifying how common it is requires testing more compounds ‚Äî that's a limitation I state explicitly."</p>
`)}

${ex('j','CLAIM: "Challenges prior literature that described R702W as destabilizing"',`
<p><strong>Challenge:</strong> "Which papers specifically? Can you cite them?"</p>
<p><strong>Defense:</strong> Know the papers: Economou et al. (2004) and earlier NOD2 structural papers describe the mutation in terms of impaired MDP recognition and reduced signaling, sometimes using language suggesting the protein is "destabilized." Your RMSD/RMSF data suggests "rigidification" not "destabilization." But be careful ‚Äî "impaired function" and "rigidification" aren't contradictory. The protein could be rigidified AND functionally impaired (rigidity prevents the conformational changes needed for signaling).</p>
`)}

<h2>üß™ SCIENTIFIC WEAK SPOTS</h2>

${ex('j','AlphaFold structure ‚Äî no experimental validation',`
<p><strong>The attack:</strong> "Your entire project is built on an AlphaFold prediction. What if the LRR pocket geometry is wrong?"</p>
<p><strong>Defense:</strong> "pLDDT >90 in the LRR region indicates very high confidence. AlphaFold2 has been extensively validated ‚Äî Jumper et al. 2021 showed median GDT-TS >90 across CASP14 targets. But you're right that pocket geometry could differ from experimental reality. This is why experimental validation (X-ray crystallography, cryo-EM) is in my future directions. The RELATIVE comparison (WT vs R702W) is more reliable than the absolute values because both use the same starting structure."</p>
`)}

${ex('j','Binding ‚â† Function ‚Äî you showed binding but not activity',`
<p><strong>The attack:</strong> "Your compounds bind NOD2. So what? Binding doesn't mean they DO anything. They could bind without affecting signaling."</p>
<p><strong>Defense:</strong> "Absolutely correct. My project identifies compounds that BIND the LRR domain with mutation-dependent affinity. Whether binding activates, inhibits, or has no functional effect requires NF-Œ∫B reporter assays in NOD2-expressing cell lines ‚Äî that's the first experimental future direction. However, any compound that binds the same pocket as MDP has a high probability of affecting MDP recognition, which is the first step in NOD2 signaling."</p>
`)}

${ex('j','Error bars: SEM (n=3) is very small for error estimation',`
<p><strong>The attack:</strong> "Your error bars are SEM with n=3. That's barely enough to estimate variability. And SEM shrinks with sample size ‚Äî shouldn't you report SD instead?"</p>
<p><strong>Defense:</strong> "SEM is standard in FEP literature for reporting precision of the mean binding energy across replicates. With n=3, SD and SEM differ by a factor of ‚àö3 ‚âà 1.7. My SEM of ¬±0.18 corresponds to SD ‚âà ¬±0.31. The 8œÉ significance uses the SEM-based propagated error; with SD-based error, it would be ~5œÉ ‚Äî still highly significant. More replicates would give tighter estimates, and that's a fair limitation."</p>
<p><strong>Know the conversion:</strong> SEM √ó ‚àön = SD. So ¬±0.18 √ó ‚àö3 = ¬±0.31 kcal/mol SD. ŒîŒîG/SD = 2.34/0.31 ‚âà 7.5œÉ. Still very significant.</p>
`)}

${ex('j','Pocket occupancy threshold: why 5 √Ö? Why not 3 √Ö or 7 √Ö?',`
<p><strong>The attack:</strong> "You define pocket occupancy as frames where the ligand stays within 5 √Ö. Why 5 √Ö and not some other cutoff?"</p>
<p><strong>Defense:</strong> "5 √Ö is a standard threshold in MD binding studies ‚Äî it approximates the maximum distance for meaningful non-covalent interactions (van der Waals cutoff is ~4-6 √Ö, H-bonds reach ~3.5 √Ö). At 3 √Ö, only very tight contacts count and occupancy drops artificially. At 7 √Ö, even partially dissociated states count as 'bound.' 5 √Ö is the community standard. But I should note the negative control Cysteamine escaped to 45.9 √Ö, so any reasonable threshold between 3-10 √Ö still gives 0% occupancy for the control."</p>
`)}

${ex('j','9 references is thin for a project of this scope',`
<p><strong>The attack:</strong> "You cite only 9 papers. A project spanning structural biology, drug discovery, machine learning, and free energy calculations should reference more literature."</p>
<p><strong>Defense:</strong> "Space constraints on the poster limited my reference count. I cite the foundational papers for each tool: Jumper (AlphaFold), McNutt (GNINA), Eastman (OpenMM), Chen (XGBoost), Shirts (MBAR), Hugot (NOD2), Sorokina (COCONUT), Pil√≥n (e-Drug3D), Economou (NOD2 variants). My full research log cites 30+ additional papers. If you'd like, I can discuss any aspect of the broader literature ‚Äî for instance, Cournia 2017 on FEP best practices, Friesner on Glide benchmarking, or Wildman and Crippen on LogP calculation."</p>
<p><strong>Prep:</strong> Have 5-10 additional paper names ready to name-drop if asked.</p>
`)}

<h2>üìã POSTER PHRASING ISSUES</h2>

<table>
<tr><th>On Poster</th><th>Issue</th><th>What to Say If Caught</th></tr>
<tr><td>"Present in <strong>all bacteria</strong> (Gram+ and Gram‚àí)"</td><td>Technically some bacteria have modified PGN. Mycoplasma lack cell walls entirely.</td><td>"MDP is present in essentially all bacteria with peptidoglycan cell walls ‚Äî which is the vast majority. Mycoplasma and a few other wall-less bacteria are exceptions."</td></tr>
<tr><td>"RIPK2... Impaired" (Figures 5, 7, 9)</td><td>The proteins aren't structurally impaired ‚Äî they're just less activated due to reduced NOD2 signaling.</td><td>"The proteins themselves are structurally normal ‚Äî what's impaired is their activation level due to weakened upstream NOD2 signaling."</td></tr>
<tr><td>"Docking alone has ~0.5 correlation with experiment"</td><td>Judge may ask: source? Which benchmark?</td><td>"This is from CASF-2016 benchmark data and multiple review papers comparing docking scoring functions. The ~0.5 Pearson correlation between predicted and experimental pKd is well-documented across Vina, Glide, and GNINA."</td></tr>
<tr><td>"Mutation restricts conformational sampling"</td><td>Could be phrased as "rigidification hypothesis needs more evidence" ‚Äî 100 ns is short.</td><td>"100 ns is standard for this type of analysis, and the signal is very clear (12.6% vs 0%). Longer simulations (microsecond) would strengthen the claim, and are in future directions."</td></tr>
<tr><td>"precision medicine" (underlined in Motivation)</td><td>Judge may say: "You're very far from precision medicine. You have no clinical data."</td><td>"I agree this is computational proof-of-concept, not clinical precision medicine. What I've shown is the molecular RATIONALE ‚Äî that the mutation differentially affects drug binding. The path from here to clinical precision medicine requires experimental validation and ultimately clinical trials."</td></tr>
<tr><td>FEP Protocol: "120 ns total (1 ns/window)"</td><td>A chemist will count: 20 windows √ó 1 ns √ó 3 legs √ó 2 compounds √ó 2 proteins = 240 ns for FEP alone. Does "120 ns total" mean per compound? Per protein?</td><td>"120 lambda windows total: 20 windows per leg √ó 3 legs (restraints, electrostatics, sterics) √ó 2 compounds. Each window runs 1 ns. So total FEP simulation time is 120 ns per protein variant, or 240 ns across WT and R702W."</td></tr>
<tr><td>"p<0.001" for Febuxostat</td><td>8œÉ actually corresponds to p < 10‚Åª¬π‚Åµ. Saying "p<0.001" is extremely conservative.</td><td>"I reported p<0.001 conservatively. The actual statistical significance at 8œÉ is approximately p < 10‚Åª¬π‚Åµ. I used the conservative bound because the normal distribution assumption may not be exact with n=3 replicates."</td></tr>
</table>

<h2>üéØ THE FIVE HARDEST QUESTIONS FROM THIS POSTER</h2>
<p><em>Ranked by "likelihood a sharp judge asks this" √ó "difficulty of answering."</em></p>

<div class="c ca">
<p><strong>#1: "Your ML model is trained on GNINA labels. Isn't that circular? What does XGBoost add that GNINA didn't already know?"</strong></p>
<p>Why it's hard: It IS somewhat circular. The honest answer is that XGBoost provides a different perspective (2D fingerprints vs 3D poses) and the scaffold-split shows generalization, but the ceiling is capped by GNINA's accuracy. Don't oversell the ML contribution.</p>
</div>

<div class="c ca">
<p><strong>#2: "You generalize from 2 compounds. How do you know ligand-dependent effects aren't just noise?"</strong></p>
<p>Why it's hard: N=2 is genuinely small. The 8œÉ significance makes the Febuxostat result robust, but the "ligand-dependent" PATTERN claim is based on 2 data points. The correct answer acknowledges the limitation: "I've proven the phenomenon exists. Quantifying its prevalence requires more FEP calculations."</p>
</div>

<div class="c ca">
<p><strong>#3: "What if the AlphaFold pocket is wrong? Your entire pipeline collapses."</strong></p>
<p>Why it's hard: It's true. Everything downstream depends on the predicted structure. pLDDT >90 is reassuring but not proof. The relative WT vs R702W comparison is more robust than absolute values, but the pocket geometry could still be off. Crystal structure or cryo-EM is the only real answer.</p>
</div>

<div class="c ca">
<p><strong>#4: "You claim allosteric effects at 79.4 √Ö, but 100 ns of APO simulation isn't enough to prove long-range communication."</strong></p>
<p>Why it's hard: They're right that 100 ns is short for allosteric studies (microsecond is more standard). Your RMSD/RMSF signal is clear, but proving MECHANISTIC communication between position 702 and the LRR pocket would require dynamic network analysis or mutual information calculations you haven't done.</p>
</div>

<div class="c ca">
<p><strong>#5: "Why didn't you test more compounds through FEP? Two seems very selective."</strong></p>
<p>Why it's hard: FEP is expensive (~40 GPU-hours per compound pair). But "expensive" is an explanation, not a justification. The real answer: "I chose Febuxostat for clinical relevance (FDA-approved) and Bufadienolide for mechanistic diversity (opposite binding mode). Two was the maximum my computational resources allowed. More compounds are in future directions."</p>
</div>

<div class="ky"><strong>GOLDEN RULE FOR HARD QUESTIONS:</strong> "That's a great point" ‚Üí Acknowledge the limitation honestly ‚Üí Explain what you DID do and WHY ‚Üí Explain what you'd do differently with more time/resources. A judge who tries to destroy you and FAILS learns you truly understand your work. A judge who tries to destroy you and you DODGE the question learns you're hiding something.</div>
`},


{id:'glo',icon:'üìñ',label:'Audio Glossary',ct:`
<h1>Audio Pronunciation Glossary</h1>
<p class="sub">75 terms. Tap üîä to hear each one pronounced. Come back here whenever a term trips you up.</p>

<h2>Biology</h2>
<div class="gg">
<div class="gi"><strong>NOD2</strong> ${au('NOD2','NOD2')}<br><small>Immune sensor protein in gut cells</small></div>
<div class="gi"><strong>MDP</strong> ${au('MDP','MDP')}<br><small>Bacterial cell wall fragment</small></div>
<div class="gi"><strong>R702W</strong> ${au('R702W','R702W')}<br><small>Arginine‚ÜíTryptophan mutation</small></div>
<div class="gi"><strong>NF-Œ∫B</strong> ${au('NF_kappa_B','NF-Œ∫B')}<br><small>Master inflammation switch</small></div>
<div class="gi"><strong>RIPK2</strong> ${au('RIPK2','RIPK2')}<br><small>Kinase in signaling cascade</small></div>
<div class="gi"><strong>LRR</strong> ${au('LRR','LRR')}<br><small>Sensor domain + drug pocket</small></div>
<div class="gi"><strong>Allosteric</strong> ${au('allosteric','Allosteric')}<br><small>Effect at a distance</small></div>
<div class="gi"><strong>Arginine</strong> ${au('arginine','Arginine')}<br><small>Charged, flexible amino acid</small></div>
<div class="gi"><strong>Tryptophan</strong> ${au('tryptophan','Tryptophan')}<br><small>Bulky, neutral amino acid</small></div>
<div class="gi"><strong>ASP1011</strong> ${au('ASP1011','ASP1011')}<br><small>Negative residue in pocket</small></div>
</div>

<h2>Computational Methods</h2>
<div class="gg">
<div class="gi"><strong>GNINA</strong> ${au('GNINA','GNINA')}<br><small>CNN-based docking tool</small></div>
<div class="gi"><strong>XGBoost</strong> ${au('XGBoost','XGBoost')}<br><small>100 sequential decision trees</small></div>
<div class="gi"><strong>Morgan FP</strong> ${au('morgan_fingerprint','Morgan FP')}<br><small>Molecular barcode (2048 bits)</small></div>
<div class="gi"><strong>Scaffold Split</strong> ${au('scaffold_split','Scaffold Split')}<br><small>Honest train/test separation</small></div>
<div class="gi"><strong>AUC</strong> ${au('AUC','AUC')}<br><small>Model accuracy metric (0-1)</small></div>
<div class="gi"><strong>ADMET</strong> ${au('ADMET','ADMET')}<br><small>Drug safety filters</small></div>
<div class="gi"><strong>Lipinski</strong> ${au('lipinski','Lipinski')}<br><small>Rule of 5 for oral drugs</small></div>
<div class="gi"><strong>PAINS</strong> ${au('PAINS','PAINS')}<br><small>False positive chemical patterns</small></div>
<div class="gi"><strong>TPSA</strong> ${au('TPSA','TPSA')}<br><small>Polar surface area (membrane crossing)</small></div>
<div class="gi"><strong>LogP</strong> ${au('LogP','LogP')}<br><small>Oiliness measure</small></div>
</div>

<h2>Physics & Simulation</h2>
<div class="gg">
<div class="gi"><strong>MD</strong> ${au('molecular_dynamics','MD')}<br><small>F=ma for every atom</small></div>
<div class="gi"><strong>AMBER14</strong> ${au('AMBER14','AMBER14')}<br><small>Protein force parameters</small></div>
<div class="gi"><strong>OpenFF</strong> ${au('OpenFF','OpenFF')}<br><small>Drug force parameters</small></div>
<div class="gi"><strong>TIP3P-FB</strong> ${au('TIP3P_FB','TIP3P-FB')}<br><small>Water model</small></div>
<div class="gi"><strong>RMSD</strong> ${au('RMSD','RMSD')}<br><small>How much structure moved</small></div>
<div class="gi"><strong>HMR</strong> ${au('HMR','HMR')}<br><small>Heavy hydrogen ‚Üí 2√ó faster</small></div>
<div class="gi"><strong>PME</strong> ${au('PME','PME')}<br><small>Fast electrostatics math</small></div>
<div class="gi"><strong>Femtosecond</strong> ${au('femtosecond','Femtosecond')}<br><small>10‚Åª¬π‚Åµ seconds</small></div>
<div class="gi"><strong>√Öngstr√∂m</strong> ${au('angstrom','Angstrom')}<br><small>10‚Åª¬π‚Å∞ meters (atom-width)</small></div>
</div>

<h2>Thermodynamics & FEP</h2>
<div class="gg">
<div class="gi"><strong>FEP</strong> ${au('FEP','FEP')}<br><small>Disappearing drug method</small></div>
<div class="gi"><strong>ŒîG</strong> ${au('delta_G','Delta G')}<br><small>Binding energy (negative = binds)</small></div>
<div class="gi"><strong>ŒîŒîG</strong> ${au('delta_delta_G','Delta Delta G')}<br><small>Mutation effect on binding</small></div>
<div class="gi"><strong>MBAR</strong> ${au('MBAR','MBAR')}<br><small>Optimal energy estimator</small></div>
<div class="gi"><strong>Lambda</strong> ${au('lambda_window','Lambda')}<br><small>Drug "dimmer switch" (0‚Üí1)</small></div>
<div class="gi"><strong>Boresch</strong> ${au('Boresch','Boresch')}<br><small>Position/orientation springs</small></div>
<div class="gi"><strong>Softcore</strong> ${au('softcore','Softcore')}<br><small>Prevents ghost-atom crashes</small></div>
<div class="gi"><strong>Enthalpy</strong> ${au('enthalpy','Enthalpy')}<br><small>Energy from contacts (H)</small></div>
<div class="gi"><strong>Entropy</strong> ${au('entropy','Entropy')}<br><small>Freedom penalty (S)</small></div>
<div class="gi"><strong>Boltzmann</strong> ${au('Boltzmann','Boltzmann')}<br><small>ŒîG ‚Üí fold-change math</small></div>
<div class="gi"><strong>kcal/mol</strong> ${au('kcal_mol','kcal/mol')}<br><small>Energy unit</small></div>
</div>

<h2>Compounds & Future</h2>
<div class="gg">
<div class="gi"><strong>Febuxostat</strong> ${au('febuxostat','Febuxostat')}<br><small>FDA gout drug, mut-sensitive</small></div>
<div class="gi"><strong>Bufadienolide</strong> ${au('bufadienolide','Bufadienolide')}<br><small>Natural product, mut-resistant</small></div>
<div class="gi"><strong>AlphaFold2</strong> ${au('AlphaFold','AlphaFold')}<br><small>AI structure prediction</small></div>
<div class="gi"><strong>SPR</strong> ${au('SPR','SPR')}<br><small>Lab binding measurement</small></div>
<div class="gi"><strong>ITC</strong> ${au('ITC','ITC')}<br><small>Calorimetry (heat of binding)</small></div>
<div class="gi"><strong>Pharmacogenomics</strong> ${au('pharmacogenomics','Pharmacogenomics')}<br><small>Drug choice by genotype</small></div>
</div>
`},

];

// ============ RENDER ============
const sb=document.getElementById('sb'),mn=document.getElementById('mn'),ct=document.getElementById('ct');
S.forEach((s,i)=>{
const b=document.createElement('button');b.className='nb'+(i===0?' on':'');b.innerHTML=`<span class="ni">${s.icon}</span>${s.label}`;b.onclick=()=>go(s.id);sb.appendChild(b);
const m=document.createElement('button');m.className='mb'+(i===0?' on':'');m.textContent=s.icon+' '+s.label;m.onclick=()=>go(s.id);mn.appendChild(m);
const d=document.createElement('div');d.id='s_'+s.id;d.className='sec'+(i===0?' on':'');d.innerHTML=s.ct;ct.appendChild(d);
});
function go(id){
document.querySelectorAll('.nb,.mb').forEach(b=>b.classList.remove('on'));
document.querySelectorAll('.sec').forEach(s=>s.classList.remove('on'));
const ix=S.findIndex(s=>s.id===id);
document.querySelectorAll('.nb')[ix]?.classList.add('on');
document.querySelectorAll('.mb')[ix]?.classList.add('on');
document.getElementById('s_'+id)?.classList.add('on');
window.scrollTo({top:0,behavior:'smooth'});
}
</script>
</body>
</html>
